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Inflammation is an important homeostatic host response. By eliciting 
inflammatory responses, the human immunosurveillance combats invading pathogens. 
However, severe infection-inflammation response syndrome may result from over-
activation of the immune system, which in turn damages the host’s tissues. Sepsis is a 
life-threatening disorder that arises from the body’s excessive responses to infection. It is 
the leading cause of death and disability for patients in an intensive care unit. Despite 
vigorous basic research on the molecular mechanisms of sepsis, the patho-physiology of 
sepsis remains unclear and many clinical trials of sepsis have failed. Therefore, there is 
still a need for new therapeutic intervention. The natural phytoalexin, resveratrol (RSV), 
is evident in its anti-inflammatory effects. However, the detailed molecular mechanisms 
relevant to its anti-inflammatory effects require more investigation. While trying to 
control the overwhelming inflammation, it is critical not to compromise the host response 
to clear pathogens. Studies have reported the critical roles of phospholipase D (PLD) and 
sphingosine kinase (SphK) in controlling inflammatory disease models both in vitro and 
in vivo. Therefore, we seek to examine the effects of RSV on lipopolysaccharide (LPS) 
mediated pro-inflammatory responses, and the possible involvement of PLD and SphK in 
LPS-mediated signaling. We also aim to investigate the therapeutic effects of RSV in a 
mice model of sepsis. 
In this study, RSV was shown to exhibit dose-dependent inhibitions of LPS-
stimulated inflammatory responses such as cytokines, chemokines and HMGB1 
production, and monocyte chemotaxis in human primary monocytes. We next delineate 
the signaling mechanisms of RSV-modulated, LPS-triggered PLD and SphK activation, 
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ERK phosphorylation and NF-κB activation, which may serve as the molecular basis for 
the anti-inflammatory effects of RSV. Furthermore, we demonstrate that therapeutic 
treatment of RSV is protective against polymicrobial sepsis in mice. Mice treated with 
RSV after sepsis induction showed improved survival rate, decreased pro-inflammatory 
cytokines, chemokines and HMGB1 production, lower local and systemic bacterial load, 
and lesser extent of leukocyte infiltration into the peritoneum in vivo. These data suggest 
a potential regimen with RSV which may aid in the clinical treatment of sepsis. 
Besides its ability to regulate pro-inflammatory signaling pathway triggered by 
exogenous stimulus such as LPS, RSV also mediates endogenous protein degradation of 
MyD88, a key adaptor molecule of TLR4. RSV-mediated MyD88 degradation was 
shown to be autophagy-dependent, and MyD88 co-localized with autophagic marker in 
cells treated with RSV. These data suggest that RSV results in autophagic degradation of 
MyD88 in the TLR4 pathway which may also contribute to its anti-inflammatory effects. 
Moreover, RSV-induced autophagy was shown to be involved in regulating LPS-
triggered SphK activity, suggesting a potential crosstalk between RSV-mediated 
endogenous autophagic degradation and RSV-modulated exogenous LPS signaling 
pathway. 
In summary, this study reports the anti-inflammatory effects of RSV in both 
endotoxin activation in vitro and polymicrobial sepsis in vivo and provides an in depth 
molecular basis for its anti-inflammatory properties, thus suggesting the potential 
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1.1 Sepsis and Inflammation 
1.1.1. Inflammation 
Inflammation is the response of host’s immune system to the damage caused to its 
cells and tissues by microbial pathogens such as viruses and bacteria, as well as by 
injurious chemicals or physical insults (Nathan, 2002). Inflammation is central to the 
pathology of sepsis, arthritis, Crohn’s disease, and contributes to the development of 
cardiovascular disease and cancer (Coussens & Werb, 2002). Inflammation can be 
classified into acute and chronic inflammation. Acute inflammation lasts from a few 
minutes to a few days. During acute inflammation, neutrophils, monocytes and 
macrophages initiate immune responses to eliminate pathogens and help in tissue repair, 
resulting in morphological changes such as intense vasodilation and increased blood flow, 
which leads to increased vascular permeability at the damaged region. If the infection is 
not controlled, the acute inflammation progresses into the chronic stage of inflammation, 
and lasts for a longer period of time. Chronic inflammation involves lymphocytes 
proliferation and macrophages activation. Down-regulation of inflammatory responses 
can be modulated by several mechanisms such as inhibition of immune cell activation, 
reduction in the synthesis and release of pro-inflammatory mediators, modification of the 
activities of inducible nitric oxide synthase (iNOS) and cyclooxygenase 2 (COX-2) 
(Pervaiz & Holme, 2009). 
1.1.2. Sepsis 
Sepsis and sepsis-associated multi-organ failure result from tissue injury after 
bacteremia and inflammatory responses. Sepsis is a life-threatening disorder and a 
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leading cause of death and disability for patients in the intensive care units. The 
documented incidence of severe sepsis worldwide is estimated to be around 20 million 
cases annually, with a mortality rate of around 40% leading to a staggering 8 million 
deaths annually (Angus et al, 2001).  In the United States alone, more than 500,000 
patients per year develop sepsis, with an estimated rising incidence of ~1.5% per year. 
Sepsis syndromes include proven or suspected infection with the presence of bacterial 
growth in the blood culture, hyperthermia (temperature higher than 38.3°C) or 
hypothermia (lower than 35.6°C), tachycardia (heart rate greater than 90 beats per 
minute), tachypnea (respiratory rate greater than 30 breaths per minutes), as well as 
evidence of altered organ perfusion (Marshall, 2003). The sepsis inflammatory response 
involves two distinct but not mutually exclusive phases: the systemic inflammatory 
response syndrome (SIRS) and the compensatory anti-inflammatory response syndrome 
(CARS) (Buras et al, 2005). The balance between SIRS and CARS is critical for host 
survival. Defective responses of SIRS or CARS will harm the host during the regulation 
of the inflammatory responses. Therefore, anti-inflammatory and pro-inflammatory 
agents play different roles at stages of sepsis correlate with the prognosis outcome of the 
patients. Sepsis-induced immunosuppression is increasingly being recognized as the 
overriding immune dysfunction in vulnerable septic patients, because the efforts to 
improve the outcome of patients by means of inhibitors of pro-inflammatory cytokines 
and mediators have been unsuccessful (Angus & Crowther, 2003; Eichacker et al, 2002). 
While immunotherapy has been introduced for sepsis, it is important to closely monitor 
the innate and adaptive immune functions, especially in patients with demonstrable 
immunosuppression (Hotchkiss & Opal, 2010). 
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Despite extensive basic research and clinical studies, the pathophysiology of 
sepsis is still poorly understood. During sepsis, homeostasis between the various 
biological systems of the inflammatory network is highly imbalanced. The inflammatory 
response in sepsis is initiated as part of the early host defense mechanism to clear 
invading bacteria, by neutrophils, monocytes-macrophages and dendritic cells (Poltorak 
et al, 1998). These immune cells express pattern recognition receptors (PRRs) that bind 
conserved molecular structures named pathogen-associated molecular patterns (PAMPs) 
shared by foreign microorganisms (Figure A). During sepsis, the releases of large 
amount of PAMPs trigger immune cells to produce excessive amounts of pro-
inflammatory mediators, free radicals and enzymes, which convert the normally 
beneficial effects of inflammation into excessive responses that damage the host. The 
sustained pro-inflammatory environment affects the functional state of immune effector 
cells, eventually causing the dysfunction of neutrophils and immunoparalysis. Alterations 
in leukocyte apoptosis in the later stages of sepsis further account for immunosuppression, 












Figure A The inflammatory network in sepsis. During sepsis, homeostasis between  the 
various biological systems of the inflammatory network is highly imbalanced. In the 
initiation of sepsis, the release of a large amount of pathogen-associated molecular 
patterns (PAMPs) or damage-associated molecular  patterns (DAMPs) from invading 
microorganisms or/and damaged host tissue results in  the overstimulation of pattern-
recognition receptors (PRRs) on immune cells. Activated  immune cells release excessive 
amounts of pro-inflammatory mediators (resulting in a  ‘cytokine storm’), free radicals 
and enzymes, which converts the normally beneficial  effects of inflammation into an 
excessive response that damages the host. (Reprinted from Rittirsch et al, Harmful 
molecular mechanisms in sepsis. Nature Reviews Immunology 8, 776-787,  2008, with 




Toll like receptor 4 (TLR4)-mediated recognition of lipopolysaccharide (LPS), a 
well-characterized PAMP that is found in the outer membrane of Gram-negative bacteria, 
is thought to be an important trigger of the inflammatory response in sepsis and studies 
have tried to identify the molecular targets in this pathway for therapeutic intervention 
(Medzhitov, 2001; Medzhitov & Janeway, 2000; Poltorak et al, 1998). Moreover, 
inflammatory mediators such as anaphylatoxin C5a, macrophage migration-inhibitory 
factor (MIF), Interleukin 17-A (IL17-A), and high-mobility group box 1 (HMGB1) have 
also been highlighted as harmful central hubs in sepsis (Rittirsch et al, 2008a; Rittirsch et 
al, 2008b; Ward, 2004). It has been postulated that crosstalk occurs between TLR4 and 
the complement system in the initiation of the inflammatory responses in sepsis 
(Riedemann et al, 2003a). C5a acts as a central mediator in sepsis by modulating 
coagulation cascade, TLR4-mediated responses and the release of cytokines (Flierl et al, 
2008a; Ward, 2004; Ward, 2010). MIF plays a pivotal role in regulating systemic and 
local inflammatory responses by linking the immune system with the endocrine system. 
Massive production of MIF is harmful in the acute phase of sepsis as plasma levels of 
MIF correlate with the severity of sepsis (Calandra et al, 2003; Calandra & Roger, 2003). 
IL-17A mediates pro-inflammatory responses by triggering the production of many other 
cytokines, such as Interleukin--1β (IL-1β), Interleukin-6 (IL-6) and Tumor necrosis factor 
alpha (TNFα), and provides crosstalk between lymphocytes and phagocytes. During 
experimental sepsis, γδ T cell-derived IL-17A promotes high levels of pro-inflammatory 
mediators and bacteremia, resulting in enhanced lethality. Hence, IL-17A may be a 
potential therapeutic target in sepsis (Flierl et al, 2008b; Weaver et al, 2007). 
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HMGB1 is a highly conserved nuclear protein, secreted by activated macrophages, 
monocytes and neutrophils (Lotze & Tracey, 2005) as well as necrotic cells to trigger 
inflammation (Scaffidi et al, 2002). HMGB1 acts as a potent pro-inflammatory cytokine 
and is involved in the delayed endotoxin lethality and SIRS (Huang et al, 2010). 
Extracellular HMGB1 stimulates the release of TNFα, IL-1β, and other inflammatory 
products by interacting with PRRs, such as TLRs and the receptor for advanced glycation 
end-products (RAGE) (Tang et al, 2009). Because of its pleiotropic effects on 
inflammatory responses and its late release in sepsis, it provides a wider time window for 
therapeutic intervention, Hence, targeting HMGB1 may be a promising therapeutic 
strategy. It has been shown that the blockade of HMGB1 or inhibition of RAGE 
significantly improves the survival of mice in models of endotoxaemia and experimental 
sepsis (Qin et al, 2006; Wang et al, 1999). 
In general, sepsis is a heterogeneous, dynamic disorder caused by imbalances in 
the ‘inflammatory network’. Hence, it is important to elucidate the molecular interactions 
that occur during sepsis as well as the nature of the dysregulated immune responses 
(Cohen, 2002; Rittirsch et al, 2008b).  
1.1.3. Animal models of sepsis 
The development and progression of sepsis is multi-factorial, and affects the 
cardiovascular, immunological and endocrine systems of the body. The complexity of 
sepsis makes the clinical study of sepsis and the development of therapeutics difficult. 
Animal models have been employed to create reproducible systems for studying the 
pathogenesis of sepsis and to facilitate the initial testing of potential therapeutic agents. 
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Currently, there are four commonly used sepsis animal models - (i) endotoxaemia, (ii) 
bacterial infection, (iii) caecal ligation and puncture (CLP) and (iv) colon ascendens stent 
peritonitis (CASP). The latter two models lead to the production of multiple bacterial 
flora, and closely mimic the septic human responses (Buras et al, 2005). All models have 
contributed significantly to our understanding of host defence mechanisms during 
infection, yet there are still caveats in some sepsis animal models. For example, 
endotoxicosis models with bolus injection of LPS induce a hypodynamic cardiovascular 
state and does not reproduce the haemodynamic changes observed in human sepsis and 
other infection models, thus continuous infusion of high dose of LPS is used to better 
mimic the responses in sepsis (Fink & Heard, 1990). The bacterial infection model 
usually leads to intoxication with endotoxins rather than a true model of infection, and 
there are different host responses infecting different body compartments. Both CLP and 
CASP models are termed as host-barrier disruption models because they involve the 
breaching of normal protective barriers that separate the sterile body compartments from 
foreign pathogens.  
The CLP animal model of sepsis 
The CLP model is considered the gold standard for sepsis research (Wichterman 
et al, 1980). A surgical procedure on the colon of the animal creates a leakage of faecal 
contents into its peritoneum to establish an infection with mixed bacterial species so as to 
provide an inflammatory source. Most importantly, the CLP model reproduces the 




Clinical trials on sepsis therapies  
Targeting bacterial toxins, host-derived mediators, as well as downstream 
processes such as coagulation and the endocrine responses have become potential 
therapeutic strategies for sepsis. Even though the therapies directed against these targets 
have shown dramatic effects in animal models, their impacts in human have been 
relatively modest. Anti-TNF antibodies, and drugs targeting activated protein C and 
corticosteroid have been tested in human clinical trials to treat severe sepsis (Fisher et al, 
1996; Keh et al, 2003; Rice et al, 2010; Spapen et al, 2010). However, only the 
recombinant activated protein C, or drotrecogin alfa (activated form), has achieved 
regulatory approval (Bernard et al, 2001; Rice & Bernard, 2004). Several factors have 
been identified and are responsible for the potential pitfalls involving the use of 
biological response modifiers in critically-ill sepsis patients (Minnich & Moldawer, 
2004). First, the physiological response in the stressed patient is complex. Second, the 
critically-ill patient population is heterogenous and important factors such as the age of 
the patient, associated co-morbidities, the nature of the original injury and the presence or 
absence of an ongoing injury can modulate the effectiveness of a specific therapy. Third, 
the timing of the therapeutic intervention can be difficult to standardize among patients 
and can often produce differing results. Fourth, the presence of genetic polymorphisms 
within the general population has identified subsets of individuals who may have 
different physiological responses to similar stresses. Thus, a better understanding of these 
issues will aid in improving the experimental design of clinical trials involving anti-




1.2 TLR4 signaling pathway 
Despite recent development of pharmaceutical drugs, inflammatory diseases still 
remain a major burden on humanity. These are mainly due to several critical issues such 
as the lack of responsiveness and resistance to the current drugs, problems in the delivery 
of the drugs, and the cost of biopharmaceuticals manufacturing. These lead to the search 
for new anti-inflammatory agents which can serve as alternatives or additional strategies 
to bypass the current problems. Advances in understanding the inflammatory signaling 
pathways have aided in the identification of new targets, notably in the pathways 
involving NF-κB, p38 MAP kinase, T lymphocyte activation and JAK/STAT. Other 
targets such as transcription factor complexes and components of pathways activated by 
TNF, TLRs and Nod-like receptors (NLRs) also present possibilities. The challenge is to 
weigh the benefits of one target relative to another, and to devise strategies to modulate 
them in a more effective way (Salomão et al, 2008). In the context of sepsis, TLR4 
signaling is the major signaling pathway. Hence, in this study, we will focus on TLR4 
and the molecules involved in TLR4-mediated signal transduction. 
1.2.1 LPS & TLR4 structures, functions, and signaling 
Toll like receptors (TLRs) signaling is one of the mechanisms by which the innate 
immune system senses the invasion of pathogenic microorganisms. TLRs recognize 
specific molecular patterns that are present in microbial components. So far, 11 members 
of TLR family have been identified in mammals. Stimulation through different TLRs 
induces distinct patterns of gene expression, which are important for the activation of 
innate immunity. In addition, they also instruct the development of antigen-specific 
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acquired immunity. Hence, understanding the molecular mechanisms mediating TLR 
signaling is of great importance for the identification of new targets to treat inflammatory 
disorders (Akira & Takeda, 2004; Medzhitov, 2001). TLRs, especially the TLR4 
signaling, are well evident in contributing to the pathogenesis of sepsis. 
Lipopolysaccharide  
 Lipopolysaccharide (LPS), which is ubiquitously displayed on the outer membrane of 
a Gram-negative bacterium, is a type of PAMPs which are conserved microbial structures 
uniquely displayed as patterns on the surface of the microbes (Beutler, 2004). Other PAMPS 
include lipoteichoic acids (LTA) on Gram positive bacteria and β-1,3-glucans on fungi, 
bacterial flagellin, peptidoglycan (PGN) and nucleic acids such as double stranded RNA and 
single stranded RNA or unmethylated CpG motifs released by viruses. These PAMPs may be 
specifically recognized by the immune-sensing proteins in the infected host, which then elicit 
host immune responses. 
LPS is vital to both the structural and functional integrity of Gram-negative bacteria, 
and contains several well-conserved domains (Erridge et al, 2002). LPS is made up of a lipid 
A portion, which is the endotoxic component, a core oligosaccharide and an “O-antigen” 
which is also a carbohydrate. The lipid A portion consists of phosphorylated diglucosamine 
and four to seven acyl chains. Synthetic lipid A moieties consisting of six lipid chains and 
two phosphate groups are optimal for endotoxicity (Erridge et al, 2002). The diglucosamine 
backbone is highly conserved, and the acyl chain length/substitution pattern is the primary 
determinant of endotoxicity. The core region can be further divided into the outer and inner 
cores due to the different sugars associated with these regions, and are known to exhibit 
moderate and low structural variabilities respectively. The “O-antigen” consists of a chain of 
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repeating units of oligosaccharide and is the most variable region (Carpenter & O'Neill, 
2009). 
Myeloid differentiation protein (MD)-2 has been recognized as a key molecule for 
LPS signaling. Recently, the crystal structure of TLR4–MD2 binding to LPS has been 
resolved. It shows that TLR4 and MD2 associate without LPS, but dimerization of the TLR4-
MD2 complex with another TLR4-MD2 complex only occurs following the binding of LPS. 
Hence, LPS is required for the dimerization of two TLR4-MD2 complexes (Park et al, 2009).         
LPS is one of the primary targets of the innate arm of the mammalian immune 
system. Recognition of LPS on foreign pathogens by immune cells such as monocytes 
and macrophages is vital in providing the host with a rapid recognition and reaction 
towards infection by Gram-negative bacteria. This rapid, innate response against LPS 
typically involves the release of pro-inflammatory mediators, such as TNFα, IL-6 and 
IL1β. When confined to the local sites of infection, the release of these pro-inflammatory 
mediators in moderate levels will benefit the host greatly by promoting inflammation and 
priming the immune system to eliminate the invading organisms. However, in conditions 
where there is excessive or systemic exposure of the body to LPS (i.e. when LPS enters 
the blood-stream), a systemic inflammatory reaction can occur, leading to multiple organ 
failure, shock and potentially death. Studies demonstrate that the majority of endotoxin 
exposure in these patients does not originate from the infection per se, but instead arises 






1.2.2 Adaptor proteins involved in TLR4 signaling pathways            
 
MyD88 
Myeloid differentiation Marker 88 (MyD88) is an adaptor molecule for the 
Toll/IL-1R pathway. MyD88 was originally isolated as a gene that is rapidly induced 
during the IL-6-stimulated differentiation of M1 myeloleukaemic cells into macrophages 
(Lord et al, 1990). The encoded protein has an amino (N)-terminal death domain (DD) 
which recruits interleukin-1 receptor-associated kinase (IRAK) to IL-1R complex 
through a DD–DD interaction upon stimulation. This pathway leads to activation of NF-
κB. MyD88 is involved in the inflammatory responses induced by IL-1, IL-18 and LPS. 
Targeted disruption of the MyD88 gene results in the loss of cellular responses to IL-1 
and IL-18, and MyD88 deficient mice lack responses to the bacterial product LPS that 
employs TLR2 and TLR4 as the signaling receptors. Recently, a second Toll/Interleukin-
1 receptor (TIR) domain-containing molecule MyD88-adaptor-like (Mal) has been 
identified due to its structural similarity with MyD88. MAL has a binding domain in its 
N-terminus that binds to phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P2). This 
mediates the recruitment of Mal to the plasma membrane and in particular to micro-
domains that contain TLR4. Similar to MyD88-deficient macrophages, toll-interleukin 1 
receptor (TIR) domain containing adaptor protein (TIRAP)/Mal-deficient macrophages 
show impaired inflammatory cytokine productions in response to TLR4 and TLR2 
ligands, but not to TLR3, TLR5, TLR7 and TLR9 ligands (Fitzgerald et al, 2001; Horng 
et al, 2002; Yamamoto et al, 2002). Therefore, TIRAP/Mal has been shown to be 
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essential for the MyD88-dependent signaling pathway via TLR2 and TLR4. So far, data 
highly suggested Mal as a bridging adaptor for MyD88. 
 
IRAK, TRAF, TRIF and TRAM 
 
Other important adaptor proteins include IRAK, TRAF, TRIF and TRAM. There 
are four members in the IRAK family: IRAK1, IRAK2, IRAK4 and IRAK-M in 
mammals (Janssens & Beyaert, 2003a). IRAK1 and IRAK4 have intrinsic kinase activity, 
whereas IRAK2 and IRAK-M have no detectable kinase activity. Tumor necrosis factor 
receptor-associated factor (TRAF) constitutes a family of six members (TRAF-1 through 
-6). In particular, TRAF6 is an important adaptor protein for both TNF-receptor 
superfamily and the TLR/IL-1R superfamily (Ye et al, 2002). TIR-domain-containing 
adaptor protein inducing IFN-β (TRIF) and TRIF related adaptor molecule (TRAM) have 
been identified through sequence homology in database searches (Sheedy & O'Neill, 
2007). They are important in the TLR4-mediated, MyD88-independent pathway. Similar 
to the role of Mal in the MyD88 signaling, TRAM functions as a bridging molecule that 
recruits TRIF to TLR4 for interferon-regulatory factor 3 (IRF3) activation. In response to 
TLR4 ligands, both TRIF-deficient and TRAM-deficient mice showed impaired 
activation of IRF3 and decreased expression of IFN-inducible genes (Yamamoto et al, 
2003). Studies indicate that both TRIF and TRAM are involved in TLR4-mediated 





1.2.3 TLR4-mediated MyD88-dependent and independent pathway 
The study of MyD88-deficient cells has revealed the existence of both MyD88-
dependent and MyD88-independent pathways in response to LPS (Figure B). In MyD88-
dependent pathway, MyD88 plays a crucial role and recruits IRAK4 to TLR4 and 
facilitates the IRAK4-mediated phosphorylation of IRAK1 upon stimulation (Zughaier et 
al, 2005). Activated IRAK1 associates with TRAF6, leading to the activation of two 
distinct signaling pathways. One pathway leads to activation of MAP kinases (MAPKs). 
Another pathway leads to the activation of the TAK1/TAB complex, to enhance the 
activity of the IκB kinase (IKK) complex. Once activated, the IKK complex induces the 
phosphorylation and subsequent degradation of IκB, which leads to nuclear translocation 







Figure B. TLR4 activates the MyD88-dependent and the TRIF-dependent pathways. 
TIRAP/Mal is required for the activation of MyD88 pathway where MyD88 recruits 
IRAK4 and TRAF6 upon ligand stimulation. TRAF6 activates 
TAK1/TAB1/TAB2/TAB3 complex which in turn activates the IKK complex consisting 
of IKKα, IKKβ and IKKγ/Nemo. This catalyzes IκBs and allows NF-κB to translocate 
into nuclei. TAK1 simultaneously activates the MAP kinase pathway, which results in 
phosphorylation and activation of AP-1. NF-κB and AP-1 control inflammatory 
responses by inducing pro-inflammatory cytokines. In Trif-dependent pathway, TLR4 
recruits TRAM and Trif, which interacts with TBK1. TBK1 together with IKKi mediates 
phosphorylation of IRF3. Phosphorylated IRF3 is dimerized and translocated into nucleus 
to bind DNA. TRIF also interacts with TRAF6 and RIP1, which mediate NF-κB 
activation. Activation of IRF3, NF-κB and AP-1 is required for induction of type I IFN, 
particularly IFNβ. (Adapted from Kawai T et al, TLR signaling, Cell death and 






TLR4-activated MyD88-independent pathway involves TRAM and TRIF (Figure 
B). TRAM is located at the plasma membrane via attachment of a myristate group, which 
lodges in the plasma membrane (Sheedy & O'Neill, 2007). Protein kinase C epsilon 
(PKCε) activates TRAM via phosphorylation thus allows its recruitment of TRIF. TRIF 
has distinct protein-interaction motifs that allow it to (directly or indirectly) recruit the 
effector proteins, TRAF-family-member-associated NF-κB -activator-binding kinase 1 
(TBK1), TRAF6 and receptor-interacting protein 1 (RIP1). TRAF6 and RIP1 then 
activate NF-κB by engaging different ends of TRIF. Activation of both NF-κB and IRF3 
contribute to the activation of the IFN-β genes. Recently, the fifth adaptor SAM and 
ARM-containing protein (SARM) has been assigned as a negative regulator of NF-κB 
and IRF activation in TLR signaling (Carty et al, 2006). 
In the clinical aspect, several drugs now target the TLR4/MD-2 signaling pathway. 
For example, eritoran, structurally similar to LPS lipid A, acts as TLR4 antagonist and 
binds to the TLR4/MD-2, thus blocks the excessive reaction triggered by this receptor 
(O'Neill et al, 2009). Other drugs include small molecular inhibitor TAK-242 (resatorvid) 
targets the signaling domain of the TIR (Rice et al, 2010). However, controversial studies 
have suggested that using a partial agonist instead of an antagonist to decrease TLR4 
activity. This is to allow some activation of TLR4 to remain so as to stimulate protective 






1.3. Cytokines and Chemokines: 
       Cytokines and chemokines are small, secreted proteins produced de novo in 
response to immune stimuli and they are often produced in a cascade by virtue of their 
ability to function in synergistic, antagonistic, paracrine, or autocrine fashion (Borish & 
Steinke, 2003). Cytokines and chemokines are involved in numerous aspects of cell 
growth, differentiation, and activation. There are several ‘pro-inflammatory cytokines’, 
but considerably fewer ‘anti-inflammatory cytokines’ known so far. The classic pro-
inflammatory cytokines include Interleukin-1 (IL-1), tumor necrosis factors (TNF), 
Interleukin-6 (IL-6), Interleukin-12 (IL-12), granulocyte macrophage colony-stimulating 
factors (GM-CSF), and interferons (IFN) which can induce both acute and chronic 
inflammatory responses. Cytokines are able to regulate vascular changes in inflammation 
(Ferrara et al., 1991). Chemokines contribute to inflammation by regulating the 
chemotaxis of neutrophils and subsequently macrophages, lymphocytes, eosinophils and 
other immune cells.  
1.3.1. Cytokines 
A prominent feature of cytokines is their effects on the immune system with 
regards to cell trafficking and development of immune tissues and organs. Every cytokine 
has numerous functions, depending on the cellular source, target, and specific phase of 
the immune response during which it is presented. Numerous cytokines have both pro-
inflammatory and anti-inflammatory potentials, depending on the immune cells present 
and their state of responsiveness to the cytokine (Borish & Steinke, 2003). Cytokines 
exert their effects by binding to cytokine receptors on the target cells. All cytokine 
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receptors have one or more transmembrane proteins whose extracellular portions are 
involved in ligand binding. The cytoplasmic portions of the cytokine receptors are 
responsible for transducing the downstream signaling.  
The cytokine-activated JAK/STAT pathway 
 A common pathway triggered by cytokine receptors is the JAK/STAT pathway 
(Shuai & Liu, 2003). Dysregulation of the JAK–STAT signaling is associated with 
various immune disorders. Binding of cytokines to their receptors leads to the activation 
of receptor-associated tyrosine kinases, known as Janus kinases (JAKs). There are four 
members of the JAK family: JAK1, JAK2, JAK3 and TYK2. Activation of cytokine 
receptors results in receptor dimerization and stimulation of receptor associated JAKs 
which in turn phosphorylate tyrosine residues in the receptors’ cytoplasmic domain. This 
leads to the recruitment of several proteins with SH2 domains, including members of a 
family of DNA binding proteins known as signal transducers and activators of 
transcription (STAT). STAT family of transcription factors includes seven members: 
STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b and STAT6. Different cytokines 
activate different combinations of JAKs and STATs. Activation of the JAK/STAT 
pathway results in the stimulation of transcription of cytokine-responsive genes and thus 
provides a rapid membrane to nucleus mechanism for the regulation of gene expression 
(Shuai & Liu, 2003; Tan & Rabkin, 2005). 
1.3.2. Chemokines 
Chemokines, a subset of cytokines, are small molecules (8 to 12 kD), which direct 
the migration of leukocytes (chemotaxis), activate inflammatory responses, and 
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participate in the regulation of tumor growth (Steinke & Borish, 2006). Chemokines were 
originally described as indicators of inflammation, since they are either produced at the 
site of infection or in response to a pro-inflammatory stimulus. They act to recruit and 
activate leukocytes in order to mount an immune response and initiate wound healing. 
Interleukin 8 (IL-8/CXCL8) is the first chemokine identified as being able to stimulate 
endothelial cell chemotaxis, proliferation, and angiogenesis in vivo (Borish & Steinke, 
2003). Other functions of chemokines include regulation of adaptive immune responses 
such as lymphocyte trafficking and hematopoiesis. To date, 52 chemokines and 20 
chemokine receptors have been described. Chemokines mediate their functions by 
interacting with G protein-coupled receptors (GPCRs). The majority of chemokine 
receptors can bind to more than one chemokine, hence allowing extensive overlapping 
and a redundancy in functions (Luster, 1998). 
1.3.3. Roles of cytokines and chemokines in inflammatory diseases 
Cytokines and chemokines orchestrate the innate and adaptive responses to 
infection. However, the un-regulated production of these factors results in serious 
pathological consequences. For example, it is reported that the balance of inflammatory 
cytokines relates to the severity and mortality of murine sepsis (Walley et al, 1996). 
Multiple genome-wide association studies have also found that the polymorphisms and 
mutations of cytokine receptors and their signaling components are associated with 
autoimmune disorders such as diabetes and multiple sclerosis (O'Shea & Murray, 2008). 
In the clinical setting, the cytokine profile of patients provides a useful indication of their 
disease state. Studying cytokines and their receptors, as well as their signal transduction 
pathways, are useful for therapeutic development because of their wide array of 
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regulatory and effector functions. As such, cytokine-based therapies are increasingly 
being deployed to treat inflammation. Cytokine/anti-cytokine-based therapies are used in 
a wide range of infectious and autoimmune diseases such as Acquired Immune 
Deficiency Syndrome (AIDS) and rheumatoid arthritis, respectively (Cutler & 
Brombacher, 2005). Understanding cytokine signaling may advance our ability to 
manipulate both acute and chronic inflammatory diseases. 
1.4. Nuclear Factor-κB (NF-κB)  
NF-κB is a transcription factor that governs the expression of numerous genes 
that are important for various cellular responses (Ghosh & Hayden, 2008; Senftleben et al, 
2001; Vallabhapurapu & Karin, 2009). Five mammalian NF-κB family members have 
been identified: NF-κB1 (also known as p105), NF-κB2 (also known as p100), RelA 
(p65), RelB (p50) and c-Rel. All family members share a highly conserved Rel homology 
domain (~ 300 amino acids) that is responsible for DNA binding, dimerization and for 
the ability to interact with IκBs, the cellular inhibitors of NF-κB. In resting cells, inactive 
NF-κB dimers associate with IκB, and are located in the cytoplasm via their N-terminus 
Rel-homolog domain, to prevent it from binding to the DNA.  
Two distinct NF-κB signaling pathways have been described. In the canonical 
(classical) NF-κB pathway, stimuli such as pro-inflammatory cytokines, bacterial and 
viral products, and stress signals like γ-radiation, ultraviolet light and oxidative stress 
induce the degradation of IκBα, leading to the nuclear accumulation of p50-p65 dimers 
that regulate the expression of immunoregulatory and anti-apoptotic genes. In the non-
canonical (alternative) NF-κB pathway, activating stimuli such as the lymphotoxin β 
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(LTβ) or B-cell-activating factor (BAFF), lead to phosphorylation of p100 by IκB kinase, 
followed by the processing of p100 to p52 and the nuclear accumulation of p52-RELB 
dimers (Ghosh & Hayden, 2008; Senftleben et al, 2001; Vallabhapurapu & Karin, 2009). 
NF-κB signaling in disease 
NF-κB signaling is of great implication in the pathogenesis of many inflammatory 
diseases. NF-κB controls the expression of genes that encode for pro-inflammatory 
cytokines (e.g., IL-1, IL-6, IL-17, and TNFα), chemokines (e.g., IL-8, MIP-1α, MCP1, 
RANTES, and eotaxin), adhesion molecules (e.g., ICAM, VCAM, and E-selectin), 
inducible enzymes (e.g., COX-2 and iNOS), growth factors, and some of the acute-phase 
proteins and immune receptors, all of which play critical roles in controlling the 
inflammatory processes (Pervaiz & Holme, 2009). Hyper-activation of NF-κB is 
frequently seen in human diseases with underlying chronic inflammatory conditions, such 
as pulmonary, cardiovascular, neurodegenerative and skin etiologies. The activation of 
NF-κB has a central role in both the development and perpetuation of autoimmune 
diseases such as arthritis, multiple sclerosis and Crohn’s diseases (Ahn et al, 2007). 
Nonetheless, the loss of NF-κB activation also results in the development of diseases 
such as incontinentia pigmenti and anhidrotic ectodermal dysplasia (Courtois & Gilmore, 
2006). 
Given that the hyper-activation of NF-κB has a central role in the development 
and progression of cancer and chronic inflammatory disorders, a substantial amount of 
effort has been put in to develop strategies that block NF-κB signaling. NF-κB inhibitors, 
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which include small molecules, biologics, inhibitory peptides, antisense RNAs and 
natural compounds, block various steps leading to NF-κB activation and can be classified 
into those that (i) block the upstream signaling players of IKK, (ii) block IKK activity, 
(iii) block IkBα degradation or (iv) prevent the nuclear translocation of NF-κB 
(Tergaonkar, 2006). Because of the well-established pro-inflammatory functions of NF-
κB, anti-inflammatory effects may be achieved by inhibiting its signaling pathway. 
However, recent studies in mice models have shown provocative results.  Studies show 
that the inhibition of NF-κB activity in epithelial cells (skin and intestinal epithelial cells 
and in liver parenchymal cells) results in the spontaneous development of severe chronic 
inflammatory conditions (Pasparakis, 2009). These effects seem to be tissue specific, as 
NF-κB inhibition in other organs did not have similar effect. Therefore, a balanced NF-
κB signaling in immune cells and non-immune cells is essential for the maintenance of 
immune homeostasis. 
1.5. Mitogen activated protein kinase (MAPK) pathway  
 
 
          The MAPK pathway plays important roles in physiological and pathological 
responses such as proliferation, differentiation, stress responses, inflammation, growth 
arrest and apoptosis (Wada & Penninger, 2004). It can be activated in response to diverse 
stimuli in many cell types, particularly in immune cells. MAPKs are a family of serine 
and threonine protein kinases with well-conserved evolutionary functions. The pathway 
consists of three sequentially activated kinases (MKKKs, MKKs, MAPKs), which are 
themselves regulated by phosphorylation. MAPK kinase kinases (MKKKs) 
phosphorylate and activate specific MAPK kinases (MKKs). MKKs then phosphorylate 
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and activate MAPK through dual phosphorylation on threonine and tyrosine residues. 
Activated MAPK in turn phosphorylate and activate various substrates (Katz et al, 2007). 
Dual-specificity phosphatases (DUSPs) are a subset of protein tyrosine phosphatases, 
many of which dephosphorylate threonine and tyrosine residues on MAPKs, and are 
referred to as MAPK phosphatases (MKPs). The regulated expression and activity of 
DUSP family members in different cells and tissues controls the intensity and duration of 
the MAPK pathway to determine the type of physiological response. For immune cells, 
DUSPs regulate responses in both positive and negative ways, and DUSP-deficient mice 
have been used to identify individual DUSPs as key regulators of immune responses 
(Jeffrey et al, 2007; Owens & Keyse, 2007). 
 Three well-characterized subfamilies of MAPK have been identified. These 
include the extracellular signal-regulated kinases (ERK), ERK1 and ERK2; the c-Jun 
NH2-terminal kinases (JNKs), JNK 1, JNK 2, and JNK 3; and p38 enzymes, p38α, p38β, 
p38γ, and p38δ. The ERK 1/2 pathway is a widely studied MAPK pathway, which is 
activated by various stimuli such as by growth factors, cytokines, ligands for GPCRs and 
tyrosine kinase receptors, transforming agents and carcinogens. The ERK kinases are 
activated by the MKK1 and MKK2, which can be activated by Ras via the Raf group of 
MKKK. Activated ERK 1/2 phosphorylate and regulate the activities of a large number 
of substrates such as nuclear and cytoplasmic proteins and transcription factors (Roberts 
& Der, 2007). Activation of the p38 cascade is initiated by MAPKKKs such as TGFβ-
activated kinase 1 (TAK-1) and apoptosis signal-regulating kinase 1 (ASK-1), which then 
phosphorylate MAPKKs MKK3 and MKK6. Downstream substrates of phosphorylated 
p38 include transcription factors, nuclear histones and heat shock proteins (Pelaia et al, 
25 
 
2005). The JNK pathway is activated by MKK4 and MKK7. The major consequences of 
activating the JNK pathway is the phosphorylation of DNA binding protein called c-Jun. 
c-Jun is normally present in the cytoplasm and translocates to the nucleus upon 
phosphorylation, where it binds with c-Fos to form activator protein-1 (AP-1) complex, 
which then binds DNA and promotes transcription. AP-1 complex contributes to the 
control of many cytokine genes and is activated in response to environmental stress, 
radiation, and inflammatory cytokines (Johnson & Lapadat, 2002). 
 
MAPK signaling in diseases 
MAPKs are pivotal for processes that are central to inflammatory responses such 
as cytokine production by immune cells. This is achieved through the activation of 
transcription factors, and through the stabilization of inflammatory cytokine mRNA using 
adenosineuridine-rich elements (AREs) (Mahtani et al, 2001). One study showed that the 
TNFα induction by LPS is regulated post-transcriptionally by a Tpl2/ERK-dependent 
pathway (Dumitru et al, 2000). MAPKs such as p38 is involved in the initiation of TNF 
translation and promotes transcriptional activation of IL1A and IL1B in LPS-stimulated 
macrophages, and specifically regulates IL-12 and IFN production in cells (Park et al, 
2002). MAPKs such as JNK is also required for the production of many cytokines, 
including type I IFNs and IL-6, following its activation by LPS or inflammatory 
cytokines (Dong et al, 2002). 
MAPKs are also important signaling elements for cell migration. JNK regulates 
paxillin, a cytoskeletal protein involved in cell motility, and controls cell migration 
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(Huang et al, 2003). This process is essential for the recruitment of leukocytes to the 
inflammatory lesion. ERK regulates cell motility by controlling both cell adhesion and 
detachment at the trailing end (McLean et al, 2005). The survival and lifespan of 
leukocytes are carefully controlled by MAPKs to ensure that the effects of inflammatory 
mediators do not harm the host. In general, ERK1/2 promotes cell survival, whereas p38 
and JNK promote apoptosis (Wada & Penninger, 2004). p38 specifically promotes the 
cell death of CD8+ T cells but not CD4+ cells by suppressing B-cell CLL/lymphoma 2 
(BCL-2). JNK is involved in the Fas-mediated cell death as well as the Bax-mediated 
apoptosis by releasing Bim to suppress the pro-survival factors BCL-2 and BCL-XL. On 
the other hand, the ERK-mediated phosphorylation of Bim inhibits its pro-apoptotic 
function and marks it for proteasomal degradation (Harada et al, 2004; Suzuki et al, 
2002). In addition, the roles of MAPKs have been studied extensively in T cells, in 
particular for T-cell development in the thymus, CD4+ T-cell differentiation to T helper 1 
(TH1) and TH2 cells, and T-cell proliferation (Berenson et al, 2006; Rincón et al, 2000). 
Owing to the pleiotropic roles played by MAPK in immune cells, pharmacological 
interruption of its signal-transduction may be effective for modifying inappropriate cellular 
immune responses. Therefore, numerous MAPK pathway inhibitors, particularly p38 
inhibitors, are currently in clinical trials for treatment of chronic inflammatory diseases 
(Kumar et al, 2003; Sweeney, 2009). 
 
1.6. Lipid modifying enzymes as signaling molecules 
         Besides their roles in maintaining the structural integrity of the cells, lipids have 
emerged as critical players in various signaling pathways. For example, eicosanoids, 
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phosphoinositides, sphingolipids and fatty acids control important cellular processes, 
such as cell proliferation, apoptosis, metabolism and migration. Extracellular signals 
from cytokines, growth factors and nutrients control the activity of a key set of lipid-
modifying enzymes: phospholipases, prostaglandin synthase, 5-lipoxygenase, 
phosphoinositide 3-kinase, sphingosine kinase and sphingomyelinase. These enzymes 
and their downstream targets constitute a complex lipid signaling network with multiple 
nodes of interaction and cross-regulation. Imbalances in this network contribute to the 
pathogenesis of human disease (Wymann & Schneiter, 2008). 
1.6.1. Phospholipase D (PLD) 
Properties of PLD 
In the mammalian system, PLD is an enzyme that hydrolyses phosphatidylcholine 
(PC) to form a potent second messenger phosphatidic acid (PA), and choline, a relatively 
inert head group (Figure C) (Exton, 1998). By itself, PA can function as a second 
messenger and act on target proteins. PA is readily metabolized by dephosphorylation by 
phosphatidic acid phosphohydrolase (PAP), to generate DAG. PA can also be 
metabolized by PA-specific phospholipase A (PLA) to lysophosphatidic acid (LPA). PA, 
LPA and DAG have effects on multiple cellular pathways, including intracellular vesicle 
trafficking, endocytosis, exocytosis, actin cytoskeleton dynamics, cell proliferation, 
differentiation, migration and survival (Jenkins & Frohman, 2005; Rudge & Wakelam, 
2009). Studies demonstrate that PA can directly activate phospholipase C (PLC) 
(Jackowski & Rock, 1989), protein kinases (Rizzo et al, 1999), protein tyrosine 
phosphatase (Cui & English, 1997), phosphoinositide 4-kinase (PI4K) (Moritz et al, 
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1992), and sphingosine kinase (SphK) (Olivera et al, 1996). PA triggers oxidative 
respiratory burst via the neutrophil-NADPH oxidase (Waite et al, 1997), as well as 
stimulating the mobilization of calcium from intracellular stores (Xu et al, 1996). 
Intracellular DAG is a well-known activator of conventional and novel PKC isoforms 
(Hug & Sarre, 1993). DAG produced from the PLD pathway is in the mono or 
unsaturated form rather than the polyunsaturated form generated via the classical 
hydrolysis of PIP2 by PLC. Even though all DAG species can activate PKC in vitro, it 
has been suggested that only the polyunsaturated DAGs can activate PKC in intact cells 





























Figure C. PLD-catalyzed hydrolysis and metabolic pathway. PLD hydrolyzes PC in 
the presence of water to generate PA and free choline. PA is further metabolized by a few 
mechanisms. By itself, PA can function as a second messenger and act on target proteins. 
PA is also readily metabolized by dephosphorylation via phosphatidic acid 
phosphohydrolase (PAP), to generate DAG. PA can also be metabolized by PA-specific 
phospholipase A (PLA) to lysophosphatidic acid (LPA), which can then act on G protein-
coupled receptors (GPCRs).Diacylglycerol kinase (DGK) converts DAG to PA and lyso-
phosphatidic acid acyltransferase (LPAAT) converts LPA back to PA. Diagram drawn 
with reference to Jenkins GM, Frohman MA (2005) Phospholipase D: a lipid centric 




There are two major isoforms of PLD (PLD1 and PLD2) and a few splice variants 
of the isoforms have been identified so far (Cadwallader et al, 2004; Iyer et al, 2006; 
Locati et al, 2001; Melendez et al, 2001). The two PLD isoforms show approximately 
50% amino acid sequence identity. They have distinct cellular functions and have been 
reported to associate with different immune cell types. PLD1 has been associated with the 
activation of monocytes/macrophages, neutrophils and mast cells (Cadwallader et al, 
2004; Iyer et al, 2006; Locati et al, 2001; Melendez et al, 2001), whereas PLD2 has been 
associated with responses in T lymphocytes (Hamdi et al, 2008; Mor et al, 2007). PLD1 
and PLD2 are both expressed in most tissues and cell lines, but have different subcellular 
locations. The cellular locations of the mammalian PLD isozymes are controversial. In 
general, over-expressed PLD1 exhibits a perinuclear and punctate cellular distribution 
and has been reported to be present in the Golgi, endoplasmic reticulum, early endosomes, 
lysosomes, secretory granules and the plasma membrane (Brown et al, 1998; Emoto et al, 
2000; Kim et al, 1999). Over-expressed PLD2 appears to be localized to the plasma 
membrane, but there is evidence that the endogenous enzyme is associated with the Golgi 
(Park et al, 2000; Vitale et al, 2001). 
Transphosphatidylation reaction to measure PLD activity 
The ability of PLD to catalyze a transphosphatidylation reaction is a unique 
property of this enzyme (Figure D) (Yang et al, 1967). The PLD-catalyzed reaction is 
based on a phosphatidyl group transfer reaction. Normally, the phospholipid substrate 
acts as a phosphatidyl group donor and water acts as the phosphatidyl acceptor. However, 
in the transphosphatidylation reaction, a short-chain primary aliphatic alcohol, such as 
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ethanol or butan-1-ol, serves as the phosphatidyl group acceptor and results in the 
generation of a phosphatidylalcohol. This is because primary alcohols are at least a 1000-
fold more nucleophilic compared with water. In contrast, secondary and tertiary alcohols 
have no access to the binding pocket of PLD because of their steric hindrance and thus, 
are generally used as a control for non-specific effects (Dawson, 1967). The non-
naturally occurring phospholipids generated, phosphatidylethanol (PtdEtOH) and 
phosphatidylbutanol (PtdBut), are produced only by PLDs and due to their unique origin, 
low basal levels and relative metabolic stability, the formation of phosphatidylalcohols 
serves as a more quantitative, convenient, sensitive and an unequivocal marker for 
determining cumulative PLD activity (Exton, 1998). As the alcohols shunt phosphatidyl 
moieties into phosphatidylalcohols, the formation of the second messenger PA is 
abrogated, resulting in the inhibition of many events, in various cell types, usually 
stimulated by receptor-directed agonists (Stutchfield & Cockcroft, 1993). Therefore, the 
transphosphatidylation reaction is commonly used as the gold standard for measuring the 
PLD activity in intact cells, as well as to study the downstream events triggered by PLDs 











Figure D. Transphosphatidylation of PLD. Following the cleavage of choline, the first 
part of the reaction involves the formation of a PA-PLD intermediate by covalent linkage 
of PA to the histidine, present in the catalytic pocket of PLD. Either water or a primary 
alcohol (butan-1-ol) can act as a nucleophile in the second stage of the reaction. In the 
presence of water, the reaction product is phosphatidic acid (PA), whereas in the presence 
of primary alcohol, the product is a phosphatidylbutanol. Reprinted from Cockcroft, 
Signaling roles of mammalian phospholipase D1 and D2 (2001) Cell Mol Life Sci. 58 









Activation and Regulation of PLD 
          PLD activity can be regulated by phosphoinositides, protein kinase C (PKC), ADP- 
ribosylation factor (ARF), Rho GTPases, protein phosphorylation and lipidation (Exton, 
2002; McDermott et al, 2004; Morris et al, 1997b). Both PLD1 and PLD2 require PIP2 
for activity and PIP2 is postulated to play a role in anchoring PLD to membranes for its 
function. Although other phosphoinositides like PIP3 may also regulate PLD activity, 
none are as effective as PIP2 (Liscovitch et al, 1994). Early studies of PLD activation by 
phorbol esters in various cell types implicated PKC in its regulation. Interestingly, in 
vitro studies demonstrated that PKC could activate PLD in the absence of ATP and 
phosphorylation and the activation of PLD1 in vitro was observed with only the α- and β-
isozymes of PKC. Moreover, PLD1 was shown to be activated by PKCα in vitro whereas 
PLD2 was not (Du et al, 2000). The interaction between PKCα and PLD1 predominantly 
involves the N-terminus and the deletion of the N-terminus of PLD1 leads to a loss of 
activation by PKCα in vitro or by phorbol ester in vivo (Walker et al, 2000). There 
appears to be multiple sites on PKCα that are involved in the interaction with PLD1 
because neither the regulatory or catalytic domain alone can activate PLD1. It may be 
possible that the PKC holoenzyme is required for this interaction with PLD (Exton, 1997).  
           PLD activity is also regulated by two subfamilies of GTPases, Rho and Arf, in the 
Ras superfamily. In the Rho family, RhoA, Rac1 and Cdc42Hs activate PLD1, but not 
PLD2. Several studies have localized the interaction site for Rho proteins on PLD1 to a 
sequence in the C-terminus (Cai & Exton, 2001). The residues involved in the PLD1 
activation in RhoA are located in the activation loop (Switch 1) of this GTPase (Brown et 
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al, 1995). Arf was the first direct regulator of PLD1 to be recognized (Nakamura et al, 
2005). All mammalian isoforms of Arf can activate the enzyme in vitro and the 
myristoylated forms are more active than the unmodified forms. PLD2, however, shows 
little or no response to Arf (Jones et al, 1999). In conclusion, PLD1 is regulated in vivo 
and in vitro by PKC and small G proteins of the Rho and Arf families whereas PLD2 has 
a high basal activity and is not affected by PKC, Rho or Arf proteins in vitro.  
PLD in signaling and diseases 
 PLD has been shown to be a key intracellular signaling molecule that is involved 
in a wide range of immune cell signaling and responses (Gomez-Cambronero, 2010; 
Gomez-Cambronero & Keire, 1998; Jenkins & Frohman, 2005; Melendez & Allen, 2002). 
In neutrophils, monocytes and macrophages, PLD has been implicated in the NADPH 
oxidative burst, calcium release, Fcγ receptor-mediated phagocytosis, degranulation, 
vesicular trafficking, chemotaxis, cytokine release, matrix metalloproteinase (MMP) 
release and activation of the mitogen-activated protein kinase (MAPK) pathway (Ibrahim 
et al, 2004; Issuree et al, 2009; Sethu et al, 2008). PLD also plays a role in degranulation 
and TNF-α production in natural killer cells. PLD plays an important role in the signal-
activated leukocyte chemotaxis (Cathcart, 2009). With the development of isoform- 
specific inhibitors from in vivo work and in knockout mice models, the roles of PLDs 
have been investigated in many pathological conditions such as cancer metastasis, 
hypertension, thrombosis, neurodegenerative disease, and infectious viral disease (Huang 
& Frohman, 2007; Peng & Frohman, 2011).  
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 Previous studies have identified the important roles of PLD in pro-inflammatory 
mice models such as C5a induced peritonitis model and TNFα mediated murine 
peritonitis (Ibrahim et al, 2004; Issuree et al, 2009; Sethu et al, 2008). TNFα-triggered 
temperature changes, cytokine and chemokine production, vascular permeability, cell 
adhesions molecule expression and neutrophil and monocyte infiltration into the 
peritoneal cavity, are inhibited in the PLD1 knock-down mice. Therefore, PLD1 is 
important to promote inflammation and therefore many studies have tried to employ 
genetic manipulations such as knocking down with siRNA in combination with the use of 
small molecule inhibitors of PLD as potential therapeutic strategies to treat inflammatory 
diseases. 
1.6.2 Sphingosine Kinase (SphK) 
Properties of SphK 
 Sphingolipids, in the recent years, have been shown to be potent signaling 
molecules. The sphingolipid signaling mediators including ceramide and sphingosine-1-
phosphate (S1P) are potent bioactive molecules associated with both physiological and 
pathological responses. They are major contributors in cellular processes such as 
proliferation, apoptosis and differentiation (Kee et al, 2005; Maceyka et al, 2005; 
Melendez, 2008; Spiegel & Milstien, 2003). The sphingolipid biosynthetic pathway is 
complex, with several points of modulation and regulation (Figure E) (Kee et al, 2005). 
The pathway is initiated with the hydrolysis of the major membrane sphingolipid, 
sphingomyelin, by sphingomyelinase to form ceramide. The generated ceramide serves as 
the precursor of other bioactive sphingolipids. Ceramide can be hydrolyzed by 
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ceramidases to form sphingosine, which is then phosphorylated by sphingosine kinase 
(SphK) to form S1P. S1P can be dephosphorylated to sphingosine by S1P 
phosphohydrolase, or by irreversible cleavage to ethanolamine phosphate and 
hexadecanal by S1P lyase (Ohanian & Ohanian, 2001). SphK and ceramidase are key 
enzymes in the sphingolipid metabolism, as they function as essential checkpoints that 
modulate the relative levels of S1P, sphingosine and ceramide, which determines cell fate. 
Alterations of the ceramide/S1P rheostat would result in the dysregulation of cellular 
functions (Kohama et al, 1998). 
The mammalian forms of SphK are encoded by two genes: SphK1 and SphK2. 
SphK1 has a lower molecular weight and exhibits higher enzymatic activity than SphK2 
(Maceyka et al, 2005). Both SphK1 and SphK2 phosphorylate erythro-sphingosine, 
dihydrosphingosine and phytosphingosine. Analogs of sphingosine, such as DL-threo-
dihydrosphingosine (DHS) and N,N-dimethylsphingosine (DMS) are the best known and 
commonly used competitive inhibitors of SphK (Buehrer & Bell, 1993). SphKs possess a 
unique kinase catalytic domain, an ATP-binding site and as well as five conserved 
domains (Melendez et al, 2000). The two SphK isoforms have distinct cellular functions 
due to the differences in kinetic properties, tissue distribution and temporal expression 








Figure E. Metabolic pathway of Sphingolipid. Hydrolysis of the membrane 
sphingolipid, sphingomyelin, leads to generation of ceramide, which can be further 
metabolized to sphingosine. SphK phosphorylates sphingosine into sphingosine-1-
phosphate (S1P), which is either cleaved by S1P lyase to palmitaldehyde and 
ethanolamine phosphate, or dephosphorylated to sphingosine by S1P phosphohydrolase. 
Diagram drawn with reference to Taha TA, Hannun YA, Obeid LM (2006) Sphingosine 





Activation and Regulation of SphK 
 
SphK can be activated by various receptors at the plasma membrane including 
growth factors, such as epidermal growth factor (EGF), platelet derived growth factor 
(PDGF), nerve growth factor (NGF) and vascular endothelial growth factor (VEGF). 
Vitamin D3 and serum have been reported to activate SphK (Watterson et al, 2003). In 
immune cells, cytokines like TNFα, anaphylactic toxin C5a, chemotatic peptide formyl-
Methionyl-Leucyl-Phenylalanine (fMLP) and Fc receptors (FcεRI and FCγRI) have been 
reported to stimulate SphK activity (Kee et al, 2005). One study showed that the 
phosphorylation of SphK1 at its Ser225 site is required for activation and translocation of 
the enzyme (Pitson et al, 2003). Ca2+/calmodulin complex may also regulate SphK1 by 
affecting its subcellular localization (Young et al, 2003). More recently, SphK1 has been 
shown to bind to PA in vitro through a region within the C-terminal end of the protein. A 
role for PLD and its product PA in regulating the sub-cellular re-distribution of SphK1 
was demonstrated in vivo using antigen-stimulated mast cells (Delon et al, 2004). Other 
regulators of SphK include PKC, protein-protein interactions and proteolysis (Taha et al, 
2006).  
The level of bioactive product, S1P, is tightly regulated by SphK, S1P 
phosphohydrolase and S1P lyase and is maintained at low level under normal condition. 
S1P is able to act both as an extracellular stimulus through specific cell surface receptors, 
and as an intracellular second messenger through direct activation of signaling proteins. 
Extracellular S1P signals through GPCR, belonging to the endothelial-differentiating 
gene (EDG) family, also known as S1P receptors, of which there are five distinct 
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members. These ubiquitously expressed receptors couple to various G proteins that 
regulate many downstream events such as MAPK, PKC, and Rho pathways (Spiegel et al, 
2002; Takabe et al, 2008). Due to its ability to activate and stimulate a diverse array of 
signal transduction pathways in different cell types, as well as within the same cell, S1P 
can result in a wide range of biological responses, depending on the cell type, which G 
proteins are present, and the S1P receptor expression pattern. S1P has been implicated in 
various cellular responses, including cell migration, differentiation, mitogenesis and 
apoptosis (Pyne et al, 2009; Pyne & Pyne, 2010; Pyne, 2002). The role of SphK1 in 
regulating autocrine/paracrine signaling of S1P is well-established. Autocrine/paracrine 
signaling of S1P is able to block S1P receptor-mediated signaling due to down-regulation 
of S1P receptors in RBL mast cells (Jolly et al, 2005). 
 
 
SphK in signaling and diseases 
 
SphK has been demonstrated as an intracellular messenger in immune cells (Choi 
et al, 1996; Kee et al, 2005; Spiegel & Milstien, 2011). For example, in monocytes and 
macrophages, both FcγRI and C5a trigger SphK1 activity that is essential for Ca2+ 
mobilization from internal stores, chemotaxis, and degranulation and cytokine production 
(Sethu et al, 2008). More recently, it has been shown that TNFα mediates SphK 
activation and S1P generation in both U-937 cells and primary human monocytes(Sethu 
et al, 2008). By knocking down SphKs using siRNA, SphK1 was identified as the 
specific isoform that is responsible for Ca2+ mobilization, chemotaxis, degranulation and 
cytokine production. SphK also regulates neutrophil activation to provide essential 
defence against infections (Vlasenko & Melendez, 2005). Platelet-activating factor, 
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TNFα and substance P analog stimulate a rapid increase in SphK activity in freshly 
isolated human neutrophils and this activity is blocked by pre-incubation with SphK 
inhibitor DMS (MacKinnon et al, 2002). The knockdown of SphK1 also blocks the C5a 
induced chemotaxis, degranulation, superoxide generation (Ibrahim et al, 2004). Mast 
cells are key players in the inflammatory response during an allergic reaction as they 
release pro-inflammatory mediators. The IgE receptor mediated activation of mast cells, 
including its calcium release and downstream pro-inflammatory responses are shown to 
be mediated by S1P (Melendez & Khaw, 2002).  A more detailed study on the role of 
SphK isoforms on mast cell activation reported that SphK2 regulates mast cell activation 
and that SphK1 increases the susceptibility to antigen challenge (Olivera et al, 2007). 
Specific siRNA knockdown of the SphK isoforms found that SphK1 is the critical 
isoform that is involved in IgE/Ag induced degranulation, migration toward antigen, and 
chemokines MCP-1 (CCL2) secretion from mast cells (Oskeritzian et al, 2008). 
There is abundant evidence linking SphK and S1P with various inflammatory 
disorders. S1P sustains inflammation in the sepsis syndrome (Niessen et al, 2008b) and is 
elevated in the bronchoalveolar lavage (BAL) fluid from asthmatics (Jolly et al, 2002). 
Studies also demonstrate that the deletion or inhibition of SphK1 prevents sepsis in 
mouse models of LPS challenge or caecal ligation and puncture (O'Neill, 2010). SphK1 
expression is also increased in the lymphoblastoid cell lines derived from rheumatoid 
arthritis patients (Pi et al, 2006). S1P is released from platelets and contributes to the 
invasion of tissues by inflammatory cells, including mast cells (Jolly et al, 2002) and 
eosinophils (Roviezzo et al, 2004). In the animal models of inflammation, pre-treatment 
with SphK inhibitors reduces neutrophil activation (Lee et al, 2004) and airway 
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inflammation (Nishiuma et al, 2008). Both DMS and SphK1 knock-down significantly 
suppress the OVA-induced inflammatory infiltrates into the bronchoalveolar lavage and 
IL-4, IL-5, eotaxin, and serum OVA-specific IgE levels (Lai et al, 2008a). Interestingly, 
over-expression of wild type SphK1 protects SphK1-/- mice from lung injury and 
attenuates the severity of the response to LPS, suggesting a protective role for SphK1 in 
lung injury (Wadgaonkar et al, 2009). On the other hand, over-expression of SphK2 in 
SphK1-/- mice exacerbates the injury. This suggests that SphK2 activation plays a 
distinctly different role in the regulation of vascular injury, as compared to SphK1 
activation (Wadgaonkar et al, 2009). SphK also modulates chronic autoimmune 
conditions such as rheumatoid arthritis. However, SphK1 and Sphk2 play very distinct 
roles in the murine collagen-induced arthritis. Mice treated with SphK1 siRNA are 
protected against arthritis whereas mice received SphK2 siRNA develop a more 
aggressive disease form (Lai et al, 2008b; Lai et al, 2009). Besides their roles in 
immunity and inflammatory diseases, SphK and S1P are also well-implicated in cancer, 
hypoxia and neurodegenerative diseases (Milstien & Spiegel, 2006; Payne et al, 2002; 








1.7 Autophagy  
Autophagy is a highly conserved cellular degradation process in which portions of 
cytosol and organelles are sequestered into a double-membrane vesicle, an 
autophagosome, which is delivered into a degradative organelle, the vacuole/lysosome, 
for the breakdown and eventual recycling of the resulting macromolecules (Figure F) 
(Yang & Klionsky, 2009). The best-studied type of autophagy is known as macro-
autophagy, which is linked to the capacity of cellular housekeeping through the 
modulation of nutrition sensing, developmental or programmed cell death, endoplasmic 
reticulum stress and immunity in various pathologies, such as neurodegeneration, cancer, 














Figure F. The cellular process of autophagy. A portion of cytoplasm, including 
organells, is enclosed by a phagophore or isolation membrane to form an autophagosome. 
The formation of the pre-autophagosomal structure can be inhibited by the 
phosphatidylinositol 3-phosphate kinase (PI3K) inhibitor 3-methyladenine (3-MA).The 
outer membrane of the autophagosome subsequently fuses with the lysosomes, and the 
internal materials are degraded in the autolysosome. The process is inhibited by the H+-
ATPase inhibitor bafilomycin A1, or by microtubule inhibitors such as vinblastine and 
nocodazole (Adapted from Kondo Y et al, The role of autophagy in cancer development 
and response to therapy, Nat Rev Cancer. 2005 Sep;5 (9):726-34., with kind permission 




1.7.1 Induction and regulation of autophagy 
Using the microorganism yeast as a powerful genetic system, researchers have 
identified 31 autophagy-related (ATG) genes that are specifically involved in autophagy 
(Klionsky et al, 2010; Yang & Klionsky, 2010). Among these Atg proteins, one subset is 
essential for autophagosome formation, and is referred to as the ‘core’ molecular 
machinery (Klionsky, 2010). These core Atg proteins are composed of four subgroups: (i) 
the Atg1/unc-51-like kinase (ULK) complex; (ii) two ubiquitin-like protein (Atg12 and 
Atg8/LC3) conjugation systems; (iii) the class III phosphatidylinositol 3-kinase 
(PI3K)/Vps34 complex I; and (iv) two transmembrane proteins, Atg9/mAtg9 and 
associated proteins involved in its movement such as Atg18/WIPI-1 and VMP1. The 
recruitment of most core Atg proteins for autophagosome formation is termed the 
phagophore assembly site (PAS). Mammalian autophagy proceeds through a series of 
steps, beginning with the initiation at the PAS, followed by the elongation and expansion 
of the phagophore, closure and completion of the autophagosome, autophagosome 
maturation via docking and fusion with an endosome and/or lysosome, breakdown and 
degradation of the autophagosome inner membrane and cargo, and finally recycling of 
the resulting macromolecules (Mizushima, 2010). Atg8/LC3 is usually used as a marker 
to monitor autophagy. It is cleaved at its C terminus by Atg4 to generate the cytosolic 
LC3-I with a C terminal glycine residue, which is conjugated to 
phosphatidylethanolamine (PE) known as LC3-II. The lipidated form LC3-II is attached 
to both faces of the phagophore membrane, but is ultimately removed from the 
autophagosome outer membrane, which is followed by fusion of the autophagosome with 
a late endosome/lysosome (Xie & Klionsky, 2007; Yang & Klionsky, 2010). 
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Autophagy is regulated by a complex signaling network of various stimulatory 
and inhibitory signals. Firstly, the activation of growth factor receptors stimulates the 
class I PtdIns3K complex that leads to the activation of the PtdIns3K–PKB (Akt)–
mTORC1 pathway. Activation of the small GTPase Ras activates the downstream Raf-1–
MEK1/2–ERK1/2 pathway. Akt and ERK1/2 phosphorylate and inhibit the GTPase-
activating protein complex TSC1/TSC2, leading to the stabilization of Rheb-GTPase, 
which then activates mTORC1, causing the inhibition of autophagy (Sarbassov et al, 
2005). Secondly, metabolic stress, such as high AMP/ATP ratios resulting from energy 
depletion, or an increase in the cytosolic free Ca2+ concentration or cytokines, cause the 
AMP-activated protein kinase (AMPK) to be phosphorylated and activated by LKB1, 
CaMKKb, and TAK1, respectively. AMPK phosphorylates and activates TSC1/TSC2, 
thus leading to the inactivation of mTORC1 and subsequent autophagy induction 
(Papandreou et al, 2008). Genotoxic and oncogenic stresses result in nuclear p53 
stabilization and activation, thereby stimulating autophagy through the activation of 
AMPK or the up-regulation of damage-regulated autophagy modulator (DRAM). In 
contrast, cytosolic p53 has an inhibitory effect on autophagy (Maiuri et al, 2009; 
Tasdemir et al, 2008). Thirdly, antiapoptotic proteins, Bcl-2 or Bcl-XL, associate with 
Beclin 1 and inhibit the Beclin 1-associated class III PtdIns3K complex, inhibiting 
autophagy (Høyer-Hansen et al, 2007; Yang & Klionsky, 2010).  
Autophagy is involved in a wide range of human physiological conditions and 
suggested to promote longevity (Madeo et al, 2010). Autophagy is important in host 
immune defense in eliminating invasive pathogenic bacteria. Yet, in some cases, bacteria 
subvert this process for their own replication. Autophagy also contributes to endogenous 
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major histocompatibility complex class II antigen presentation, reflecting its role in 
adaptive immunity. In certain neurodegenerative diseases, which are associated with 
aggregation-prone proteins, autophagy plays a protective role in preventing or reducing 
cytotoxicity by clearance of the toxic proteins. However, the autophagy-dependent 
processing of some components correlates with the pathogenesis of certain myopathies 
(Huang & Klionsky, 2007). Moreover, autophagy is reported to promote longevity. 
Recently, the life span-prolonging effect of SIRT-1 has been suggested to be mediated by 
autophagy (Morselli et al, 2010a; Morselli et al, 2010b). 
1.7.2. Autophagy in immunity and inflammation 
          The immune system uses autophagy as an effector mechanism to clear intracellular 
pathogens as well as to monitor their products for any evidence of pathogen invasion and 
cellular transformation (Deretic & Levine, 2009; Levine et al, 2011b; Munz, 2009; Saitoh 
& Akira, 2010). At the same time, the immune system can be regulated by cellular 
machinery associated with protein degradation, which includes autophagy. Recent 
developments reveal a crucial role for the autophagy pathway and its proteins in 
immunity and inflammation. They appear to balance the beneficial and detrimental 
effects of immunity and inflammation, thereby protecting the host against infectious, 
autoimmune and inflammatory diseases (Deretic & Levine, 2009; Levine et al, 2011b; 
Munz, 2009; Saitoh & Akira, 2010). There is a complex reciprocal relationship between 
the autophagy pathway/proteins, immunity and inflammation. The autophagy proteins 
function in both the induction and suppression of the immune and inflammatory 
responses, while immune and inflammatory signals in turn function in the induction and 
suppression of autophagy (Delgado, 2009). Hence, defects in autophagy may underlie the 
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pathogenesis of many infectious diseases and inflammatory syndromes (Levine et al, 
2011a). 
         The autophagy pathway and/or proteins play key roles in controlling inflammatory 
signaling. Their major effects are on the regulation of inflammatory transcriptional 
responses. Increased levels of the adaptor protein p62 (SQSTM), which accumulates in 
autophagy-deficient cells, activate the pro-inflammatory transcription factor NF-κB 
through a mechanism involving TRAF6 oligomerization (Moscat & Diaz-Meco, 2009). 
The role of autophagy in human immunity is validated in the Crohn’s disease (CD), a 
form of inflammatory bowel disease. Studies have linked CD to the genes for the core 
autophagy factor ATG16L1 and an autophagy related factor, immunity-related GTPase 
family, M (IRGM) (McCarroll, 2008). In the murine models of chemically induced colitis, 
transgenic mice deficient in Atg16L1 have shown either increased pro-inflammatory (IL-
1β) signaling or Paneth cell deficiency. Atg16L1- or Atg7- deficient mouse macrophages 
produce increased levels of mature IL-1β and IL-18 after TLR4 stimulation by endotoxin 
(Cadwell et al, 2008). These studies suggest the primary anti-inflammatory role of 
autophagy. In addition, the autophagy pathway may prevent tissue inflammation through 
its role in apoptotic corpse clearance. Retinas and lungs of embryonic mice lacking Atg5 
have a defect in apoptotic corpse engulfment that is associated with the infiltration of 
inflammatory cells (Qu et al, 2007). There are also growing evidence that autophagy 
proteins may function in the TLR-mediated phagolysosomal pathways (Sanjuan, 2007). 
Autophagy-dependent functions in the dying cells and/or phagocytic cells may promote 
efficient corpse clearance, thereby limiting inflammation. Recently, a study has reported 
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that defective autophagy was detected at late stage of sepsis and this may contribute to 
the functional liver failure during polymicrobial sepsis (Chien et al, 2011). 
 
           Several studies have demonstrated specific interactions between immune signals, 
particularly the TLR pathway, and autophagy proteins. TLRs, MyD88 and TRIF are of 
great importance in the control of immunological autophagy (Delgado & Deretic, 2009; 
Delgado et al, 2008b; Shi & Kehrl, 2008). For example, the interaction between beclin 1 
and BCL2 (which inhibits autophagic activity) is thought to be disrupted by the TLR 
adaptors MyD88 and TRIF, as well as by HMGB1, which bind to beclin 1 and displace 
BCL2 (Kroemer et al, 2010; Tang et al, 2010; Tang et al, 2009). Both Atg5 and beclin 1 
are required for the induction of autophagy in macrophages after TLR7 stimulation. 
Although MyD88 is not required for the formation of GFP-LC3 dots after stimulation by 
zymosan, it is involved in the formation of GFP-LC3 dots after stimulation of TLR7 
(Delgado et al, 2008a; Sanjuan, 2007). Xu et al reported that TLR4 stimulation results in 
the PI3K-dependent formation of GFP-LC3 dots and enhances the elimination of 
mycobacteria in macrophage cell lines. The signal transducers, TRIF, RIPK1 (receptor-
interacting protein kinase 1), and p38, are required for the TLR4-induced formation of 
GFP-LC3 dots in macrophage cell lines (Xu, 2007). 
PLD and SphK are also implicated in autophagic processes. PLD1 knock-out 
mice exhibit dramatically decreased levels of autophagy (Dall'armi et al, 2010) even 
though they are viable and generally normal (Elvers et al, 2010). Autophagy catabolizes 
cellular proteins and organelles so as to generate energy and nutrients for cells under 
starvation conditions (Xie & Klionsky, 2007). In cell lines, PLD1 has been shown to co-
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localize with autophagosomes upon nutrient starvation. In addition, 5-fluoro-2-indolyl 
des-chlorohalopemide (FIPI), a PLD pharmacological inhibitor, decreases starvation-
induced autophagosome expansion and impairs autophage-mediated clearance of protein 
aggregation (Dall'armi et al, 2010). In wild-type mice deprived from food for 24 hours, 
autophagosome expansion was observed. In contrast, food starvation failed to enlarge the 
autophagosome compartment in the livers of PLD1 knock-out mice. It has been shown 
that over-expression of catalytically active SphK1 leads to an autophagic response. 
Knocking down Atg7 or SphK1 by siRNA is able to abolish starvation-induced 
autophagy (Lavieu et al, 2006). Moreover, a novel SphK inhibitor, ABC294640, has been 
shown to promote tumor cell autophagy, which ultimately results in non-apoptotic cell 
death and a delay of tumor growth in vivo (Beljanski et al, 2010). Another group has 
reported that Safingol (L-threo-sphingosine), which is also an inhibitor of SphK, induces 
autophagy directly in solid tumor cells through inhibition of PKC and the PI3K pathways 
(Coward et al, 2009). Taken together, these studies have demonstrated the involvement of 
PLD and SphK as signaling molecules in autophagic mechanisms. 
 
1.8 Resveratrol and its anti-inflammatory properties 
1.8.1 Resveratrol (RSV) 
 RSV, trans-3,5,4’-trihydroxystilbene, is a major active ingredient of stilbene 
phytoalexins, first isolated from the roots of the oriental medicinal plant Polygonum 
Capsidatum (Ko-ji-kon in Japanese) (Baur & Sinclair, 2006; Pervaiz, 2003). It is a 
natural polyphenolic, non-flavonoid antioxidant found in many plants including grapes, 
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nuts and berries. As a constituent of red wine, RSV is associated with multiple health 
benefits such as anti-inflammation (Figure G) and is used to explain the famous “French 
Paradox” ‐  the low incidence of heart disease among the French people despite the intake 
of relatively high-fat diet. In addition to anti-inflammatory property, RSV also exhibits 
antioxidant and antiproliferative properties (Clément et al, 1998; Das & Das, 2007). 
Extensive in vitro studies revealed multiple intracellular targets of RSV, which affect cell 
growth, inflammation, apoptosis, angiogenesis, and invasion and metastasis (Athar et al, 
2009). RSV has been shown to regulate cyclooxygenases in inflammation; cyclins, CDKs 
in cell cycle progression;  Bax, Bak, PUMA, Noxa, TRAIL, APAF, survivin, Akt, Bcl2 
and Bcl-X(L) in apoptosis and survival pathways and transcription factors NF-κB, AP-1, 
c-Jun, and c-Fos. Recently, human sirtuin Sirt-1 has also been shown to be a target of 
RSV in vitro (Bastin et al, 2011). In addition to its well-documented anti-oxidant 
properties, there is increasing evidence that RSV exhibits pro-oxidant activity under 
certain experimental conditions, resulting in oxidative DNA damage (Zheng et al, 2006).  
 However, the detailed molecular mechanisms by which RSV exerts such a wide 
range of beneficial effects are still unclear. Currently, studies are on-going to understand 
whether RSV exerts its effects via random interactions with multiple proteins inside the 
cells or through specific pathways. In signal transduction pathways, RSV regulates 
hormone signaling, growth factor signaling, second messengers, cAMP/cGMP-mediated 
signaling, PI3K/AKT signaling, MAP kinase signaling, JAK/STAT signaling and ion 

















Figure G: health benefits of resveratrol. 
 
 Being lipophilic in nature, RSV is able to cross plasma membranes and is well-
absorbed when given orally (Asensi et al, 2002). Pharmacokinetic studies of RSV have 
indicated that circulating RSV is rapidly metabolized (Wenzel et al, 2005). The main 
metabolites of RSV in mammals are RSV-3-sulfate, RSV-3-O-glucuronide, and 
dihydroresveratrol. Even though RSV has a relatively short half-life, its metabolites can 
be detected in the plasma for up to 72 hours. Yet, it is not clear whether the metabolites 
represent inactivated forms of the compound, act as resources for RSV release in specific 
tissues, or are themselves exerting health benefits. Therefore, caution should be taken 
when interpreting the physiological relevance of in vitro studies where high 
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concentrations of RSV are used. In vivo results then become critical in order to better 
understand how RSV exerts its efficacy in the treatment of different diseases. Baur et al 
provide a comprehensive review of the in vivo evidence demonstrating the therapeutic 
potential of RSV (Baur & Sinclair, 2006).  
1.8.2. Resveratrol in inflammation 
Many protective properties of RSV have been linked to the fact that it is an 
effective anti-inflammatory compound (Das & Das, 2007). It also exhibits effects at 
multiple phases of inflammation by acting on several types of immune cells including 
mast cells, neutrophils and macrophages. In vitro, RSV has been shown to be an effective 
inhibitor of cyclooxygenase activity which synthesizes pro-inflammatory mediators such 
as prostanoids and leukotrienes (Kundu et al, 2004). Via inhibition of the PI3K signaling, 
RSV inhibits respiratory burst in human monocytes (Poolman et al, 2005). Moreover, its 
effects have been well-studied in several in vivo animal models. Oral treatment with RSV 
ameliorates acute small intestinal inflammation by down-regulating Th1-type immune 
responses and prevents bacterial translocation (Bereswill et al, 2010). In a mouse model 
of C5a stimulated acute peritonitis, RSV modulates sphingosine kinase (SphK) and 
phospholipid D (PLD) activities, to attenuated the release of cytokines and chemokines 
such as IL-1β, TNF-α, IL-6, and MIP-1α (CCL3), thereby regulating neutrophil activity 
(Issuree et al, 2009). RSV also significantly reduces both acute and chronic chemically-
induced oedema, LPS induced airway inflammation and osteoarthritis (Baur & Sinclair, 
2006). RSV is shown to be protective in the endotoxemia-induced acute phase responses 
in rats (Sebai et al, 2009). In addition to its suppressive effects in inflammation, RSV also 
enhances immune responses in mice. RSV protects mice from infection by the herpes 
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simplex virus (Docherty et al, 2005) and modulates phagocytosis of bacteria through a 
NF-κB-dependent gene program (Iyori et al, 2008). 
RSV demonstrates potential in modulating the TLR signaling pathway, which 
may contribute to its anti-inflammatory effects. RSV appears to inhibit TRIF signaling in 
the TLR3 and TLR4 pathways by targeting TANK-binding kinase 1 and RIP1 in TRIF 
complex (Youn et al, 2005). In vascular smooth muscle cells, RSV reverses the LPS-
induced IL-6 expression via ERK1/2, p38 MAPK, NF-κB, and C/EBP (Son et al, 2008). 
In addition, RSV inhibits the LPS-induced airway neutrophilia and the inflammation 
mediators such as TNFα, IL-1β and cytokine-induced neutrophil chemoattractant-1 
(CINC-1) through a NF-κB-independent mechanism (Birrell et al, 2005). This magnitude 
of inhibition was similar to that achieved using, budesonide, a glucocorticoid steroid for 
the treatment of asthma and non-infectious rhinitis. Hence, RSV may be useful as an 
alternative or additional therapy in treating patients who are resistant or not suitable for 
conventional glucocorticoid drugs. 
1.8.3. Resveratrol in autophagy 
RSV is a potent inducer of autophagy in several cell types (Opipari et al, 2004; 
Scarlatti et al, 2008a).  RSV causes non-canonical Beclin 1-independent autophagic cell 
death in human breast cancer cells (Opipari et al, 2004; Scarlatti et al, 2008a). RSV 
induces autophagy in the chronic myelogenous leukemia cells via JNK-mediated 
p62/SQSTM1 expression and AMPK activation (Puissant et al, 2010b). In addition, 
analogues of RSV enhance autophagy and amyloid-β peptide degradation both in 
HEK293 cells and in mice (Vingtdeux et al, 2010). RSV has been suggested to promote 
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longevity through the Sirtuin-1-dependent induction of autophagy (Morselli et al, 2010a). 
However, so far, there are no mechanistic studies done on the relationship between RSV-
induced autophagy and RSV mediated anti-inflammatory effects.  
1.8.4. Dose-dependent effects of resveratrol 
Numerous amount of evidence have demonstrated that RSV exerts differential 
properties depending on its dose (Athar et al, 2009). On one hand, it protects cells by 
potentiating survival signals. On the other hand, it selectively kills cancer cells. RSV 
behaves as an antioxidant, yet it can induce redox signaling. At low concentrations, RSV 
scavenges ROS, but at higher concentrations, it behaves like a pro-oxidant. At low doses, 
RSV stimulates angiogenesis, but at higher doses, it blocks angiogenic response (Robich 
et al, 2010). Therefore, RSV has been proposed to be a “miracle” compound, and its 
potential inhibitory response on inflammation is likely to open a new horizon for the 
health benefits of RSV. 
1.9. Aims and rationale of experimental approaches 
 Inflammation is a local, protective response to microbial invasion or injury. It 
must be fine-tuned and regulated precisely, because deficiency or excess of the 
inflammatory response cause morbidity and mortality in several inflammatory diseases 
including sepsis. Sepsis is a life-threatening disorder that arises from the body’s response 
to infection and is the leading cause of death and disability for patients in an intensive 
care unit. Despite the intensive basic research into the molecular mechanisms of sepsis, 
the patho-physiology of sepsis remains unclear and many clinical trials of sepsis fail to 
bring therapeutic advances. We have tried to investigate mechanisms to control the 
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overwhelming inflammation while not compromising the host response to clear 
pathogens. The natural antioxidant, RSV, has been well evident in its anti-inflammatory 
effects. However, the detailed molecular mechanisms relevant to its anti-inflammatory 
effects remain unclear, especially in the context of endotoxin activation. Our rationale 
and strategy for this project are based on the following studies and observations. 
Two lipid modifying enzymes PLD and SphK have been demonstrated to play 
crucial and novel roles in receptor activated signaling mechanisms in immune cells as 
well as in vivo inflammatory disease models (Lai et al, 2008a; Lai et al, 2009; Sethu et al, 
2008; Sethu et al, 2010). Our previous study reported that RSV effectively attenuates 
C5a-induced inflammatory responses in vitro and in vivo by inhibiting SphK and PLD 
(Issuree et al, 2009). In concordance to this, Tou et al has shown that RSV inhibits PLD 
activity and degranulation in stimulated human neutrophils (Tou et al, 2001). Hence, we 
hypothesize that PLD and/or SphK may play important roles in LPS-activated signaling 
mechanisms and RSV may be able to modulate the activities of these two enzymes to 
exert its anti-inflammatory effects in human monocytes. 
Studies have highlighted the protective effects of RSV in several inflammatory 
models including LPS-induced endotoxemia and sepsis in rats. However, most of the 
studies employ the prophylactic approach where the mice were pre-treated with RSV for 
a period of time before induction of sepsis (Sebai et al, 2009). This is less relevant in the 
clinical setting compared with providing RSV after sepsis is induced. Hence, we aim to 
investigate the therapeutic effects of RSV in a mice model of polymicrobial sepsis. 
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      Moreover, RSV has been shown to induce autophagy (Opipari et al, 2004) and 
autophagy is shown to be associated with sepsis despite its unclear function (Chien et al, 
2011; Hsieh et al, 2009; Opipari et al, 2004). Autophagy is also implicated in regulating 
immune systems, particularly in TLR signaling, and plays crucial anti-inflammatory roles 
(Deretic, 2009). Therefore, we hypothesize that RSV may be able to induce autophagy-
mediated mechanisms which crosstalk with TLR4 signaling components. The findings 
might help further explain the anti-inflammatory roles of RSV in LPS signaling.  
       Overall, we aim to investigate the above molecular mechanisms in detail and 
validate the effects of RSV in dampening inflammatory responses, especially in 
endotoxins-mediated condition and in sepsis. We believe the findings in this study would 
offer insights into the physiological and molecular mechanisms of RSV that modulate the 
























2.1: Chemical, reagents and buffers 
Chemicals and reagents: 
Ammonium persulphate (Bio-Rad Laboratories, Singapore)  
30% Bis-acrylamide (Bio-Rad Laboratories, Singapore) 
BSA fraction V (Sigma-Aldrich, Singapore) 
t-butanol (Calbiochem, Merck Singapore)  
chloroquine diphosphate salt (Sigma-Aldrich, Singapore) 
N,N-dimethylsphingosine (Calbiochem, Merck Singapore) 
dimethyl sulfoxide (Sigma-Aldrich, Singapore) 
ELISA kit for human TNFα, IL-6, IL-8, IL-1β (BD Singapore) 
ELISA kit for human MCP-1 (CCL2), MIP-1α (CCL3) and MIP-1β (CCL3) (R&D 
research) 
Fetal Bovine Serum (HyClone Laboratories) 
Gelatin, Epon-Araldite, Osmium tetroxide (Ted Pella) 
Glutaraldehyde (Agar Scientific) 
Human recombinant IFN-gamma protein (PeproTec, Rocky Hill, NJ) 




Kaleidoscope protein standard (Bio-Rad Laboratories, Singapore) 
Lactacystin (Enzo Life Sciences International, Inc.PA.USA) 
Lipopolysaccharides (LPS) was from Salmonella typhimurium (Calbiochem, Merck 
Singapore) 
Lead Citrate (Lead Nitrate + Sodium Citrate) from Analar 
Monocyte isolation kit II (Miltenyi Biotech, Bergisch Gladbach, Germany) 
Na3VO4 (Calbiochem, Merck Singapore) 
NF-κB p65 transcription factor kit EZ-DetectTM (Pierce Biotech, Rockford, IL, USA) 
PD98059 (Calbiochem, Merck Singapore) 
Phosphatidylethanol and phosphatidyl-1-butanol standard (MP Biomedicals Inc, 
Singapore) 
Protease Inhibitor Cocktail Tablets-Complete, Mini (Roche Molecular Biochemicals, 
Singapore) 
QCMTM Chemotaxis 3μM 96-well cell migration assay kit, Human IgG1 Fc protein 
(Chemicon International, Temecula, CA, USA) 
Resveratrol (Sigma-Aldrich, Singapore) 
RPMI 1640 (HyClone Laboratories) 
TEMED (Bio-Rad Laboratories, Singapore) 
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Triton-X 100 (Bio-Rad Laboratories, Singapore) 
Tween-20 (Bio-Rad Laboratories, Singapore) 
Uranyl Acetate (TAAB) 
Antibodies 
Goat anti-mouse IgG-HRP (Santa Cruz Biotech, Santa Cruz, CA) 
Goat anti-rabbit IgG-HRP (Santa Cruz Biotech, Santa Cruz, CA) 
Goat anti mouse IgG antibody Alexa Fluor® 488 (Molecular probes Invitrogen) 
Goat anti rabbit IgG antibody Alexa Fluor® 568 (Molecular probes Invitrogen) 
Mouse monoclonal anti-MyD88 (Cell Signaling Inc. Danvers, MA) 
Mouse monoclonal anti-GAPDH (Santa Cruz Biotech, Santa Cruz, CA) 
Mouse monoclonal anti-p62 (Santa Cruz Biotech, Santa Cruz, CA) 
Rabbit monoclonal anti-phosphorylated ERK1/2 (Cell Signaling Inc. Danvers, MA) 
Rabbit monoclonal anti-ERK1/2 (Cell Signaling Inc. Danvers, MA) 
Rabbit monoclonal anti-phosphorylated JNK (Cell Signaling Inc. Danvers, MA) 
Rabbit monoclonal anti-JNK (Cell Signaling Inc. Danvers, MA) 
Rabbit monoclonal anti-LC3 (Cell Signaling Inc. Danvers, MA) 




Rabbit monoclonal anti-MyD88 (Cell Signaling Inc. Danvers, MA) 
Buffers for monocyte isolation: 
MACS buffer: 2mM EDTA in 1 x PBS 
RBC lysis buffer: 200mM NH4Cl, 10mM NaHCO3, 10mM EDTA 
Buffers for nuclear extraction: 
Lysis Buffer for nuclear extract preparation: 10 mM HEPES (pH 7.9), 10 mM KCl, 0.1 
mM EDTA, 0.1 mM EGTA, 1 mM DTT, 1 mM PMSF  
Extraction Buffer for nuclear extract preparation: 20 mM HEPES (pH 7.9), 0.4 M NaCl, 
1 mM EDTA, 1 mM EGTA, 1 mM DTT, 1 mM PMSF 
Buffers for western blot analysis: 
RIPA buffer for total cell lysate preparation: 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 
mM EDTA, 0.25% sodium deoxycholate, 1% NP-40, 1 mM PMSF, 1mM Na3VO4 
12% Resolving gel for SDS-PAGE: distilled water, 30% acrylamide/bis, 1.5 M Tris (pH 
8.8), 10% SDS, 10% APS, TEMED 
5% Stacking gel for SDS-PAGE: distilled water, 30% acrylamide/bis, 1.0 M Tris (pH 6.8), 
10% SDS, 10% APS, TEMED 
Running buffer for SDS-PAGE: 25 mM Tris base, 250 mM glycine (pH 8.3), 0.1% SDS 
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Transfer buffer for SDS-PAGE: 48 mM Tris base, 39 mM glycine, 0.037% SDS, 20% 
methanol 
1 x SDS gel-loading buffer for SDS-PAGE: 50 mM Tris-HCl (pH 6.8), 100 mM β-
mercaptoethanol, 2% SDS, 0.1% bromophenol blue, 10% glycerol 
Washing buffer for SDS-PAGE: 1 x TBS, 0.1% Tween-20 
Blocking agent for SDS-PAGE: 5% non-fat milk in 1 x TBST 
1 x TBS for SDS-PAGE: 137 mM NaCl, 20 mM Tris-HCl (pH 7.6) 
Buffers for ELISA: 
Coating buffer for cytokine ELISA: NaHCO3 in 1 x PBS 
Assay buffer for cytokine ELISA: 1% FCS in 1 x PBS 
Wash buffer for cytokine ELISA: 0.05% Tween-2 in 1 x PBS 
Substrate solution for cytokine ELISA: 1 tablet TMB in 10 ml 0.05 M citrate phosphate in 
1 x PBS and 2 μl of 30% H2O2 
Stop solution for cytokine ELISA: 1 M H2SO4 
Other buffers: 
Sphingosine kinase assay buffer: 20 mM Tris-HCl (pH7.4), 1 mM β-mercaptoethanol, 
1mM EDTA, 20% glycerol, phosphatase inhibitors (20mM ZnCl2, 1 mM sodium 
orthovanadate and 15 mM sodium fluoride), protease inhibitors (10 μg/ml leupeptin, 10 
μg/ml pepstatin A, 10 μg/ml aprotinin and 1 mM PMSF) and 0.5 mM 4-deoxypyridoxine 
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• PLD assay running buffer: Ethyl acetate, iso-octane, acetic acid and distilled water in 
the ration of 65:10:15:50 (v:v:v:v). 
2.2 RSV preparation 
Trans-RSV and DMSO were obtained from Sigma (St. Louis, MO, USA). A 200 
mM stock solution of RSV (MW 228.2) was prepared in DMSO, and aliquots were stored 
in the dark at -20°C. Subsequent dilutions to obtain a dose range of 0-40 µM were done 
in plain RPMI or PBS. In experiments where RSV was used, control samples were 
treated with PBS containing the same amount of DMSO (0.02%) as that in samples 
treated with RSV. 
2.3 Culturing of U-937 Cell line 
The human histiocytic lymphoma U-937 cell line was purchased from ATCC 
(Rockville, MD). The cell line was cultured in RPMI 1640 supplemented with 10% FBS 
(Gibco, Invitrogen Singapore), 2 mM glutamine, 10 U/ml penicillin and 10 mg/ml 
streptomycin at 37°C, 5% carbon dioxide in a water saturated atmosphere. The cells were 
primed with 200 ng/ml of recombinant human IFN-γ (Biosource, Invitrogen Singapore) 
for 16 h prior to experiments. This priming augments the inflammatory response 
triggered by LPS. 
2.4 Isolation of human primary monocytes 
Human peripheral blood monocytes were isolated from heparinized venous blood 
obtained from fasting healthy donors. Initially peripheral blood mononuclear cells 
(PBMCs) were isolated from whole blood using Ficoll-Paque which separates the buffy 
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coat into its components by size and density. This was done by carefully layering 
heparinized whole blood on Ficoll-PaqueTM (GE Healthcare Bio-Sciences, Singapore) 
gradient (density – 1.077 g/liter) and centrifuging at 500 x g, without breaks for 30 
minutes at room temperature. During centrifugation, red blood cells (RBC) aggregate 
with polysucrose and rapidly sediment, and granulocytes which are of higher density will 
tend to move towards the bottom of the centrifuge tube. Mononuclear cells such as 
lymphocytes and monocytes remain at the plasma-Ficoll-Paque interface as a distinct 
opaque layer. Mononuclear cells were then aspirated into a separate tube and washed 
twice with 2 mM EDTA-PBS. The collected pellet was lysed using RBC lysis buffer to 
remove the remaining red blood cells. Finally the PBMCs were obtained and the number 
of cells was counted using a hemocytometer.  
To isolate monocytes from PBMCs, we used the Monocyte Isolation Kit II 
(Miltenyi Biotec Inc, Auburn CA, USA.) which uses the magnetic cell sorting (MACS) 
principle. This kit involved the isolation of monocytes by depleting non-monocytes 
(negative selection) from PBMCs. Non-monocyte PBMCs are indirectly magnetically 
labeled with a mixture of biotin conjugated monoclonal antibodies specific for lineage 
marker and anti-biotin monoclonal antibodies conjugated to the microbeads. When 
magnetically labeled PBMCs are passed through the column in a magnetic field, the 
magnetically labeled non- monocytes are retained in the column and only the unlabeled 
monocytes will pass through the column to be collected in the eluate. The procedures 
were followed according to instruction provided by the manufacturer. This negative 
selection procedure also prevents the activation of monocytes compared to those isolated 
by MACS assisted positive selection of monocytes or by adherence. The isolated 
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monocytes were then washed three times and then cultured with plain RPMI 1640 and 
incubated at 37°C in 5% carbon dioxide in a water-saturated atmosphere. Cell viability 
was determined by Trypan Blue prior to all the experiments. 
2.5 Flow cytometry 
5 x 105 primary monocytes isolated from human PBMCs were washed twice with 
PBS and fixed in 4% (w/v) paraformaldehye for 15 min. After two washes with PBS, 
cells were sequentially stained with primary antibody (anti-CD14, 1:200 or MHC Class I 
1:200 as positive control) and phycoerythrin-conjugated secondary antibody (goat anti-
rabbit, 1:200, Invitrogen). After three washes, cells were diluted into a density of 1 x 105 
cells/ml and flow cytometry was performed using Beckman Coulter Epics Altra 
(Beckman Coulter, Brea, CA). 
2.6 Cell viability assay 
The viability of cells following incubation with different doses of RSV was 
determined using MTT. Yellow 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) (Sigma Chemical Co, St Louis, MO) is reduced to a purple formazan by 
an active mitochondrial reductase, which only takes place in living cells, thus this 
conversion reaction is directly related to the number of viable cells and is commonly 
utilized to determine cell viability. Briefly, 1 x 104 cells were added to each well of a 96 
well culture plate (Nunc, Denmark) containing 100 µl medium with various doses of 
RSV and incubated for 4 to 24 hours at 37°C in a 5% CO2. After the incubation period, 
50 µl of the MTT solution (4 mg/ml in plain RPMI) was added to each well and the cells 
were incubated at 37°C for 2 hours in the dark. After that, the plate is spun down at 4000 
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rpm for 10 minutes, the supernatant removed, and the formazan crystals were 
resuspended in 190μl DMSO and 10 μl Sorenson’s Glycine Buffer [0.1M Glycine, 0.1M 
NaCl, pH 10.5]. The absorbance for the MTT was measured using a spectrophotometer 
(TECAN Spectrophor Plus) at 570 nm. Percentage of viable cells was calculated based on 
the difference in the Optical Density (OD) values between the controls and the treated 
categories. 
2.7 Measurement of cytokines, chemokines and HMGB1 release 
A total of 2 x 105 cells per sample, pretreated for 2 hours with or without various 
doses of RSV (10-40 μM), were stimulated by the addition of 100 ng/ml LPS Salmonella 
typhimurim (Calbiochem, U.S.) for 18-24 hours. Following stimulation of the cells, 
supernatants were collected at the indicated time points and stored at -20°C until use. 
Human IL-6, TNFα, IL-1β, MCP-1 in the supernatants were evaluated using OptEIATM 
Kit (BD Biosciences, San Jose, CA, USA) whereas MIP-1α were measured using DuoSet 
ELISA Development System (R&D System, USA) following the manufacturer’s 
instructions. Human HMGB1 productions were measured using Shino-Test’s HMGB1 
ELISA kit II (326054329; Shino-Test Corporation, Japan). 
To briefly describe the procedure, a 96-well ELISA plate was initially coated with 
specific capture antibody in coating buffer and incubated at 4°C overnight. The following 
day, the plate was washed three time with ELISA wash buffer (0.5% TWEEN in 1 x PBS) 
and remaining wash buffer was removed from the wells. This was followed by 2 hour 
incubation with ELISA blocking buffer at room temperature. The plate was washed as 
described earlier. Serial dilutions of relevant standards were made and added to the 
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designated wells and 50μl of the supernatant was added to the sample wells and 
incubated for 2 hours at room temperature. The plate was again washed as described 
earlier and incubated with detection antibody for 1 hour, followed by another round of 
washing. Enzyme concentrate avidin-HRP was added to all of the wells and incubated in 
the dark for half an hour. The plate was then washed six times and incubated in the dark 
for another half hour with 100μl of TMB substrate. This reaction was quenched by the 
addition of 100μl of 1M H2SO4. The OD was then measured using a spectrophotometer 
(TECAN Spectrophor Plus) at 450 nm with reference to 570 nm. Based on the raw OD 
data obtained, a standard curve was plotted and the concentrations of each cytokine were 
then calculated. 
Levels of mouse TNFα, IL-1β, IL-6, MCP-1, IFNγ, MIP-1α and MIP-1β in serum 
were measured using ELISA (R&D Systems, Minneapolis, MN and Bio-Plex Pro mouse 
cytokine and chemokine 23-plex assay, Bio Rad, US). Mouse HMGB1 levels were also 
measured using Shino-Test’s HMGB1 ELISA kit II (326054329; Shino-Test Corporation, 
Japan). 
2.8 Measurement of SphK activity 
After LPS stimulation, activation of SphK was measured in total cell lysates. 
Protocol was adapted from Billich et al (Billich & Ettmayer, 2004). Briefly, cells were 
resuspended in ice-cold 0.1M PBS (pH 7.4) containing 20% glycerol, 1mM 
mercaptoethanol, 1mM EDTA, phosphatase inhibitors (20mM ZnCl2, 1mM sodium 
orthovanadate, and 15mM sodium fluoride), and protease inhibitors cocktail and then 
disrupted by freeze-thawing. Reactions were started by incubating SphK-containing 
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protein samples with sphingosine derivative labeled with of 7-nitrobenz-2-oxa-1,3-
diazole moiety (15-NBD-Sph) (20 μM) and ATP (1mM) in SphK buffer for 30 min at 
37°C. Reaction was quenched with 1M potassium phosphate buffer and CHCl3/MeOH 
2:1. Phases were separated by centrifugation at 5000 rpm. An aliquot of the upper 
aqueous layer was removed and placed into the wells of white 96-well polystyrene 
microplates, followed by dimethylformamide. Fluorescence intensity was measured at 
485/535nm. A reaction mixture without protein served as blank. 
2.9 Measurement of PLD activity 
PLD activity was measured using the transphosphatidylation assay. This reaction 
yields a biologically stable and inert phosphatidyl-alcohol instead of the second 
messenger, PA (Jenkins & Frohman, 2005; McDermott et al, 2004). PLD activity 
measurement in intact cells can be done by overnight radio-labeling of endogenous 
substrates, followed by the addition of an extracellular stimulus in the presence of a 
primary alcohol. Subsequent to this process, detection and quantification of the 
metabolically stable phosphatidyl alcohols produced by PLD catalyzed reaction can be 
performed (Morris et al, 1997a). Primary human monocytes were labeled (106 cells/ml) 
with [3 h] palmitic acid (5 µCi/ml; Amersham Biosciences) in the cell culture medium for 
16 h. 
Following washing, the cells were incubated at 37°C for 15 min in RPMI 1640 
medium containing ethanol (0.3% final and incubated with inhibitors whenever 
applicable). Following LPS stimulation for 30 minutes at 37°C, cells were then lysed and 
lipids extracted by Bligh-Dyer phase separation (BLIGH & DYER, 1959). An aliquot of 
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the lower organic phase was obtained from all the samples to determine the content of 
radioactivity in the total lipid fraction and equal amount of aliquot was also taken from 
the phase to quantify the product generated. Phosphatidylethanol (PtdEtOH) or 
Phosphatidyl-1-butanol (PtdBut-1-ol) standard was added to all the latter samples and 
dried under vacuum (Savant ISS110). The lipid containing samples were then re-
dissolved in 50 μl of 19:1 (v:v) chloroform/methanol and spot dropped on pre-run, heat-
activated thin-layer chromatography plates-TLC silica gel G60 plates (Whatman, 
Maidstone, UK). The separation was performed by placing the plates in the organic phase 
of the solvent (ethyl acetate/iso-octane/acetic acid/water) for around 90 minutes and the 
separated phosphatidylalcohol product was detected by visualizing the standard using 
iodine vapour staining. [3 h] phosphatidylalcohol ([3 h] PtdOH) containing silica was 
scraped into vials containing scintillation fluid and the amount of radioactivity was 
quantified by liquid scintillation spectrometry using a scintillation counter (Wallace 1414 
WinSpectral Liquid Scintillation Counter, PerkinElmer). The amount of PLD activity is 
measured as the ratio of [3 h] PtdOH to [3 h] total lipids. 
2.10 Gel electrophoresis and Western blots 
Following LPS stimulation at various time points, the cell lysates were prepared 
using RIPA lysis buffer and then protein concentrations were estimated using Braford 
protein assay. The Bradford reagent contained 0.01% (w/v) Coomassie Brilliant Blue G-
250, 8.5% (v/v) orthophosphoric acid and 4.7% ethanol. One ml of this reagent was 
mixed with 50μl of diluted protein sample by vortexing. The absorbance at 595 nm was 
measured after 2 min. The protein content in each sample was calculated from a standard 
curve plotted from the absorbance readings of bovine serum albumin (BSA fraction V, 
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Sigma-Aldrich) in a range of 1μg to 50μg. For each sample, triplicate readings were 
obtained. 
40μg of proteins were then resolved in 12% polyacrylamide gels (SDS-PAGE) 
under denaturing conditions in 1x SDS-PAGE running buffer at a constant voltage of 
120V. The resolved proteins were then transferred to methanol-activated 0.45μm 
polyvinylidene difluoride membranes (Millipore) using wet transfer method at a constant 
ampere of 0.35A. The polyvinylidene difluoride membranes were handled as per the 
manufacturer’s instructions. The membranes were incubated with the relevant primary 
antibodies for 2 - 4 hours at room temperature and appropriate horseradish peroxidase–
conjugated secondary antibody at room temperature for another 2 hours. The membranes 
were washed with washing buffer (1% Tween 1x PBS) three time for 5 minutes after 
primary and secondary antibody incubation. The bands were visualized by 
autoradiography using enhanced chemiluminescence (ECL) Western Blotting Detection 
System (Amersham, Buckinghamshire, United Kingdom). 
2.11 NF-κB DNA-binding activity assay 
NF-κB activity was analyzed from cells left untreated or with pre-treated with 40 
μM RSV and stimulated with LPS (100 ng/ml) using the EZ-Detect transcription factor 
kit (Pierce Biotechnology, Rockford, IL, USA) following the manufacturer’s instructions. 
NF-κB activation was determined directly by measuring the levels of p65 subunits of the 
NF-κB complex in the nucleus. These subunits translocate from the cytosol to the nucleus 
on activation. NF-κB activity was analyzed in the cells subsequent to LPS stimulation for 
30 minutes at 37°C, in resting cells and in those pre-treated with various inhibitors prior 
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to LPS stimulation. The determination of the presence or increase in the amounts of NF-
κB subunits in the nucleus were analyzed using an ELISA based technique. The kit is 
provided with a 96-well format with the bound biotinylated-consensus sequence for the 
respective subunits. The biotinylated-consensus duplexes will bind only to the active 
forms of the transcription factor subunits of interest. Subsequent to stimulations the cells 
were washed with 1 x PBS and then lysed using the cell lysis buffer and centrifuged at 
10,500 rpm for 20 minutes at 4°C. The supernatant is the cytosolic fraction, is collected 
in a separate tube. The remaining crude nuclear pellet is then treated with nuclear 
extraction buffer and centrifuged at 13,000 rpm for 5 minutes at 4°C. The supernatant 
obtained is the nuclear extract and is collected in a fresh tube and stored at -20°C prior to 
its use. Bradford assay was done to estimate the protein concentration in the nuclear 
extract. 20μg of the nuclear extract was used for the assay by adding it to the pre-coated 
wells and incubated at room temperature for an hour. The plate was then washed using 
the wash buffer and the appropriate primary antibody (anti-p65) was added to the wells 
and incubated for an hour on a shaker at room temperature. This is followed by another 
round of washing and incubated with HRP conjugated secondary antibody for another 
hour at room temperature. After washing, a luminol based chemiluminescent substrate 
TMB provided with the relevant kits was added to the wells and the signals were detected 
using a luminometer or a spectrophotometer. 
2.12 Chemotaxis assay 
Chemotaxis was assayed using the Chemicon QCMTM Chemotaxis 3-µm 96-well 
Cell Migration Assay kit (catalog no. ECM 515; Chemicon, Temecula, CA, USA) 
following the manufacturer’s instructions. A total of 2 x 105 cells per sample were placed 
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in the upper chamber, and 100 ng/ml LPS is placed in the lower chamber, and cells are 
incubated at 37°C for 2-4 h. Migratory cells found on the lower chamber are collected, 
and migratory cells attached on the bottom of the insert membrane are dissociated with 
the Cell Detachment Buffer provided. These cells are subsequently lysed and detected 
using the CyQuant GR dye (Molecular Probes, Eugene, OR, USA) provided in the kit. 
This green fluorescent dye exhibits strong fluorescence enhancement when bound to 
cellular nucleic acids, which can be measured by a fluorescence plate reader using 
480/520 nm filter set. To convert the OD values to number of migrated cells, known 
number of cells were lysed and OD values detected using the dye. These OD values were 
used to plot the standard curve and by plotting the OD values of the sample along the 
standard curve, the number of migrated cells can be determined. 
2.13 Fluorescent confocal microscopy 
 The formation of autophagosomes and the co-localization of autophagic marker 
microtubule-associated protein1 light chain 3 (LC3) and MyD88 were analyzed using 
confocal microscopy. After RSV treatment at indicated time points, the suspended cells 
were fixed in 4% paraformaldehyde and deposited on microscope slides using a cytospin 
centrifuge. They were then permeabilised for 2 min in 0.1% Triton X- 100 in PBS. The 
permeabilised cells were blocked for non-specific binding with 1% BSA for 1 hour at 
room temperature. Fluorescent labeling was performed by incubating the cells with 
relevant primary antibodies specific for the targets of interest (mouse anti-MyD88 and 
rabbit anti-LC3) for 2 hour at room temperature. The cells were washed with PBS and 
then incubated with appropriate Alexa-fluro-conjugated IgG based secondary antibodies. 
Cells were similarly washed three times with 1x PBS before the cover slips were 
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mounted on glass slides and imaged with Olympus Fluoview FV1000 confocal 
microscope and images analyzed using Olympus Fluoview 2.0 viewer.  
2.14 Transmission electron microscopy 
Cells with or without treatment were fixed in 2.5% glutaraldehyde at 4°C 
overnight. On the next day, the cells were washed with PBS for three times before they 
were post-fixed in 1% osmium tetroxide for 1 h on rotator. The cells were then washed 
three times and resuspended in 6% gelatin for 10mins before it was spun down at 3000 
rpm. Excessive gelatin was removed and the pellet was again fixed with 2.5% 
glutaraldehyde for another 10 min. After three washes with distilled water, the sample 
was cut into 1mm3 cube. Next, the samples in cubes were dehydrated with increasing 
concentrations of ethanol (from 25% alcohol to 100% alcohol and then 100% acetone). 
Then the samples were gradually infiltrated with Epon-Araldite (starting with 1:6 ratio of 
Epon-Araldite : acetone to 100% Epon-Araldite). Three changes of fresh Epon-Araldite 
were made on the next day at 40°C to 50°C. Samples were polymerized at 60°C for 24 
hours. Ultrathin sections (90-100nm) were cut on Leica EM UC6 microtome and 
collected on copper slot grids. Sections were counter-stained with uranyl acetate and lead 
citrate, and then examined using a Philips transmission electron microscope JEOL JEM-
1010 operating at beam energy of 100keV. Images were acquired by using a Gatan 
ES500W Erlangshen camera with 1350 x1040 pixels. 
2.15 Mice 
Male C57 black 6 mice (C57BL/6) (8-10 weeks) were purchased from the 
Laboratory Animal Centre (Sembawang, Singapore). The study was conducted according 
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to the NUS guidelines for animal experimentation and project licenses approved by the 
National University of Singapore. 
2.16 Caecal Ligation and puncture induced sepsis in mice and treatment with RSV 
Sepsis was induced by caecal ligation and puncture (CLP) as previously described 
(Nguyen et al, 2009; Puneet et al, 2006). Briefly, mice were anesthetized with ketamine 
(75mg/kg, intramuscular injection) and xylazine (20mg/kg). An abdominal midline 
incision was then performed and the cecum was isolated. Cecum was ligated at 5 mm 
from the cecal tip, away from the ileocecal valve, and the ligated cecal stump was then 
perforated by two “through and through” punctures (22-gauge needles). Cecum was 
placed back into its normal intra-abdominal position and closed the abdomen with a 
running suture of 5-0 prolene. Sham operated mice were subjected to similar laparotomy 
without CLP. Immediately after surgery, all animals received a subcutaneous injection of 
1 ml of sterile saline (0.9% NaCl). Different doses of RSV were intraperitoneally (i.p.) 
injected into the mice at 1 h, 3 h, 6 h, 24 h, 48 h and 72 h after CLP in the treatment 
group. In the combination treatment, co-amoxiclav, 30mg/kg, was co-injected with RSV 
at the same time points. Survival was recorded every 12 h for 7 days. 
For the therapeutic study, 1 mg/kg body weight of RSV (diluted in 200μl sterile 
PBS) was injected 1 h, 3 h and 6 h after induction of CLP in the RSV-treated group. 24 h 
after CLP induction, both groups were sacrificed and blood, peritoneal lavage and organs 
were collected for analysis. For the infiltration study, mice were sacrificed at indicated 




2.17 Collection of blood from mice 
Maximum amount of good quality blood samples from mice are required for the 
collection of serum for cytokines and chemokines analysis and for bacterial counts. In 
order to meet this requirement, the cardiac puncture technique was chosen to collect 
whole blood from mice. Mice were fully anaesthetized prior to the procedure and were 
held in a dorsal recumbent position. A sterile 1 ml syringe with a 25 gauge needle was 
used for the procedure. The needle was inserted 0.5cm to 1cm deep under the xyphoid 
cartilage slightly to the left of midline. The needle was inserted at a 25° to 30° angel from 
the horizontal axis to the sternum to enter the heart. The blood flow from the heart was 
checked by slightly aspirating and when successful, the blood was drawn slowly taking 
care to prevent the sudden collapse of the heart. The drawn blood samples were collected 
in eppendorf tubes and placed on ice for further processing. 
2.18 Collection of peritoneal lavage from mice 
The peritoneal lavage was obtained to analyze the cytokine levels and cellular 
infiltrations, if any. The mice were fully anaesthetized at specific time points after the 
intended treatments and their peritoneal cavity was washed with 1.5 ml of ice cold PBS 
with 0.1% BSA. The peritoneal lavage collected were either stored in -20°C for cytokine 
or chemokine concentration, HMGB1 measurement and bacterial counts or analyzed 





2.19 Bacterial count 
Twenty-four hours after CLP, mice were anesthetized and peritoneal lavage fluid 
and blood were collected. 10μl of freshly collected blood and lavage or serial-diluted 
blood and lavage (in PBS) were spread evenly onto the Trypticase Soy Agar with 5% 
sheep blood and incubated at 37⁰C for 24 h. The colony forming units (cfu) were counted 
and tabulated. 
2.20 Collection of serum from mice blood 
In order to collect serum samples from mice, whole blood was collected in non-
heparinized microfuge collection tubes and allowed to clot spontaneously on ice. Once 
the clot is formed at the bottom of the tube, the serum was gently pipetted out to a fresh 
tube. This collected serum was further clarified by centrifugation at 3000 rpm for 10 
minutes and the supernatant (serum) was collected gently without disturbing the pellet 
and stored at -80°C until use. 
2.21 Examination of peritoneal infiltration 
Pooled leukocytes obtained from each group of mice were washed, counted, and 
adjusted to 6 x 106 cells/ml. Then 0.1ml of the leukocyte preparation was added to 0.1 ml 
of fetal bovine serum, and a cytocentrifuge preparation was made by centrifugation at 
450 rpm for 3 min. Neutrophil and monocytes infiltration in the peritoneal lavage was 
analyzed by using Turk or Giemsa staining, which enables the visualization of the 
different leukocytes under a light microscope. Hemocytometer was used to quantify the 
number of neutrophils and monocytes infiltrated into the peritoneal lavage for the various 
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test categories. Differential cell counts were performed by two independent observers 
counting 100 cells from randomly selected fields at x 100 using an oil-immersion lens. 
2.22 Statistical analysis 
Values presented are mean ± standard deviation where n ≥ 3. Statistical significance was 
determined by a two-tailed unpaired student’s t-test or log-rank test for Kaplan-Meier 
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First aim of the study is to examine the effects of RSV on LPS-triggered 
inflammatory responses in human primary monocytes and to identify novel molecular 
targets of RSV in LPS signaling pathways. 
Excessive production of pro-inflammatory cytokines and chemokines is a 
characteristic of overwhelming inflammatory responses. Pro-inflammatory cytokines 
such as IL-1β, TNFα, and IL-6 are produced mainly by activated leukocytes such as 
monocytes, macrophages and neutrophils, and are involved in the further up-regulation of 
other pro-inflammatory cytokines and chemokines. These cytokines are produced upon 
endotoxin activation in the early stage of sepsis (Riedemann et al, 2004; Riedemann et al, 
2003c). In this chapter, we examined the effects of RSV on LPS activated IL-1β, TNFα, 
and IL-6 cytokine production. 
In a wide variety of diseases, excessive secretions of chemokines have been 
detected and they cause the accumulation and activation of leukocytes in tissues. The 
capacity to control precisely the movement of inflammatory cells suggests that various 
chemokines and their receptors may provide novel targets for therapeutic interventions. 
Macrophage inflammatory protein-1 alpha (MIP-1α, also known as CCL3) is a member 
of the C-C subfamily of chemokines, a large superfamily of low-molecular weight, 
inducible proteins that exhibit a variety of pro-inflammatory activities in vitro such as 
leukocyte chemotaxis. However, MIP-1α inhibits the proliferation of hematopoietic stem 
cells in vitro and in vivo (Cook, 1996). Monocyte chemoattractant protein 1 (MCP-1, also 
known as CCL2) plays an important role in leukocyte recruitment to sites of infection and 
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inflammation. Endogenous MCP-1 has been shown to promote lung inflammation 
induced by LPS (van Zoelen et al, 2011). Here, we examined the effects of RSV on LPS 
activated MCP-1 and MIP-1α production. 
HMGB1 is a potent pro-inflammatory cytokine involved in the delayed endotoxin 
lethality and systemic inflammatory responses (Huang et al, 2010). Extracellular HMGB1 
can stimulate the release of TNFα, IL-1β, IL-6 and other inflammatory products by 
interacting with PRRs, including TLRs on macrophages and RAGE on endothelial cells 
(Tang et al, 2009). It also induces iNOS expression in enterocytes, resulting in nitric 
oxide release, increased vascular permeability and bacterial translocation. Because of its 
pleiotropic effects on the inflammatory response and late release in sepsis, targeting 
HMGB1 may be a promising therapeutic strategy (Riedemann et al, 2003b; Yin et al, 
2005). In fact, it has been demonstrated that the blockade of HMGB1 or the inhibition of 
RAGE significantly improves the survival of mice in endotoxaemia and experimental 
sepsis (Qin et al, 2006; Wang et al, 1999). Hence, it is important to investigate if RSV is 
able to modulate HMGB1 production upon LPS stimulation. 
NF-κB regulates transcription of inflammatory genes that includes cytokines, 
chemokines, cell adhesion molecules and other immune response mediators. NF-κB plays 
an essential role in the TLR4 signaling pathway as well. Studies using cell lines and 
knockout mice have shown that MyD88-dependent pathway and TRIF-dependent 
pathway lead to early- and late-phase activation of NF-κB respectively. In addition, 
transcriptional activation of the IFN-β gene can be induced by TRIF-mediated late-phase 
NF-κB activation alone (Akira & Takeda, 2004). Nonetheless, the effect of RSV on the 
TLR4-mediated NF-κB activity has yet to be examined. 
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MAPK signaling cascade plays a vital role in many receptor-activated signaling 
pathways, including TLR stimulation. All three subfamilies of MAPKs (ERK, p38 and 
JNK) are reported to be either agonistically or antagonistically modulated by RSV 
(Nguyen et al, 2008; Shen et al, 2007; Stewart & O'Brian, 2004). This variability is 
related to the cell type and dosage. As illustrated by Miloso et al, at a concentration 
between 1pM-10 µM, RSV induces the phosphorylation of ERK1/2, but at 50-100µM it 
inhibits ERK1/2 phosphorylation in neuroblastoma cell lines (Miloso et al, 1999). In 
addition, RSV antagonizes the EGFR-dependent, PKCα-mediated ERK1/2 activation in 
the human androgen-independent prostate cancer cells (Stewart & O'Brian, 2004). In this 
chapter, we are interested to investigate the effect of RSV on TLR4-mediated MAPK 
activation in immune cells. 
 
Studies have previously demonstrated the crucial signaling mechanisms of PLD 
and SphK in immune cells as well as in in vivo disease models (Lai et al, 2008a; Lai et al, 
2009; Sethu et al, 2010). In addition, we demonstrated that RSV effectively attenuates the 
C5a-induced inflammatory responses in vitro and in vivo by inhibiting SphK and PLD 
(Issuree et al, 2009). In accordance to this, Tou et al has shown that RSV inhibits PLD 
activity and degranulation by stimulated human neutrophils (Tou & Urbizo, 2008). Hence, 
we seek to investigate novel roles of PLD and/or SphK in TLR4-stimulated signaling 







3.1 Percentage of primary monocytes isolated from PBMCs 
In this chapter, the effects of RSV in primary monocytes freshly isolated from 
human PBMCs are investigated. First of all, PBMCs were separated from the blood of 
healthy donors with consensus using Ficoll-Paque. Human monocytes were then isolated 
from these PBMCs using the monocyte isolation kit II, which uses the magnetic cell 
sorting principle. Monocytes originate from hematopoietic stem cells in the bone marrow, 
subsequently commit to myeloid and monocyte lineages. In response to macrophage 
colony-stimulating factor (MCSF), these hematopoietic stem cells differentiate into 
monoblasts and then pro-monocytes, before entering the bloodstream as monocytes. The 
heterogeneity of circulating human monocytes is not completely understood. Human 
monocytes that are CD14highCD16- are considered classical monocytes, whereas 
CD14+CD16+ cells are non-classical monocytes (Ziegler-Heitbrock et al, 1993). Hence, 
the measurement of cell surface CD14 expression is the most common method used to 
identify the human monocyte population. Here, we assessed the purity by measuring the 
percentage of monocytes isolated by examining CD14 expressions using flow cytometry. 
As shown in Figure 1, after isolation, 94% of the cells obtained were stained positive for 
CD14. In addition, more than 90% of cells obtained were CD14 positive in all the 
isolations done. This indicates that the method we use to isolate primary monocytes for 













Figure 1. Percentage of cells expressing CD14 after isolation from human PBMCs. 
Isolated cells were stained with rabbit primary anti-CD14 at 1:200 dilution or isotype 
matched rabbit IgG control at 1:200 dilution, and phycoerythrin-conjugated secondary 





3.2 Pre-treatment of human primary monocytes with RSV inhibits the LPS-
mediated cytokine, chemokine production and HMGB1 release  
When sepsis or endotoxemia occurs, excessive production of pro-inflammatory 
cytokines such as TNFα, IL-1β and IL-6 may lead to over-stimulation of immune cells 
and result in severe tissue damage. In addition, large amount of chemokines such as 
MCP-1 and MIP-1α provide chemoattractive properties for infiltration of more immune 
cells. Sustained increased level of HMGB1 is associated with higher mortality 
(Andersson et al, 2000). Hence, it is critical to lower the massive production of these 
cytokines and chemokines as well as HMGB1 production during inflammation. 
In this study, we first examined the modulating effect of RSV on cytokines (IL-6, 
IL-1β, TNFα) and chemokines (MCP-1, MIP-1α) and HMGB1 production in human 
primary monocytes upon LPS activation. In monocytes triggered with 100 ng/ml LPS, 
there were massive increases in IL-6, IL-1β, TNFα, MCP-1, MIP-1α and HMGB1 
production compared with monocytes at basal. However, pre-treatment of monocytes 
with 10-40 µM of RSV decreased the LPS-triggered IL-6, IL-1β, TNFα, MCP-1, MIP-1α 
and HMGB1 productions in a dose-dependent manner (Figure 2A). The amounts of 
TNFα, IL-1β and IL-6 released in monocytes pre-treated with 40 µM of RSV were 42%, 
43% and 50% lower compared with the monocytes activated with LPS that were not pre-
treated with RSV. The amounts of human MCP-1, MIP-1α and HMGB1 released in 
monocytes treated with 40 µM of RSV were 98%, 51% and 68% lower compared with 
the monocytes activated with LPS that were not pre-treated with RSV (Figure 2B). These 
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IL‐6  5±0.6  23±0.8  42±0.6  0.000261 
IL‐1β  32±1.3  35±1.1  43±1.5  0.005473 
TNFα  10±0.8  45±0.7  50±1.2  0.009638 
MCP‐1  51±1.4  77±0.2  98±0.2  0.003685 
MIP‐1α  20±2.7  29±1.0  51±1.8  0.005441 
HMGB1  10±2.5  51±11  68±4.4  0.00015  
Figure 2(A) RSV inhibits the LPS-induced pro-inflammatory cytokines, chemokines 
and HMGB1 production in a dose-dependent manner and (B) % of inhibition of 
LPS-triggered cytokine/chemokine production with RSV treatment. Human primary 
monocytes were pre-treated with PBS or varying doses of RSV for 15 min, and then 
stimulated with LPS (100 ng/ml) for 24 h. Supernatant of each sample was collected and 
the levels of IL-6, IL-1β, TNFα, MCP-1, MIP-1α and HMGB1 were measured using 
ELISA. For each cytokine or chemokine, all LPS-triggered samples with RSV pre-
treatment were compared with LPS-triggered samples in PBS (LPS + PBS, shown in 
black). Depicted are means ± SD of triplicate measurements using a two-tailed unpaired 




3.3 Pre-treatment of human primary monocytes with RSV decreases the LPS 
activated monocyte chemotaxis 
Another physiological response upon endotoxin activation is the massive 
migration and recruitment of monocytes and macrophages to the site of infection. This 
may lead to a prolonged inflammatory state in the tissues. As RSV reduces the release of 
LPS-activated pro-inflammatory mediators (cytokines and chemokines) and some 
chemokines are important in regulating immune cells chemotaxis. We next investigated 
the role of LPS as a chemo-attractant in primary monocytes and the effects of RSV in this 
response. LPS triggered a significant chemotactic response in primary monocytes 
(Figure 3). Pre-incubation of primary monocytes with 10-40 µM of RSV blocked the 
LPS-activated monocyte migration in a dose dependent manner, with a complete 
inhibition by RSV at a dose of 40 µM (Figure 3). Hence, RSV is effective in attenuating 
monocyte chemotaxis towards LPS. 
SphK has been reported to be involved in the signaling pathways activated by 
several pro-inflammatory stimuli, including TNF-α and C5a in human macrophages and 
neutrophils (Kee et al, 2005; Sethu et al, 2008; Zhi et al, 2006). Therefore, we 
hypothesize that SphK may also be involved in LPS-triggered monocyte migration. Our 
previous studies have shown that N,N-dimethylsphingosine (DMS), which is a 
pharmacological inhibitor of SphK, effectively blocks TNFα and C5a activated SphK 
activities. Our result showed that 10 µM DMS could significantly block chemotaxis of 
monocyte towards LPS. Hence, blockade of SphK activity effectively blocked the LPS-
stimulated monocyte migration (Figure 3). This suggests that SphK potentially plays a 
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Figure 3. RSV inhibits the LPS-induced human primary monocyte migration. 
Primary monocytes were either left untreated or pretreated with varying doses of RSV or 
10 µM DMS. The migration of monocytes toward PBS-containing chambers (basal) or 
toward LPS-containing (100 ng/ml) chamber were measured using a 96-well cell 
migration assay kit based on the Boyden chambers principle. The number of monocytes 
migrated in the presence of LPS without RSV treatment were compared with basal 
samples in the absence of LPS (§p <0.05). The number of monocytes migrated in the 
RSV or DMS pre-treated wells towards LPS were compared with that in PBS treated 
samples towards LPS (LPS+PBS) (**p <0.01). Depicted are means ± SD of triplicate 
measurements using a two-tailed unpaired Student’s t-test. Data are representative of 






3.4 Effects of RSV on cell viability of human primary monocytes 
It has been shown that RSV may induce cell proliferation and cell death 
depending on the dose and the length of treatment. Hence, it is important to ascertain that 
the inhibitory effects of RSV observed in this study are due to its modulation of 
important signaling molecules in LPS/TLR4 pathway, instead of its effect on cell death. 
A cell viability assay was carried out in human primary monocytes to examine the 
potential cytotoxicity of RSV. Monocytes were treated with various doses of RSV (0 μM 
to 80 μM) for 4 h, 12 h and 24 h. As shown in Figure 4, there were no significant 
differences observed in cell viability when monocytes were treated with 0 μM to 40 μM 
of RSV up to 24 h. Significant cell death was only observed in monocytes treated with 80 
μM or higher dose of RSV for 12 h and 24 h (Figure 4). Therefore, treatment of human 
primary monocytes with RSV up to 40 μM for 4 h to 24 h did not result in any significant 
cell death. In addition, trypan blue staining was performed regularly to examine the cell 
viability after incubation of RSV after 24 hours. There was so significant change in the 
number of viable cells. The monocytes used in these experiments were from the same 
batch of donors as those used in figure 2 and figure 3. These suggest that the decreased 
pro-inflammatory responses of primary monnocytes treated RSV are indeed due to the 
inhibitory effect of RSV on important signaling products in the pathway rather the 































Figure 4. Viability of human primary monocytes treated with increasing doses of 
RSV. Human primary monocytes were left untreated or treated with 0 to 80µM of RSV 
for 4 h, 12 h and 24 h and cell viability was examined using the MTT assay. 0µM RSV-
treated samples contained 0.04% DMSO (same concentration as that in 80µM of RSV). 
RSV-treated samples were compared with the untreated samples (Basal) of their 
respective incubation times. Depicted are means ± SD of triplicate measurements using a 







3.5 Pre-treatment of human primary monocytes with RSV blocks the LPS-induced 
NF-κB activation which is regulated by SphK 
 To understand if RSV inhibits the release of the pro-inflammatory mediators 
through modulating NF-κB activity, we examined the effects of RSV on the LPS-
triggered NF-κB activity. Upon LPS stimulation for 30 minutes, the amount of p65 
subunits that binds to DNA were significantly increased by 2-folds compared with the 
basal levels (Figure 5). However, pre-treating primary monocytes with 40 µM RSV 
blocks this LPS-activated p65 binding activity (Figure 5). Taken together with previous 
findings (Figure 2), the inhibitory effects of RSV on the LPS-triggered TNFα, IL-1β, IL-
6 cytokine production and MCP-1 and MIP-1α chemokine and HMGB1 production may 
be attributed to its inhibition on NF-κB activity. 
Studies have demonstrated that SphK plays a role in regulating the receptor-
activated NF-κB in immune cells (Sethu et al, 2008). Hence, it is interesting to examine if 
the LPS-stimulated NF-κB activity in primary monocytes is also dependent on SphK. Our 
data showed that blockade of SphK activity using 10 µM of DMS significantly blocked 
the LPS-activated NF-κB activity (Figure 5). This suggests that SphK may be involved 
in LPS-mediated NF-κB activation in primary monocytes. 
Several pro-inflammatory stimuli, including anaphylatoxin C5a, TNFα, and 
immune complexes, activate SphK on human neutrophils and macrophages, and blockade 
of SphK activity inhibits several downstream pro-inflammatory responses triggered by 
these stimuli (Ibrahim et al, 2004; Issuree et al, 2009; Melendez et al, 2000; Sethu et al, 
2008). Therefore, we hypothesize that LPS may also activate SphK to trigger downstream 
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pro-inflammatory responses in primary monocytes. Our results showed that upon LPS 
trigger, SphK activity increased rapidly after 5 minutes and peaked from 5-10 minutes 
(Figure 6). At 10 minutes, SphK activity was increased by 75% in primary monocytes 
treated with LPS compared with the cells at basal. Pre-treatment of primary monocytes 
with 40 µM of RSV significantly inhibited this LPS-triggered SphK activity at 5 and 10 
minutes (Figure 6). Monocytes pre-treated with 10 µM DMS served as a positive control. 
Our results confirmed that DMS significantly inhibited LPS-triggered SphK activity at 5 
and 10 minutes. These suggest that LPS could trigger SphK activity in primary 
monocytes that could be modulated by RSV.  
 Taken together, these data suggest that LPS-triggered NF-κB activity is 
downstream of SphK activity in this signaling pathway and the inhibition of RSV on 
LPS-mediated NF-κB activity is most probably due to its inhibition of LPS-activated 

































Figure 5. Both RSV and DMS both block LPS-induced NF-κB activation. Levels of 
NF-κB p65 DNA binding in human monocyte were assessed using the EZ-Detect 
transcription factor kit. Cells were pre-treated with PBS (with 0.02% DMSO) or 40 µM 
RSV or 10 µM DMS for 15 min before LPS (100 ng/ml) trigger, and level of NF-κB p65 
DNA binding was measured after 30 min. RSV or DMS pre-treated and LPS triggered 
samples were compared with LPS triggered samples in PBS. Depicted are means ± SD of 
triplicate measurements using a two-tailed unpaired Student’s t-test p value (**p <0.01). 
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Figure 6. RSV blocks LPS-triggered SphK activity in human primary monocytes. 
Human primary monocytes (3 × 106) were stimulated with 100 ng/ml LPS over 5, 10, 30 
and 45 min time points with PBS (with 0.02% DMSO) or 40 µM RSV or 10 µM DMS 
pre-treatment (15 min) and SphK activity was measured as described in Materials. RSV 
or DMS pre-treated and LPS triggered samples were compared with LPS triggered 
samples in PBS at the corresponding time point (*p <0.05), SphK activities after LPS 
trigger at 5, 10, 30 and 45 min are compared with cells at basal in each treatment group 
(§p <0.01) using a two-tailed unpaired Student’s t-test. Depicted are means ± SD of 







3.6 Pre-treatment of human primary monocytes with RSV blocks the LPS-activated 
ERK1/2 phosphorylation, but not p38 or JNK 1/2 phosphorylation 
The MAPK activation is well-evident in inflammatory conditions, especially in 
the activation and migration of neutrophils, monocytes and macrophages. ERK1/2 and 
p38 phosphorylation are induced by C5a in neutrophils and TNFα in monocytes (Ibrahim 
et al, 2004; Sethu et al, 2008). In addition, others have demonstrated that LPS could 
stimulate ERK1/2 phosphorylation in macrophages and dendritic cells (Kang et al, 2007; 
Nakayama et al, 2003). In accordance to this, Lee et al has shown that RSV reduces the 
glutamate-mediated MCP-1 expression via inhibition of ERK1/2 pathways in rat’s brain 
(Lee et al, 2010). Therefore, we hypothesize that RSV may regulate the ERK1/2 pathway 
stimulated by LPS in the human primary monocytes. 
We investigated whether all three MAPKs (ERK1/2, p38, JNK) are activated 
upon LPS stimulation. As shown in Figure 7A and Figure 7B, the exposure of human 
primary monocytes to 100 ng/ml LPS leads to an increase in ERK1/2, p38 and JNK1/2 
phosphorylation after 5 minutes. Importantly, pre-treatment of primary monocytes with 
40 µM of RSV inhibited only the LPS-stimulated ERK1/2 phosphorylation at 5 and 10 
minutes (Figure 7A). The LPS-stimulated p38 and JNK phosphorylation remained 
unchanged in monocytes pre-treated with 40 µM of RSV (Figure 7B). These data 
indicate that RSV only blocks LPS-activated ERK1/2 activation, but not LPS-stimulated 























                         
Figure 7. (A) RSV blocks LPS-triggered EKR1/2 phosphorylation. Human primary 
monocytes were treated with or without 40 µM RSV for 15 min and then triggered with 
100 ng/ml LPS for 5, 10 and 30 min. Whole cell extracts were then prepared, and 40 µg 
of extracts were resolved on 10% SDS-PAGE gel, electrotransferred on PVDF 
membranes, and probed for phospho-ERK1/2. Same blots were probed with total ERK1/2 










































Figure 7. (B) RSV does not block LPS-stimulated p38 nor JNK1/2 phosphorylation. 
Human primary monocytes were treated with or without 40 µM RSV for 15 min and then 
triggered with 100 ng/ml LPS for 5, 10 and 30 min. Whole cell extracts were then 
prepared, and 40 µg of extracts were resolved on 10% SDS-PAGE gel, electrotransferred 
on PVDF membranes, and probed for phos-p38 and phos-JNK1/2. Same blots were 
probed with total respective MAPK antibodies and GAPDH to verify equal protein 




3.7 The LPS-triggered SphK activity and ERK1/2 phosphorylation are independent 
of each other in human primary monocytes 
There have been reports of interplay between ERKs and SphK in various 
signaling pathways (Kono et al, 2010). It is interesting to investigate if there is such 
cross-talking occurring in human primary monocytes stimulated with LPS. To investigate 
if ERK1/2 regulates SphK activity in primary monocytes stimulated with LPS, 
monocytes were pretreated with PD98059 (inhibitor of MEK) for 15 min before 
stimulating with LPS up to 45 min. Our result showed that pre-treatment of cells with 20 
µM of PD98059 did not significantly reduce LPS-triggered SphK activity at 5min and 
10min (< 5% reduction in SphK activity) (Figure 8).  
Reciprocally, to investigate if SphK activity regulates LPS-stimulated ERK1/2 
phosphorylation, primary monocytes were pre-treated with the SphK inhibitor, 10 µM 
DMS for 15 min before stimulating monocytes with LPS. The result showed that 
blockade of SphK activity using DMS did not significantly block the LPS-triggered 
ERK1/2 phosphorylation (Figure 9).  
 Taken together, it appears that the LPS-activated SphK activity and ERK1/2 
phosphorylation are two independent events. However, RSV could inhibit these two 
independent pathways triggered by LPS (Figure 8 and Figure 9), leading us to 











































Figure 8. Inhibition of ERK1/2 activity with PD98059 does not block LPS-triggered 
SphK activity in human primary monocytes. Human primary monocytes were 
stimulated with 100 ng/ml LPS over 5, 10, 30 and 45 min time points after prior 
treatment (15 min) with PBS or 20 µM PD98059, and SphK activity was measured as 
described in Materials & Methods. PD98059 pre-treated and LPS triggered samples were 
compared with LPS triggered samples in PBS at corresponding time points. SphK 
activities after LPS trigger at 5, 10, 30 and 45 min are compared with cells at basal in 
each treatment group (§p <0.01) using a two-tailed unpaired Student’s t-test. Depicted are 





























Figure 9. SphK inhibitor DMS does not block LPS-triggered ERK1/2 
phosphorylation. Human primary monocytes were pre-treated with or without 10 µM 
DMS for 15 min and then triggered with 100 ng/ml LPS for 5, 10 and 30 min. Whole cell 
extracts were then prepared, and 40 µg of extracts were resolved on 10% SDS-PAGE gel, 
electrotransferred on PVDF membranes, and probed for phos-ERK1/2.  Same blots were 
probed with total ERK1/2 antibody and GAPDH to verify equal protein loading. Data are 








3.8 The LPS-triggered SphK activity is downstream of PLD in human primary 
monocytes  
PLD has been suggested to regulate both SphK and ERK1/2 in immune cell 
signaling (Gomez-Cambronero & Keire, 1998; Sethu et al, 2008). To investigate if LPS-
induced SphK activity and ERK1/2 phosphorylation in human primary monocytes are 
also regulated by PLD, we examined the LPS-triggered SphK activity by blocking PLD 
signaling. The lack of a commercially available small molecule inhibitor of PLD and the 
difficulty in obtaining sufficient knockdown of the enzyme by RNAi approaches have 
resulted in the utilization of butan-1-ol as an extremely useful tool in studying PLD 
function and regulation. Butan-1-ol is a short chain primary aliphatic alcohol and 
functions as an alternative nucleophilic acceptor in the PLD-catalysed 
transphosphatidylation reaction, resulting in reduced PtdOH production and thus second 
messenger generation. Butan-3-ol, a tertiary alcohol, is unable to function in this manner, 
and therefore, acts as a negative control for Butan-1-ol. Here, we used 0.3% of Butan-1-
ol as an inhibitor of PLD signaling, and 0.3% Butan-3-ol as a non-specific control, 
respectively. Pre-incubation of primary monocytes with 0.3% of Butan-1-ol for 15 mins 
significantly reduced the LPS-triggered SphK activity to basal whereas 0.3% tertiary 
butanol did not exert the same inhibitory effects (Figure 10). This suggests that PLD 














































Figure 10. PLD regulates the LPS-activated SphK activity in human primary 
monocytes. Human primary monocytes were stimulated with 100 ng/ml LPS over 5, 10, 
30 and 45 min time points with prior treatment (15 min) of PBS, or 0.3% Butan-1-ol or 
0.3% Butan-3-ol and SphK activity was measured. Butan-1-ol or Butan-3-ol pre-treated 
and LPS triggered samples were compared with LPS triggered samples in PBS at 
corresponding time points (**p <0.01). SphK activities after LPS trigger at 5, 10, 30 and 
45 min are compared with cells at basal in each treatment group (§p <0.01) using a two-
tailed unpaired Student’s t-test. Depicted are means ± SD of triplicate measurements. 






3.9 The LPS-activated ERK1/2 phosphorylation is downstream of PLD in human 
primary monocytes 
After dissecting the relationship of PLD and SphK in human primary monocytes 
stimulated with LPS, it is also important to examine the relationship of PLD and ERK1/2 
in the signaling mechanism. To investigate if PLD plays a role in regulating the LPS-
mediated ERK1/2 phosphorylation, we also utilized Butan-1-ol as inhibitor of the PLD 
activation pathway. Our data showed that pre-treatment of primary monocytes with 0.3% 
Butan-1-ol significantly blocked the LPS-triggered ERK1/2 phosphorylation at 5 min and 
10 min while 0.3% butan-3-ol did not exert similar effects (Figure 11). This suggests that 

















Figure 11. PLD regulates the LPS-activated ERK1/2 phosphorylation in human 
primary monocytes. Human primary monocytes were pre-treated with or without 0.3% 
Butan-1-ol or 0.3 % Butan-3-ol (control for butan-1-ol) for 15 min and then triggered 
with 100 ng/ml LPS for 5, 10 and 30 min. Whole cell extracts were then prepared, and 40 
µg of extracts were resolved on 10% SDS-PAGE gel, electrotransferred on PVDF 
membranes, and probed for phos-ERK1/2. Same blots were probed with total ERK1/2 








To ascertain that PLD is indeed upstream of SphK and ERK1/2 in human primary 
monocytes stimulated with LPS, we performed the reverse experiment to examine if the 
inhibition of SphK activity using DMS or the inhibition of ERK1/2 phosphorylation 
using PD98059 has any effect on the LPS-triggered PLD activity in primary monocytes. 
Stimulation of human primary monocytes with 100 ng/ml of LPS induced significant 
increase (50%) in PLD activity (Figure 12). In cells pre-treated with 10 µM DMS or 20 
µM PD98059, LPS stimulation also increased PLD activity by 45% and 49% respectively 
(Figure 12). Hence, neither DMS nor PD98059 pre-treatment blocked LPS-triggered 
PLD activity in primary monocytes. Taken together, our findings (Figure 10 - 12) 
suggest that PLD regulates SphK activity and ERK1/2 phosphorylation in human primary 


















































Figure 12. Inhibition of SphK activity or ERK1/2 phosphorylation does not inhibit 
LPS-stimulated PLD activity in human primary monocytes. PLD activity of human 
monocytes (5 × 106) was measured after stimulation with LPS (100 ng/ml) for 30 min 
with pre-treatment with PBS or 10 µM DMS or 20 µM PD98059. Samples triggered with 
LPS are compared with the samples without LPS stimulation for each treatment group. 
Depicted are means ± SD of triplicate measurements using a two-tailed unpaired 








3.10 Pre-treatment of human primary monocytes with RSV blocks the LPS-
activated PLD activity 
Having demonstrated that PLD regulates SphK activity and ERK1/2 
phosphorylation in human primary monocytes stimulated with LPS, another important 
question to address is if the inhibitory effects of RSV on SphK activity and ERK1/2 
phosphorylation is through inhibiting PLD activity. Hence, we next examined if PLD 
activity in human primary monocytes stimulated with LPS is affected when the 
monocytes are pre-treated with 40 µM of RSV. Our result showed that RSV significantly 
decreased the LPS-induced PLD activity in the primary monocytes (from 70% increase to 
18% increase) (Figure 13). Hence, we conclude that RSV inhibits PLD activity, which in 
turn regulates downstream SphK activity and ERK1/2 phosphorylation in human primary 

















































Figure 13. RSV blocks the LPS-triggered PLD activity in human primary 
monocytes. PLD activity of human monocytes (5 × 106) was measured after stimulation 
with LPS (100 ng/ml) for 30 min with pre-treatment with PBS or 40 µM RSV. Depicted 
are means ± SD of triplicate measurements using a two-tailed unpaired Student’s t-test p 










In this chapter, we have elucidated the signaling cascade involving PLD, SphK, 
ERK1/2 and NF-κB upon LPS stimulation in human primary monocytes. Activation of 
TLR4 by LPS leads to the activation of PLD, which regulates downstream SphK activity 
and EKR1/2 phosphorylation. This results in the activation of the transcription factor NF-
κB, thus modulating the production of pro-inflammatory cytokines and chemokines. We 
further demonstrated that pre-treatment of human primary monocytes with RSV 
significantly attenuates the LPS-mediated pro-inflammatory responses by blocking PLD 
















Figure 14. Molecular targets of RSV in LPS-mediated signaling pathway in human 
primary monocytes. On the left, stimulation of TLR4 by LPS leads to the activation of 
PLD, which results in downstream ERK1/2 phosphorylation and SphK activation. These 
lead to the activation of the transcription factor NF-κB and the production of pro-
inflammatory mediators. On the right, pre-treatment of monocytes with RSV leads to the 
blockade of LPS-triggered PLD activity, thus abrogating its downstream signaling and 





The pathogenesis of sepsis is mediated in part by bacterial endotoxin, which 
stimulates monocytes, macrophages and neutrophils to sequentially release early and late 
pro-inflammatory mediators (Riedemann et al, 2003c). Significant advances have been 
made to understand the roles of these pro-inflammatory mediators in the pathogenesis of 
sepsis. In addition, effort has been put into developing drugs to lower cytokine and 
chemokine-mediated inflammation, by blocking transcription of cytokine and chemokine 
genes or by targeting cytokine and chemokine receptors. For example, the vasoactive 
intestinal peptide  (VIP) is a widely distributed neuropeptide that displays potent anti-
inflammatory and immunomodulatory activity by down-regulating pro-inflammatory and 
T-cell cytokines in immune-mediated diseases (Delgado et al, 2000). The beneficial 
effect of VIP on the experimental animal models of acute and chronic inflammation 
including septic shock and LPS-induced acute inflammation has been demonstrated 
(Delgado et al, 2000). However, a major difficulty in developing therapeutics that target 
early cytokines production (e.g. TNFα, IL-1β) is that they are released in the early stages 
of inflammatory responses. This leaves a narrow therapeutic window for the 
administration of antagonists. Therefore, numerous studies have explored the possibility 
of targeting mediators that are released later in the inflammatory cascade, such as 
HMGB1. HMGB1 elicits a second wave of inflammatory responses has been shown to be 
an important mediator of inflammation in sepsis and sustained elevated levels of HMGB1 
are associated with higher mortality (Huang et al, 2010). Extracellular HMGB1 induces 
the synthesis of TNFα, IL-1β, and IL-6 in monocytes and macrophages. In our study, we 
showed that RSV not only lowered the LPS-activated TNFα, IL-1β, IL-6, MCP-1 and 
MIP-1α release, but also decreased LPS-stimulated HMGB1 production. Therefore, RSV 
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may be effective in modulating the production of pro-inflammatory mediators in both 
early and late phages of endotoxins activation and attenuating the excessive inflammatory 
responses.  
Next, our results suggest that RSV inhibits the production of the inflammatory 
cytokines and chemokines via blocking LPS-mediated NF-κB activity. The modulating 
effects of RSV on NF-κB activity in many inflammatory conditions have been examined 
by others. Kumar et al investigated the effect of RSV on NF-κB inflammatory cascade, 
COX-2, TNFα and IL-6 levels in experimental diabetic neuropathy (Kumar & Sharma, 
2010). The authors found that RSV treatment in rats decreased the expression of p65 and 
levels of TNF-α, IL-6 and COX-2. In another study, pre-treatment with RSV completely 
inhibits the Receptor Activator of NF-κB Ligand (RANKL)-induced NF-κB activation in 
bone-derived and preosteoblastic cells, and subsequent osteoclastogenesis (Shakibaei et 
al, 2011). In the in vivo model of angiotensin-II-mediated vascular inflammation, chronic 
administration of RSV reduced monocyte and endothelial CAM expression, chemokine 
release, phosphorylation of p38 MAPK, and phosphorylation of the p65 subunit of NF-
κB (Rius et al, 2010). However, since NF-κB is the transcription factor that can be 
regulated by different pathways upon receptor activation. It is of importance to 
understand if RSV modulates LPS-mediated NF-κB via modulation of the upstream 
signaling mechanisms. 
Understanding the intracellular signal transduction mechanisms that regulate the 
LPS-mediated responses has profound implications, especially in the identification of 
novel molecules for potential therapeutic treatment. We next showed that the LPS-
stimulated PLD activation in human primary monocytes leads to the downstream SphK 
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activation and ERK1/2 phosphorylation. The important roles of PLD and SphK in 
monocytes have been discussed in MyD-1 (CD172)-mediated inhibition of TNFα 
secretion (Smith et al, 2003). Ligation of MyD-1 recruits the tyrosine phosphatase SHP-2 
and promotes the sequential activation of PI3K, PLD and SphK (Smith et al, 2003). 
Interestingly, our results show that the LPS-activated SphK activation and ERK1/2 
phosphorylation appear to be two independent mechanisms because pre-treatment with 
PD98059 (an inhibitor of MEK) did not inhibit the LPS-activated SphK activity and pre-
treatment with DMS (an inhibitor of SphK) did not affect the LPS-stimulated ERK1/2 
phosphorylation. In addition, we found that the inhibition of SphK activity using DMS 
blocks the LPS-mediated NF-κB activation, suggesting that SphK regulates NF-κB in 
human primary monocytes stimulated with LPS. Others have shown that ERK1/2 is able 
to regulate NF-κB activity upon LPS trigger (O'Hara et al, 2011). Hence, together with 
our data, it is possible that the LPS-induced and PLD regulated SphK and ERK1/2 may 
converge at NF-κB level and drive the pro-inflammatory responses in human primary 
monocytes. In this way, RSV may effectively block the LPS triggered NF-κB activation 
via its inhibition of LPS-stimulated PLD activity, which in turn regulates SphK activation 
and ERK1/2 phosphorylation in human primary monocytes. 
Signaling cascades usually function as a network rather in isolation, thus crosstalk 
between pathways is a characteristic of physiologically relevant cellular processes. We 
have shown that in human primary monocytes, PLD regulates the LPS-mediated ERK1/2 
phosphorylation whereas the inhibition of ERK1/2 does not affect the LPS-mediated PLD 
activity. In accordance with our results, Wakelam et al have demonstrated no inhibition 
of PLD activity in Hela cells pre-incubated with PD184352 (Wakelam et al, 2010). In 
113 
 
these cells, ERK did not phosphorylate PLD. Even though both p38 and ERK interact 
with PLD and function upstream of this enzyme, only the p38 protein phosphorylates 
PLD. In contrast, the interaction of PLD with ERK1/2 and a role for ERK in PLD 
activation have been previously reported in lung microvesicular endothelial cells 
(Varadharaj et al, 2006). Besides ERK1/2, the relationship between PLD and p38 has also 
been examined in a few studies. Stimulation of astrocytes with Epigallocatechin Gallate 
(EGCG) activates PLD in a p38-dependent manner (Kim et al, 2004). On the other hand, 
PLD activity appears to be upstream of p38 in the fMLP-stimulated HL60 cells (Bechoua 
& Daniel, 2001). Phosphorylation of PLD1 and PLD2 by p38 has also been shown in 
vivo (Natarajan et al, 2001). Possible significance for the crosstalk between PLD and 
MAPK signaling is that PLD recruits the MAPK target protein(s) to the appropriate 
membrane within the cells, enabling compartmentalisation and interaction of the target 
proteins with MAPK signaling modules. 
In addition to our finding that RSV inhibits LPS-mediated ERK1/2 
phosphorylation, RSV is shown to modulate ERK1/2 signaling, down-regulates c-Jun, 
and suppresses AP-1 activity in A431 cells (Kim et al, 2006; Malemud, 2007; Van 
Slambrouck et al, 2005). Moreover, RSV is reported to down-regulate glutamate-induced 
IL-1β expression and reduced the expression of MCP-1 mRNA and protein release via 
the inactivation of ERK1/2 (Lee et al, 2010). Besides RSV, other natural compound 
including tangeretin and ligustilide are shown to inhibit MAPK signaling in vitro, but in a 
non-specific manner (Kim et al, 2006; Malemud, 2007; Van Slambrouck et al, 2005). The 
major problem with these natural compounds is that they work on several molecular 
targets. Therefore, new generations of small molecule SAP/MAPK inhibitors are 
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synthesized and have demonstrated increasing specificity for each of the JNK, ERK and 
p38 kinase isoforms (Malemud, 2007). Some of them have shown promising results in 
animal studies and may eventually prove effective for treating human diseases. These 
compounds are currently being tested in human subjects to assess their oral 
bioavailability, pharmacokinetics and toxicity. Therefore, it is important to weigh 
specificity against toxicity between natural and synthetic compounds as MAPK inhibitors. 
Taken together, the data presented in this chapter suggest that LPS triggers pro-
inflammatory responses including the production of several cytokines, chemokines, the 
release of HMGB1 and chemotaxis in human primary monocytes. These physiological 
responses are regulated by a novel signaling pathway involving PLD, SphK, ERK1/2 and 
NF-κB. More importantly, we have identified PLD as a target of RSV in this LPS-
mediated signaling pathway. RSV appears to attenuate the LPS-mediated pro-
inflammatory responses by modulating PLD activity and its downstream signaling 
molecules. Moreover, inhibition of one specific signaling pathway via targeting PLD and 
SphK could be a potentially advantageous strategy as it may not inhibit the normal 
function of downstream multi-target effectors that are activated by other physiological 
stimulus. In this way, it is possible to attenuate the excessive inflammatory responses 
while maintaining the normal immune function inside the cells. Therefore, our findings 
have profound implications for the use of RSV as therapeutic intervention against 
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In view of the profound effects of RSV on the LPS-mediated signaling pathways 
that lead to decreased production of pro-inflammatory cytokines, chemokines and 
HMGB1 in human primary monocytes, it is of interest to study the potential therapeutic 
implications of RSV in an animal experimental model of polymicrobial sepsis. Since 
RSV is a pleiotropic compound that plays different roles in various cell types, it is also 
important to investigate its effects in in vivo systems to validate its therapeutic potential. 
RSV appears to be effective in protecting the endotoxin-mediated inflammation in 
animal models. For example, Sebai et al have demonstrated the protective effect of RSV 
in endotoxemia-induced acute phase response in rats via a nitric oxide-independent way 
(Sebai et al, 2009). In a separate study, they also showed that pre-treatment with RSV for 
up to 7 days protects mice against the LPS-induced oxidative stress and effectively 
counteracts the LPS-induced tissue lipoperoxidation and catalase activity depletion 
(Sebai et al, 2010). RSV may reduce sepsis-induced remote organ injury, at least in part, 
through its ability to balance oxidant-antioxidant status, to inhibit neutrophil infiltration 
and to regulate the release of inflammatory mediators (Kolgazi et al, 2006). Recently, 
Gacar et al also showed that RSV treatment decreases the elevated levels of TNFα and 
IL-6 levels in septic animals (Gacar et al, 2011). They suggested that the functional 
impairment of the ileal tissues were due to the inflammatory responses and the 
detrimental effects of sepsis on ileal contractility may be prevented by the anti-
inflammatory effects of RSV. Shigematsu et al further demonstrated that RSV prevents 
superoxide-dependent inflammatory responses induced by ischemia/reperfusion 
(Shigematsu et al, 2003). Taken together, these studies highlight the protective effects of 
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RSV in several inflammatory models including the LPS-induced endotoxemia and sepsis 
in rats. Nonetheless, most studies have employed the prophylactic approach whereby the 
mice were pre-treated with RSV for a period of time before the induction of sepsis (Cao 
et al, 2011; Gacar et al, 2011; Kolgazi et al, 2006). Clinically, this is less relevant 
compared to the therapeutic treatment with RSV as patients usually seek treatment after 
developing symptoms of sepsis. In addition, there is no detailed study on the effects of 
RSV on the survival rates of mice subjected to sepsis. There is also a lack of 
comprehensive analysis of the pro/anti-inflammatory mediators in the serum or lavage of 
the mice following therapeutic treatments of RSV. Therefore, in this chapter, we aim to 
study the possible mechanisms and physiological parameters that are modulated by RSV 
in an in vivo mouse model of sepsis. 
In this study, we employ the gold-standard mice model for sepsis called caecal 
ligation and puncture (CLP) model. In this model, sepsis originates from a polymicrobial 
infectious focus within the abdominal cavity, followed by bacterial translocation into the 
blood compartment, which triggers a systemic inflammatory response (Figure 15). A 
requirement of this model is that it should be performed with high consistency to obtain 
reproducible results. It has been shown that accompanying inflammatory responses vary 
with the severity grade of sepsis, which in turn is highly dependent on the extent of cecal 
ligation. In contrast to the endotoxemia model, this CLP model mimics patho-
physiological changes typically seen in septic patients and thus the results obtained 









Figure 15. Caecal ligation and puncture model of sepsis. Adapted from Buras JA et al, 
animal models of sepsis: setting the stage. Nat Rev Drug Discov 2005 Oct; 4(10):854-65, 











The pharmacokinetics of RSV has been studied extensively in both animals and 
humans even though it appears to be confusing and contradictory in some cases. RSV is 
well-tolerated in animals, with little toxicity, at doses as high as 3000 mg/kg body weight 
(Wenzel et al, 2005). In humans, studies have shown that it is safe to take 5 g/day of RSV 
for one month. RSV is rapidly absorbed and metabolized, mainly as sulfo- and glucuro-
conjugates, which are excreted in urine (Baur & Sinclair, 2006). The total sulphate 
conjugates account for 37% and total glucuronide conjugates account for around 19% of 
the metabolites in the urine. Walle et al found that the serum half-life of total RSV 
metabolites was ~ 9.2 hours (Walle et al, 2004). In this study, we would like to bypass 
the bioavailability issue of RSV and investigate the direct effect of RSV instead of its 
metabolites. Therefore, we examined the effects of RSV in vivo using peritoneal injection 












4.1 Therapeutic treatment with RSV protects mice against CLP-induced mortality 
In order to translate our in vitro findings to in vivo, we investigated the effects of 
RSV in the CLP model described previously (Hubbard et al, 2005; Niessen et al, 2008a; 
Spite et al, 2009). This CLP murine model closely resembles the clinical syndrome in 
sepsis.  
We compared the survival rates of the RSV treated and untreated mice in the CLP 
sepsis model. In the treatment group, different doses of RSV (2 mg/kg.b.w, 1 mg/kg.b.w 
and 0.5 mg/kg.b.w) were administered intraperitoneally to C57BL/6 mice 1 h, 3 h, 6 h, 24 
h, 48 h and 72 h after CLP. In the control group, mice were injected with plain saline at 
the corresponding time points. Mice were monitored for 7 days (168 hours) and the 
detailed clinical scores were recorded. The Kaplan Meier Survival curve showed that 
treatment with RSV for 3 days significantly improved the survival rates of mice subjected 
to CLP (60-80% survival in the treated groups compared with 0% in the CLP group) 
(Figure 16). Injecting mice with 1 mg/kg body weight of RSV led to the best survival 
rate (only 1 mouse died after 72 h) compared with 2mg/kg body weight of RSV (1 mouse 
died after 60h and 2nd mouse died after 80h);  and compared with 0.5mg/kg body weight 
of RSV (1 mouse died after 60h). Sham-operated mice appeared to be normal and 100% 
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Figure 16. Therapeutic treatment with RSV protects mice against CLP-induced 
mortality. Survival of sham operated mice (Sham), or mice given CLP and injected with 
saline (CLP+Saline), or mice given CLP and injected with various doses of RSV 
(CLP+RSV) were followed until day 7 after CLP. Saline or RSV was i.p. injected into 
the mice at 1 h, 3 h, 6 h, 24 h, 48 h and 72 h after CLP. Sham operated mice appeared to 
be normal and 100% survival was observed throughout the study. The results are 
expressed as percentage of survival of mice every 12 hours. Survival of mice in different 
groups were compared with the survival of mice in the saline treated group (n = 5 







4.2 Combination therapy of RSV and Co-amoxiclav enhances the protection of mice 
against CLP-induced mortality 
Co-amoxiclav is a broad-spectrum antibiotic currently used to treat patients with 
sepsis. Co-amoxiclav is combination of amoxicillin trihydrate (a β-lactam antibiotic), 
with potassium clavulanate (a β-lactamase inhibitor). This combination results in an 
antibiotic with an increased spectrum of action and increased efficacy against β-
lactamase-producing Amoxicillin-resistant bacteria. Co-injection of Co-amoxiclav with 1 
mg/kg body weight of RSV at 1 h, 3 h, 6 h, 24 h, 48 h and 72 h after CLP further 
prolongs the lifespan of one mouse by 1 day (Figure 17). Sham-operated mice appeared 
to be normal and 100% survival was observed throughout the study. Results from Figure 
16 and Figure 17 together indicate that the peritoneal injection of RSV is protective in 
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Figure 17. Combination therapy of RSV and Co-amoxiclav enhances the protection 
of mice against CLP-induced mortality. Survival of sham operated mice (Sham), or 
mice given CLP and injected with saline (CLP+Saline), or mice given CLP and injected 
with 1 mg/kg of RSV without amoxicillin-clavulanic (CLP+RSV [1 mg/kg b.w.]) or with 
amoxicillin-clavulanic (CLP+RSV [1 mg/kg b.w.] + Co-Am) was followed until day 7 
after CLP. Saline or RSV or RSV + Co-amoxiclav was i.p. injected into the mice at 1 h, 3 
h, 6 h, 24 h, 48 h and 72 h after CLP. Sham operated mice appeared to be normal and 
100% survival was observed throughout the study. The results are expressed as 
percentage of survival of mice every 12 hours. Survival of mice in different groups were 
compared with the survival of mice in the saline treated group (n = 5 mice/group), log 







4.3 RSV lowers the bacterial load in mice subjected to CLP 
One of the major features of sepsis is the replication and dissemination of bacteria. 
A major concern of anti-inflammatory agents is that they may suppress the immune 
system in its ability to eliminate the bacteria. We therefore investigated the bacterial load 
in both the peritoneal lavage and blood of mice subjected to CLP. In mice treated with 1 
mg/kg body weight of RSV (1 h, 3 h and 6 h after CLP), peritoneal bacterial counts 
decreased by 90% (from 105 to 104 in 10 µl peritoneal lavage) 24 h after CLP. Similarly, 
bacterial counts in blood in the treatment group were also decreased by 95% (from 100 to 
5 in 10 µl blood) 24 h after CLP (Figure 18). These results suggest that RSV reduces 
both local and systemic bacterial load, and this may contribute to the enhanced survival 
















Figure 18. RSV lowers the bacterial load in mice subjected to CLP. Bacterial count in 
whole blood and peritoneal lavage fluid were measured by the colony-forming unit (cfu) 
method 24 hours after CLP. cfu counts are compared between RSV treated group 
(CLP+RSV) with PBS treated group (CLP+PBS) using a two-tailed unpaired Student’s t-
test (**p <0.01), (n = 5 mice/group). 
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4.4 RSV attenuates excessive cytokines and chemokines production in the serum 
and peritoneal lavage of CLP-induced polymicrobial sepsis in mice 
In addition to the cytokines IL-1β, IL-6, TNFα, and chemokines MCP-1, MIP-1α, 
which showed importance in LPS-mediated inflammatory responses in human primary 
monocytes, it is useful to examine the levels of a few more cytokines that also play 
important role in vivo model of sepsis including IL-3 (Wolach, 1997), IL-5 (Linch et al, 
2009; Yousefi et al, 2008), gamma interferon (IFNγ) (Qiu et al, 2003) and keratinocyte-
derived chemokine (KC) (Hassan-Khabbar et al, 2010). Hence, the levels of pro-
inflammatory cytokines IL-1β, IL-3, IL-5, IL-6, TNFα, IFNγ and chemokines MCP-1, 
MIP-1α, MIP-1β and KC in both serum (Figure 19) and peritoneal lavage (Figure 20 A) 
of sham operated mice, RSV-treated mice or PBS-treated mice were examined and 
percentage inhibition is calculated (Figure 20 B). Our data showed that the levels of the 
above mentioned cytokines and chemokines in the serum and peritoneum of mice were 
excessively elevated upon CLP induction, and their levels in mice treated with RSV were 
lower compared with that in mice treated with PBS (Figure 19-20). To note, upon RSV 
treatment, the decreases of IFNγ and KC levels in the serum were not statistically 
significantly compared with the PBS treated group, but the decreases of these two factors 
were significant in the peritoneal lavage. In contrast, the decrease of IL-1β, IL-3 and 
MCP-1 in the peritoneal lavage was not significant compared with the PBS treated group, 
but the decreases of these three factors were significant in the serum. One logical 
explanation would be the variability of responses among the mice in the same group. 
Another reason may be the selective modulation of cytokines and chemokines by RSV 
































































Figure 19. RSV lowers the cytokine and chemokine production in the serum of mice 
subjected to CLP. IL-1β, IL-3, IL-5, TNFα, MIP-β IFNγ, MCP-1, IL-6, MIP-1α and KC 
in serum of sham-operated mice (Sham), or mice given CLP and injected with either PBS 
(CLP+PBS) or 1 mg/kg of RSV (CLP+RSV) were assessed 24 h after CLP by ELISA 
(R&D Systems, Minneapolis, MN and Bio-Plex Pro Mouse cytokine and chemokine 23-
plex assay, Bio Rad, US). Values in the RSV treated groups and the corresponding 
percentage of inhibition were compared with that in the control group (CLP+PBS) for 





























































































IL‐1β  22±4 0.007563 16±2 0.097624
IL‐3  46±16 0.047641 27±4 0.158681
IL‐5  29±6 0.028078 47±6 0.022739
TNF‐α  81±10 0.002737 78±13 0.00035
MIP‐1β  42±10 0.060839 41±6 0.051496
IFN‐γ  24±2 0.044777 25±10 0.038077
IL‐6  22±6 0.045794 55±8 0.009351
MCP‐1  24±8 0.014522 31±11 0.097346
MIP‐1α  21±6 0.04752 55±22 0.036449
KC  4±4 0.138354 55±4 2.65E‐05
 
Figure 20. (A) RSV lowers the cytokine and chemokine production in peritoneal 
lavage of mice subjected to CLP. Cytokines IL-1β, IL-3, IL-5, IL-6, TNFα, chemokine 
CXCL1 (KC), MCP-1, MIP-1α and MIP-β in peritoneal lavage of sham-operated mice 
(Sham), mice given CLP and injected with either PBS (CLP+PBS) or 1 mg/kg of RSV 
(CLP+RSV) were assessed 24 h after CLP by ELISA (R&D Systems, Minneapolis, MN 
and Bio-Plex Pro Mouse cytokine and chemokine 23-plex assay, Bio Rad, US). Values in 
the RSV treated groups and the corresponding percentage of inhibition were compared 
with that in the control group (CLP+PBS) for each cytokine or chemokine, using a two-
tailed unpaired Student’s t-test (n = 5 mice/group). (B) % of inhibition of CLP-induced 
cytokine/chemokine production in serum & peritoneal lavage in mice treated with 
1mg/kg body weight RSV compared with CLP-induced mice with PBS treatment. 
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4.5 RSV decreases excessive serum HMGB1 production in CLP-induced 
polymicrobial sepsis in mice  
HMGB1 has been reported to stimulate pro-inflammatory cytokines synthesis in 
human monocytes and it is important for triggering the second wave of inflammatory 
responses (Andersson et al, 2000; Riedemann et al, 2003b). Hence, it is important to 
prevent further cytokine storms and this may be possible by controlling HMGB1 release. 
To look at the systemic effect of RSV, we examined the HMGB1 levels in the serum of 
mice treated with RSV and mice treated with PBS only. Our data showed that upon CLP 
induction, HMGB1 level in the serum was significantly elevated, but serum HMGB1 
level decreased by 45% in RSV-treated mice when compared to PBS-treated mice 24 h 
after CLP induction (Figure 21). Therefore, RSV is effective in lowering sepsis-mediated 































Figure 21. RSV reduces CLP-induced serum HMGB1 production in mice. Serum 
HMGB1 levels were measured by ELISA 24 hours after CLP. Values in RSV treated 
group (CLP+RSV) were compared with that in PBS treated group (CLP+PBS), using a 












4.6 RSV reduces neutrophil infiltration into the peritoneal cavity during CLP-
induced sepsis in mice 
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In the CLP-induced sepsis model, neutrophils and monocytes are the first to be 
recruited into the peritoneum and they play important roles in host defense (Nguyen et al, 
2009). As shown in Figure 22, 2 h and 6 h after CLP, there was massive increase in the 
amount of neutrophils infiltrated into the peritoneal lavage in the PBS-treated group. In 
comparison, the number of infiltrated neutrophils in the peritoneum of RSV-treated mice 
was significantly lower. This lesser extent of neutrophils recruitment may be attributed to 
lower amounts of pro-inflammatory mediators present in the RSV-treated group. 
Interestingly, our data also showed that the number of infiltrated monocytes in the 
peritoneum of RSV-treated mice was not significantly changed compared with that of 
PBS-treated mice. This is in contrast with the in vitro result that RSV attenuates 
chemotaxis of monocyte towards LPS. It is possible that monocytes infiltrated into the 
peritoneum play important role in the elimination of bacteria in vivo. While RSV prevents 
the infiltration of excessive infiltration of neutrophils, there might be a compensatory 






















































Figure 22. RSV reduces the CLP-mediated peritoneal neutrophil infiltration in mice. 
Peritoneal lavage from sham operated mice (Sham), mice given CLP and treated with 
RSV or PBS 1 h after CLP induction (CLP+RSV) or PBS (CLP+PBS) were obtained 2 
and 6 h after CLP. Number of neutrophils or monocytes infiltrated into peritoneal region 
was counted. Values were compared between RSV treated group (CLP+RSV) with PBS 






In summary, the data in this chapter have demonstrated the protective effects of 
RSV in a in vivo model of sepsis. In sepsis-induced mice treated with RSV, we found 
decreased mortality, lower local and systemic bacterial load, decreased pro-inflammatory 
cytokines, chemokines and HMGB1 production, and reduced neutrophils infiltration in 























RSV has been demonstrated to be protective in several inflammatory models in 
animals including bowel inflammation; C5a induced peritonitis and endotoxemia 
(Bereswill et al, 2010; Issuree et al, 2009; Sebai et al, 2009). However, its implications 
and mechanisms of action in experimental sepsis have yet to be reported. In our present 
study, we validated the anti-inflammatory effects of RSV using a CLP-induced sepsis 
model in mice. The results in this chapter are in concordance with our earlier in vitro 
findings that RSV attenuates inflammatory responses induced by endotoxin (LPS) in 
human primary monocytes. This is the first study which investigates the therapeutic 
treatment of RSV in a clinically relevant sepsis model. We found that RSV confers 
protection against CLP-induced sepsis and increases the survival rate of the mice even 
when it is given after the induction of sepsis. Intra-peritoneal injection of RSV at a dose 
of 1 mg/kg body weight results in the best survival of mice subjected to CLP among all 
the doses tested (0.5, 1 and 2mg/kg body weight). As RSV may acts as an anti-oxidant at 
low doses and pro-oxidant at high doses in vitro, 1 mg/kg of RSV may provide the 
optimal concentration in vivo to suppress the CLP-induced sepsis. 
It has been reported that the balance of inflammatory cytokines relates to the 
severity and mortality of murine sepsis (Walley et al, 1996). The advantage of the in vivo 
animal model is that we can examine a wider range of cytokines and chemokines both 
locally at the site of infection and systemically. In this study, we found that RSV reduces 
the systemic levels of HMGB1 in the CLP-induced sepsis. Extracellular HMGB1 behaves 
like a cytokine in that it is a potent pro-inflammatory molecule that induces the synthesis 
of TNFα, IL-1β, and IL-6, but not IL-10 in monocytes/macrophages (Yin et al, 2005). 
Therefore, the regulation of HMBG1 levels by RSV may be an important effect that 
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contributes to RSV conferred protection in sepsis. In the future study, it may be 
interesting to examine whether RSV modulates HMGB1 transcription, translocation or its 
process of release during sepsis. Another anti-oxidant quercetin has been recently 
identified as an experimental therapeutic that significantly protects against oxidative 
injury (Tang et al, 2009). Quercetin attenuates lethal systemic inflammation caused by 
endotoxemia, even if the treatment is started after the early TNF response. Similar to 
RSV, quercetin treatment reduces circulating levels of HMGB1 in animals with 
established endotoxemia. In macrophage cultures, quercetin inhibits the release as well as 
the cytokine activities of HMGB1, such as limiting the activation of MAPK and NF-κB 
(Tang et al, 2009).  
It is important to understand the various dynamics of patho-physiological 
responses in sepsis leading to the hyperactivity or suppression of immune and 
inflammatory responses. Neutrophils are critical for the rapid eradication of bacterial 
pathogens, but they may also contribute to the development of multiple organ failure in 
sepsis (Alves-Filho et al, 2008). In the animal models of sepsis, reducing the neutrophil 
recruitment to the focus of infection has improved survival in some studies (Ness et al, 
2003; Walley et al, 1997). Our results showed that RSV reduces neutrophil infiltration 
into the peritoneal cavity after CLP induction. This may be due to the reduced chemokine 
secretion (eg. KC) in the peritoneal cavity, which is important in the recruitment of 
neutrophils. Notably, with decreased neutrophils in the peritoneum, bacterial clearance 
was not compromised in the RSV-treated group. Instead, mice treated with RSV exhibit 
better bacterial clearance both in the blood and peritoneal lavage. Therefore, RSV may 
act on other immune and non-immune cells in vivo that help to lower bacterial load. It has 
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been reported that RSV modulates the phagocytosis of bacteria through a NF-κB-
dependent gene program in monocytic THP1 cells (Iyori et al, 2008). In concordance to 
this, our result showed that number of monocytes in the peritoneal lavage is not reduced 
upon RSV treatment which may contribute to the ability to clear bacteria. Furthermore, as 
shown in the mouse cytokine profile in peritoneal cavity (Fig. 21), RSV reduced IFNγ 
production compared to PBS injection. The inhibition of IFNγ decreases the bacterial 
load in peritonitis by accelerating the peritoneal fibrin deposition and tissue repair (Qiu et 
al, 2003). Thus, it ameliorates systemic inflammation by sealing off the injured ceacum 
and reducing bacterial spread. This may provide another explanation for the decreased 
bacteria count observed upon RSV treatment. However, perhaps a more logical 
explanation may be that with RSV treatment, the number of neutrophils recruited to the 
peritoneal cavity is sufficient to combat bacteria in the cavity while maintaining a 
“healthy” level of neutrophils in the blood stream that account for the low bacteria count 
in the blood. This interesting yet complex paradigm should be investigated in future 
studies. 
Although there are quite a number of studies done to investigate the effects of 
RSV in mice, relatively fewer studies were carried out in larger animals. Therefore, there 
are minimal data available on the optimal dosage of RSV in large animals and humans. 
Recently, RSV has been shown to improve myocardial perfusion in a swine model of 
hypercholesterolemia and chronic myocardial ischemia (Robich et al, 2010). Yorkshire 
swine were fed hypercholesterolemic diet with supplemental RSV at a dose of 100 
mg/kg/day orally for four weeks before the results were measured. However, there are 
concerns regarding the bioavailability  of such orally-delivered RSV, and some studies 
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have shown low systemic concentrations (Cottart et al, 2010). Early studies in animal 
models and humans demonstrated no adverse effects at doses up to 5 grams for a adult 
(Patel et al, 2011). Thus, compared with our study, a higher dose is usually chosen in an 
attempt to achieve adequate tissue levels in many in vivo studies. 
The history of clinical trials in sepsis demonstrates that even the most successful 
results from animal models cannot necessarily be translated to the clinical setting. 
Therefore, great care is warranted when interpreting experimental data from animals 
(Dyson & Singer, 2009). Many possible explanations have been suggested. Firstly, the 
dosage of drugs may not be optimal in human due to the rapid metabolic clearance inside 
the body. Secondly, patients groups are often very heterogeneous, making the 
interpretation of the results inconclusive. Thirdly, the causes of sepsis are important in 
determining the outcomes of the treatment. For example, LPS is only relevant to gram-
negative sepsis, and not gram positive sepsis (Noursadeghi & Cohen, 2000). Therefore, 
therapies targeted against LPS may not be effective in gram-positive sepsis. Fourthly, 
patients with high risk of death are more likely to benefit from such interventions 
compared with patients with mild sepsis. Lastly, there may be possible complications 
resulting from the drug-drug interactions during the process of treatment. In conclusion, 
the above confounding factors have to be addressed carefully before translating the 
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In chapter III, we have demonstrated the effects of RSV in modulating TLR4 
signaling pathway triggered by exogenous endotoxin LPS. Interestingly, our data also 
showed that RSV treatment alone in human monocytes leads to degradation of 
endogenous TLR4 key adaptor protein MyD88 (Figure 24). Therefore, it is of great 
interest to investigate the molecular mechanisms that mediate RSV-induced MyD88 
degradation. 
Autophagy is an important cellular mechanism that can lead to protein 
degradation and it protects against inflammation (White et al, 2010). RSV is able to cause 
non-canonical beclin 1-independent autophagic cell death in human breast cancer cells 
(Scarlatti et al, 2008b), and RSV and its analogues enhance autophagy and amyloid-β 
peptide degradation in mice (Vingtdeux et al, 2010). RSV also promotes longevity 
through Sirtuin-dependent induction of autophagy (Morselli et al, 2010a). Therefore, it is 
possible that RSV induces autophagy in human monocytes. Even though studies have 
demonstrated the specific interactions between immune signals, particularly TLR4 
pathway, and autophagy proteins, there is no study reporting the relationship between 
RSV-induced autophagy and TLR4-mediated inflammatory responses. 
Autophagic vacuolization in hepatocytes is observed in sepsis from a clinical and 
laboratory-based study, but it is not clear whether autophagy represents a beneficial or 
detrimental role in sepsis (Chien et al, 2011; Hsieh et al, 2009; Watanabe et al, 2009). 
The relationship between autophagy and immunity is bidirectional. The autophagic 
machinery serve effector function in innate and adaptive immune responses, but 
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autophagy can be stimulated and regulated by several immune mediators (cytokines, 
receptors and ligands) that are involved in controlling innate and adaptive immunity 
(Delgado, 2009). 
Based on the current literature and our findings, we hypothesize that RSV-
mediated MyD88 protein degradation may be the result of RSV-induced autophagy in 
human monocytes. Moreover, there may be a crosstalk between RSV-mediated 
autophagic mechanism and the immune-modulating effect of RSV on LPS triggered 
TLR4 signaling pathway. The findings will provide a mechanistic insight to the anti-















5.1 RSV treatment decreases MyD88 protein levels and induces autophagic process 
in human monocytes 
MyD88 is the key adaptor protein in TLR4 signaling (Janssens & Beyaert, 2003b). 
Molecular mechanisms that regulate MyD88 level is of importance in regulating LPS 
mediated responses. Western blot analysis showed a significant decrease of MyD88 
expression in primary monocytes treated with 40 μM RSV for 2, 4 and 6 h compared 
with the untreated monocytes (Figure 24). In contrast, there were no significant changes 
in MyD88 protein levels in monocytes treated with 100 ng/ml LPS for 2, 4 and 6 h 
(Figure 24). To investigate whether this RSV-decreased protein levels of MyD88 is 
related to RSV-induced autophagy, we monitored autophagic process by examining 
protein levels of microtubule-associated protein 1 light chain 3 (LC3)-II. LC3 is a 
ubiquitin-like molecule that is conjugated to phosphatidylethanolamine by Atg7 to form 
LC3-II and then localized to autophagic structures upon autophagic stimulation. Cellular 
LC3-II levels correlate with autophagosome numbers and monitoring LC3-II level using 
immunobloting is a reliable assay for autophagosome formation (Klionsky et al, 2007). 
Our result showed a significant increase in LC3-II expression in monocytes treated with 
RSV for 2h and 4 h, suggesting formation and accumulation of autophagosomes. The 
LC3-II level was then reduced after 6 h of RSV treatment (Figure 24). This reduction 
may be due to degradation of LC3-II at later stage of autophagy. These data suggest that 
RSV treatment in primary monocytes leads to a decrease in MyD88 protein level, which 
may correlate with RSV-induced autophagic process. In cells treated with 100 ng/ml LPS 
for 2, 4 and 6 h, there was no significant change in LC3-II protein level (Figure 24), 
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Figure 24. RSV treatment decreases MyD88 protein levels and induces autophagic 
process in human primary monocytes. Human primary monocytes were treated with 40 
µM RSV for the indicated time points (2-6 h). Whole cell extracts were then prepared, 
and 40 µg of extracts were resolved on 12% SDS-PAGE gel, electrotransferred on PVDF 
membranes, and probed for MyD88 and LC3-II. Same blots were probed with β-tubulin 
antibody to verify equal protein loading, and quantified using image J software. For each 
sample, MyD88 or LC3-II level was calculated as the ratio between MyD88 or LC3-II 
and β-tubulin. MyD88/β-tubulin and LC3-II/β-tubulin values in the control sample were 






5.2 The RSV-induced MyD88 degradation in human monocytes is autophagy-
dependent  
Induction of autophagy does not necessarily lead to maturation step where 
autophagosomes fuse with lysosomes and the internal materials are degraded. 
p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated 
protein aggregates by autophagy (Pankiv et al, 2007) and thus p62/SQSTM1 has been 
used as a marker to monitor effective/matured autophagy. To ascertain that the 
autophagic process observed in the previous result (Figure 24) is efficient, we examined 
p62 levels upon RSV treatment as low/decreased p62 level is an indicator of effective 
autophagy. Our data showed that p62 protein level was significantly decreased, with 
concomitant decrease of MyD88 level in human monocytic U-937 cells treated with RSV 
for 5h and 6 h (Figure 25A), suggesting RSV induces efficient autophagic process 
resulting in degradation of MyD88. 
To prove autophagy is indeed the mechanism regulating MyD88 expression, cells 
were pre-incubated with 5mM phosphatidylinositol-3-OH kinase inhibitor 3-
methyladenine (3MA), which blocks the autophagic process, for 1 h before adding RSV 
up to 6 h. Our data showed that protein levels of MyD88 remained unchanged in U-937 
cells pre-incubated with 3MA (Figure 25B). To further validate this result, similar 
experiment was performed in human primary monocytes. MyD88 levels were 
significantly reduced upon RSV treatment for 5 and 6 h compared with the control 
sample, with concomitant low p62 level. With 3MA pre-incubation, MyD88 appeared to 
be unchanged upon RSV treatment and relatively higher level of p62 was observed. 3MA 
treatment alone did not result in significant change of MyD88 protein level (Figure 25C). 
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Together, these data suggest that the decrease in MyD88 protein level may be mediated 
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Figure 25 (A&B). MyD88 and p62 protein expression upon RSV treatment in 
human monocytic U-937 cells. Immunoblot analysis of expression of MyD88 and p62 in 
U-937 cells treated with 40 μM RSV for 0 (ctrl), 2, 3, 4, 5 and 6 h (A) and in U-937 pre-
incubated with 5mM 3MA for 1 h and then treated with 40 μM RSV for 0 (ctrl), 1, 2, 3, 4, 
5 and 6 h (B). Whole cell extracts were then prepared, and 40 µg of extracts were 
resolved on 12% SDS-PAGE gel, electrotransferred on PVDF membranes, and probed 

























Figure 25 (C). MyD88 and p62 protein expression upon RSV treatment in human 
primary monocytes. Immunoblot analysis of expression of MyD88, p62 in human 
primary monocytes left untreated, or treated with 40 μM RSV, or treated with 40 μM 
RSV with 3MA pre-incubation, or 3MA alone for the indicated time points. Whole cell 
extracts were then prepared and 40 µg of extracts were resolved on 12% SDS-PAGE gel, 
electrotransferred on PVDF membranes, and probed for p62 and MyD88. Same blot was 








5.3 The RSV-mediated MyD88 degradation in human monocytes is lysosome-
dependent 
There are limitations to the interpretation of autophagic process based on LC3-II 
levels since LC3-II is both produced and degraded during autophagy. To circumvent this, 
it has been proposed that to monitor efficient autophagy, LC3-II levels are better 
evaluated and compared in the presence and absence of inhibitors which block LC3-II 
degradation. Here, we used chloroquine (50 µM), or E64D (10 µg/ml) + pepstatin A (10 
µg/ml) as lysosomal inhibitors and lactacystin (10 µM) as proteosomal inhibitor to 
examine whether RSV-induced protein degradation is lysosome-dependent. In U-937 
cells treated with 40 μM RSV for 6 h, there was higher LC3-II level compared with the 
control. However, LC3-II level was significantly higher in cells treated with chloroquine 
and E64D + pepstatin A, but appeared to be the same in cells treated with lactacystin 
(Figure 26A). Hence, LC3-II degradation was blocked in the presence of lysosomal 
inhibitors. This indicates that RSV treatment resulted in efficient autophagy which led to 
lysosomal degradation of autophagosome and LC3-II. More importantly, RSV-decreased 
protein levels of both p62 and MyD88 were significantly reversed in cells pre-treated 
with chloroquine and E64D + pepstatin A, but not rescued in cells pre-treated with 
lactacystin (Figure 26A). A similar experiment was also performed in human primary 
monocytes. RSV-mediated MyD88 degradation is also blocked in the presence of 
chloroquine and E64D + pepstatin A (Figure 26B). Taken together, this set of data 
demonstrated that RSV-mediated MyD88 degradation is lysosome-dependent, but 
proteosome-independent which further confirms that RSV mediates autophagic 







































Figure 26. RSV-mediated MyD88 degradation is lysosome-dependent. Immunoblot 
analysis of expression of p62, MyD88 and LC3 in human monocytic U-937 cells (A) or 
human primary monocytes (B) treated with 40 µM RSV for 6 h with pre-incubation of 
either 50 µM chloroquine, or 10 µg/ml E64D+10 µg/ml pepstatin A or 10 µM lactacystin. 
Whole cell extracts were then prepared, and 40 µg of extracts were resolved on 12% 
SDS-PAGE gel, electrotransferred on PVDF membranes, and probed for p62, MyD88 
and LC3. Same blots were probed with GAPDH antibody to verify equal protein loading.  
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5.4 RSV induces autophagic vacuole formation in human monocytic cells  
RSV promotes autophagy in many cell types (Puissant & Auberger, 2010; 
Puissant et al, 2010a; Puissant et al, 2010b). To examine autophagosome formation, 
human monocytic U-937 cells were pre-treated with 40 µM RSV for the indicated time 
points and observed at the ultra-structural level using transmission electron microscopy. 
The number of double-membrane vacuoles typical of autophagosomes was markedly 
increased in U-937 cells treated with 40 µM RSV for 2 h compared to control cells 
(Figure 27). This increase in large autophagic vacuoles in the cytoplasm remained in the 
U-937 cells treated with 40 µM of RSV for 6 h and 18 h, respectively. In cells with 18 h 
RSV treatment, autophagic vacuoles containing mitochondrial membranes were also 
observed (Figure 27). Cells left untreated showed no/few autophagic vacuoles (Figure 
27). These suggest that RSV may induce autophagosome formation in human monocytic 
cells. 
100 ng/ml LPS has been shown to induce autophagy in mouse monocytes at late 
time point such as 16 h of LPS treatment (Xu et al, 2007). To validate the results shown 
in Figure 24, we also observed the morphology of the intracellular organelles in cells 
treated with 100 ng/ml LPS for the same time course (2 h, 6 h and 18 h) as that in RSV 
treated cells. Our result showed that LPS-induced autophagosome formation was only 
detected at 18h time point, not at 2 h or 6 h time point (supplementary Figure 1). This 
set of data is consistent with the results shown in Figure 24, and they indicate that RSV 
is able to induce autophagy as early as 2 h whereas LPS-induced autophagosome 
formation is only detected after 18h. These two autophagic mechanisms are probably 




Figure 27. RSV induces autophagosome formation in U-937 cells. Electron 
microscopy of human monocytic U-937 cells left untreated (basal) or treated with 40 µM 
RSV for 2 h (RSV 2 h), or 6 h (RSV 6 h) or 18h (RSV 18 h). Red arrows indicate the 




 To validate the results obtained from the transmission electron microscopy 
(Figure 27), we used the immunofluorescence staining method to observe the cellular 
distribution of endogenous LC3. Our result showed that incubation of U-937 cells with 
40 µM RSV for 2 h, 6 h and 18 h led to a redistribution of LC3 from diffuse pattern to 
punctate formation (red dots), which are indications of autophagosome formation (Figure 







Figure 28. RSV treatment results in autophagosome punctate staining in U-937 cells. 
Immunostaining of endogenous LC3 (red) in human monocytic U-937 cells left untreated 
(basal), or treated with 40 µM RSV for 2 h, 6 h and 18 h. The red dots indicate 
autophagosomal punctate staining. Nucleus is indicated by DAPI staining shown in blue. 
Data are representative of three independent experiments. 
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5.5 Intracellular co-localization of MyD88 and LC3 upon RSV treatment in human 
monocytic cells 
We showed that MyD88 concomitantly degrades with autophagic proteins LC3 
and p62 upon RSV treatment for 6 h. Next, to investigate whether MyD88 physically co-
localizes with autophagosomes/autophagolysosomes, we examined the localization of 
endogenous MyD88 (green) and autophagosomal marker LC3 (red) in U-937 cells treated 
with RSV. In cells treated with RSV for 6 h, there were significant numbers of punctate 
staining of LC3 (red dots), indicating autophagosome formation. However, there were 
only one or two yellow dots (marked by white arrows), indicating only little amount of 
MyD88 co-localized with LC3 at 6 h after RSV treatment (Figure 29). One possible 
reason is that 6 h may not be the optimal time point to observe co-localization of MyD88 
with autophagosomes and most of the MyD88 protein associated with autophagosomes 
may have already been degraded in the lysosomes. Therefore, we re-examined the 
intracellular localization of MyD88 and LC3 in U-937 cells treated with RSV for 4 h, an 
earlier time point. There were increased numbers of yellow dots (marked by white 
arrows), indicating co-localization of MyD88 (green) and LC3 (red) compared to that in 
U-937 cells treated with RSV for 6 h (Figure 29). These results suggest that the MyD88 
protein is likely to be sequestered in the autophagolysosomes before getting degraded. 
Hence, our results suggest that the RSV-induced autophagic mechanism may regulate the 
intracellular protein levels of MyD88, which in turn regulates the LPS-activated TLR4 










Figure 29. Intracellular localization of MyD88 and LC3 upon RSV treatment in U-
937 cells. Intracellular localization of MyD88 (green) and LC3 (red) in monocytic U-937 
cells treated with or without RSV for 4 h or 6 h and observed using confocal fluorescence 






5.6 RSV-induced autophagy appears to regulate LPS stimulated SphK activity in 
human monocytic cells 
 To link RSV-induced autophagic mechanism to the ability of RSV in blocking 
LPS-triggered signaling pathway, we examined LPS-triggered SphK activity again in 
human monocytic U-937 cells with or without 3MA pre-incubation and RSV treatment 
for 2h before LPS stimulation. Our results showed that upon LPS trigger, SphK activity 
increased rapidly after 5 minutes and peaked from 5-10 minutes (Figure 30). At 5 
minutes, SphK activity was increased by 2-fold in U-937 cells treated with LPS 
compared with the control cells. Pre-treatment of U-937 cells with 40 µM of RSV 
inhibited this LPS triggered SphK activity at 5, 10 and 30 minutes (Figure 30). This RSV 
blockade of LPS stimulated SphK was no longer observed in U-937 cells pretreated with 
40 µM RSV and 5 mM 3MA (Figure 30). LPS-induced SphK activity was not 
significantly changed in U-937 cells pre-incubated with 3MA and triggered with LPS 
compared with U-937 cells triggered with LPS without any pre-incubation (Figure 30). 
These data suggest that RSV-induced autophagy may contribute to the modulation of 
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Figure 30. RSV no longer blocks LPS-triggered SphK activity in the presence of 
autophagy inhibitor 3MA in U-937 cells.  U-937 cells were stimulated with 100 ng/ml 
LPS over 5, 10, 30 and 45 min in cells pre-treated (2 h) with PBS or 40 µM RSV or 40 
µM RSV + 5 mM 3MA or 5mM 3MA, and SphK activity was measured as described in 
Materials. RSV or RSV+3MA or 3MA pre-treated and LPS triggered samples were 
compared with LPS triggered samples in at the corresponding time point (*p <0.05), 
SphK activities after LPS trigger at 5, 10, 30 and 45 min are compared with cells at basal 
in each treatment group (§p <0.01)  using a two-tailed unpaired Student’s t-test. Depicted 








In summary, we have demonstrated in this chapter that RSV induces autophagic 
vesicles formation and efficient autophagic flux in human monocytes. This RSV-
mediated autophagic mechanism may be implicated in the RSV-induced degradation of 
the TLR4 key adaptor molecule, MyD88 (Figure 31). This may be a novel mechanism 








Figure 31. Molecular mechanism of RSV-mediated autophagic degradation of 
MyD88 in human monocytic U-937 cells. Upon RSV treatment, autophagic vesicles are 
formed, which encloses TLR4 adaptor molecule MyD88. Eventually MyD88 are 
degraded in the autolysosome/autophagolysosome. 
 
Autophagy is well studied for its role in regulating cell fate and providing 
protection from a range of pathologies, including degenerative disorders and cancer. 
There is increasing evidence that autophagy regulates innate and adaptive immune 
responses and helps in the clearance of microbial infection and preventing autoimmunity. 
For example, during microbial infection, the TLR-mediated induction of autophagy has 
been suggested to be an antimicrobial mechanism (Delgado & Deretic, 2009). Our results 
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in this chapter demonstrated that in human monocytes, RSV decreases the protein 
expression of TLR4 key adaptor protein MyD88, which is a sequential result of the RSV-
mediated autophagic process. Therefore, the TLR4 signaling pathway may be modulated 
by the RSV-mediated autophagic mechanism.  
A recent study showed that the inhibition of autophagy with the phos-
phatidylinositol-3-OH kinase inhibitor 3-methyladenine (3MA) leads to the hyper-
induction of IL-1β in response to LPS (Crişan et al, 2011). Our data in this chapter 
indicate that RSV does not block the LPS-mediated SphK activity in the presence of 
3MA. These suggest that RSV-mediated autophagy may be a mechanism of the 
inhibitory effect of RSV on LPS-activated SphK activity. Since SphK activation 
contributes to the LPS-induced pro-inflammatory responses (shown in Chapter III), we 
hypothesize that the RSV-mediated autophagy may provide an alternative mechanism for 
the anti-inflammatory effects of RSV. 
Few studies have looked at the role of autophagy in regulating inflammation. One 
study demonstrated that autophagy attenuates the endotoxin-induced inflammatory 
responses in the intestinal epithelium by inhibiting NF-κB activation, resulting in the 
maintenance of intestinal homeostasis (Fujishima et al, 2011). Aberrant production of 
pro-inflammatory cytokines has been found in autophagy-defective macrophages (Saitoh 
et al, 2008). The involvement of autophagy in the secretion of pro-inflammatory 
cytokines is further demonstrated in mice with deletion of the gene encoding the 
autophagy protein ATG16L1 (Saitoh et al, 2008). These mice produce excessive amounts 
of IL-1β and IL-18 in response to LPS and other pathogen-associated molecular patterns. 
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This suggests that mutations in genes encoding autophagy proteins may directly or 
indirectly deregulate the secretion of IL-1β and IL-18. However, the mechanism by 
which autophagy regulates cytokine secretion is still poorly understood. Therefore, our 
study provides a plausible explanation that agents such as RSV may stimulate the 
autophagic activity and confer beneficial anti-inflammatory effects through the regulation 
of either the TLR4 adaptor molecule MyD88 or the modulation of downstream signaling 
pathways. 
The scaffolding adaptor protein p62/SQSTM1 (p62) acts as a link between the 
ubiquitination and autophagy machineries. Since p62 accumulates when autophagy is 
inhibited, and decreased levels can be observed when autophagy is induced, p62 may be 
used as a marker to study autophagic flux (Bjørkøy et al, 2009). Our results showed 
MyD88 and p62 protein expressions were decreased at similar time points upon the 
induction of autophagy with RSV treatment. This may be due to the selective 
sequestration and ubiquitination of MyD88 by p62, where these two proteins are 
subsequently degraded in the autophagolysosomes. Hence, the RSV-mediated efficient 
autophagy may down-regulate the TLR4 signaling through MyD88 degradation. 
Interestingly, p62 is up-regulated by TLR ligands in a MyD88-dependent manner in 
primary human keratinocytes, and this synthesis of p62 is required for NF-κB activation 
and inflammation (Lee et al, 2011). The silencing of p62 blocks NF-κB activation, and 
the production of IL-6 and TNF. Inhibition of autophagy results in significantly increased 
inflammatory cytokine productions as well as p62 expression. These studies suggest that 




MyD88 has been implicated in TLR4 or TLR7 induced autophagy (Delgado et al, 
2008a; Xu, 2007). MyD88, together with TIR-domain–containing adapter-inducing IFN-
β, modulate the interaction between Bcl-2 and Beclin-1, thereby triggering and regulating 
autophagy (Shi & Kehrl, 2008). Together, these data suggest that key adaptor molecules 
in the innate immune signaling may be involved in the activation of autophagy pathways. 
Even though MyD88 is involved in activation of autophagy, its protein level may also be 
regulated by autophagy. Our data showed that the RSV-induced autophagy controls 
MyD88 expression and thus modulates the TLR4 mediated pro-inflammatory responses. 
Our data further showed that the RSV-mediated MyD88 degradation is not observed at 
the initial stage of the RSV-induced autophagy (after 2h) and is only detected after cells 
were treated with RSV for longer time-points such as 6 h. This suggests there may be a 
feedback loop regulating MyD88 protein level and the autophagic process upon treatment 
with RSV. MyD88 may be necessary for the initial induction of autophagy, but 
prolonged/sustained autophagy may lead to the subsequent down-regulation of MyD88 so 
as to maintain the homeostasis of the cell. In addition, one study has shown that deletion 
of MyD88 protects against sepsis-induced lymphocyte apoptosis but worsens survival 
(Palmer et al, 2008). MyD88 is a proximal adaptor protein that transduces signals from 
multiple receptors and complete inhibition of MyD88 reduces host response to pathogens. 
In contrast, our study has demonstrated that RSV is able to decrease MyD88 levels and 
inhibit cytokine production which may both contribute to decreased lymphocyte 




Our data have shown that RSV results in autophagosome formation and efficient 
autophagic flux, as well as the lysosomal degradation of the TLR4 adaptor protein 
MyD88. These suggest that the RSV-mediated autophagy, in combination with the 
inhibitory effects of RSV on TLR4 signaling and production of pro-inflammatory 
mediators, represent a potent anti-inflammatory strategy to treat diseases such as sepsis. 
However, there are limitations in this study. Here, we observe the formation of punctate 
staining using antibodies against endogenous LC3. However, it is better to examine the 
autophagic processes inside the cells using live imaging technique rather than fixing the 
cells at discrete time points, as autophagy is a dynamic cellular process. Furthermore, in 
order to draw reliable conclusions, RSV-induced autophagy may be further examined in 
cells with  Atg genes knockdown (e.g. ULK1, Atg5 or Atg7). The use of mice with 
defects in the autophagic machinery may also help to address the issue of beneficial or 
adverse effects of autophagy upon the induction of sepsis. Nonetheless, results obtained 
in this chapter have provided new insights into the novel role of the RSV-induced 














































Our study has demonstrated the anti-inflammatory effects of RSV in vitro and in 
vivo. In human monocytes, RSV modulates the activities of novel signaling molecules 
such as PLD and SphK in the TLR4 pathway upon exogenous LPS activation, thus 
attenuates the downstream pro-inflammatory signaling mechanisms. RSV also induces 
endogenous autophagic process which leads to the down-regulation of an adaptor 
molecule MyD88 in the TLR4 signaling pathway. Our results also suggest that there may 
be potential cross-talk between these two molecular mechanisms modulated by RSV 
because the inhibition of autophagy reverses the blockade effect of RSV on the LPS-
stimulated SphK activity (Figure 32). The findings in this study provide a molecular 
basis for the anti-inflammatory properties of RSV in the context of endotoxin activation 
and in sepsis. It further suggests the potential therapeutic implication of RSV in treating 
sepsis. 
Despite substantial efforts made to develop effective treatments for sepsis, many 
clinical trials have failed. The pathogenesis of sepsis is mediated in part by bacterial 
endotoxin, which stimulates monocytes, macrophages and neutrophils to sequentially 
release early and late pro-inflammatory mediators. Significant advances have been made 
to understand the role of pro-inflammatory mediators in the pathogenesis of sepsis. 
However, it is difficult to develop therapeutics that target cytokines such as TNFα and 
IL-1β that are released early (in the first 30–90 minutes) upon exposure to endotoxins 
(Cohen, 2002). Patients often seek medical attention at later stages of the disease, and 
thus it may be too late to block early cytokine release. Moreover, it is also challenging in 























Figure 32. Proposed molecular mechanisms underlying the RSV-mediated anti-
inflammatory effects in the TLR4 signaling pathway. In human monocytes, RSV 
modulates novel signaling molecules such as PLD and SphK in the TLR4 pathway upon 
exogenous LPS activation, thus inhibits the downstream pro-inflammatory signaling 
mechanisms. RSV also induces endogenous autophagic mechanism which leads to the 
down-regulation of the adaptor molecule MyD88 in TLR4 pathway. The proposed 




In contrast, HMGB1 has recently been identified as a cytokine-like product of 
monocytes and macrophages. In our study, we have also shown that RSV is able to block 
HMGB1 production both in LPS-stimulated primary monocytes and in mice subjected to 
CLP-induced sepsis. HMGB1 is detected much later after LPS stimulation and thus may 
potentially be a more tractable target for intervention (Wang et al, 2001). Patients with 
sepsis have elevated serum levels of HMGB1, and high level of HMGB1 in the serum is 
associated with increased mortality (Qin et al, 2006). In addition, when mice are injected 
with LPS, serum concentrations of HMGB1 increase after a delay of 24 hours, after the 
initial peak of IL-1β and TNFα had declined (Wang et al, 1999). Importantly, mice are 
rescued from the LPS-induced shock by administering an antibody targeted against 
HMGB1, 2 hours after the lethal injection of LPS. Therefore, given the ability of RSV to 
block HMGB1 production both in vitro and in vivo, RSV may be a viable option to the 
clinical intervention of blocking HMGB1 to treat sepsis. Besides RSV, another natural 
product, quercetin, also attenuates lethal systemic inflammation caused by endotoxemia. 
In macrophage cultures, quercetin inhibits the release and cytokine activities of HMGB1, 
and limits the activation of MAPK and NF-κB, the two signaling pathways that are 
critical for HMGB1-induced subsequent cytokine release (Tang et al, 2009). Quercetin 
pharmacologically inhibits HMGB1 release at clinically achievable concentrations, thus it 
warrants further evaluation in sepsis and other systemic inflammatory disorders (Tang et 
al, 2009). For future studies, it would be interesting to examine whether RSV exerts 
similar effects like quercetin, in affecting HMGB1 transcription and/or the release of 
HMGB1 in human monocytes. 
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Studies have suggested that dampening the excessive inflammation triggered by 
TLRs may provide potential novel therapies to treat sepsis (Alves-Filho et al, 2006). 
Understanding the intracellular signal transduction mechanisms that regulate the LPS-
mediated responses have profound implications, especially in the identification of novel 
molecules as potential therapeutic targets. In our study, we identified the molecular 
targets of RSV in the LPS/TLR4 signaling pathway that contributes to its anti-
inflammatory effects such as blocking the LPS-stimulated pro-inflammatory cytokines, 
chemokines and HMGB1 productions as well as monocyte migration in human primary 
monocytes. Upon LPS stimulation in these monocytes, PLD is activated which leads to 
the downstream SphK, ERK1/2 and NF-κB activations. Blocking PLD by RSV in this 
signaling pathway effectively down-regulates the LPS-triggered SphK, ERK1/2 and NF-
κB activities. Consistent with our findings, Tou et al has reported that RSV inhibits the 
formation of both diacylglycerol (DAG) and ether-linked acylglycerol (EAG) induced by 
fMLP in human neutrophils (Tou & Urbizo, 2008). PLD has been reported to regulate 
SphK in TNFα and C5a-activated monocytes and neutrophils respectively (Sethu et al, 
2008; Issuree et al, 2009). Our findings on the role of PLD in LPS signaling and how 
treatment of monocytes with RSV effectively blocks the LPS-stimulated PLD activity 
further contribute to the field.  
Most studies that established roles for PLD in immune cell functions rely heavily 
on the use of primary alcohols (such as Butan-1-ol) to act as inhibitors of PA production. 
However, recent work have raised concerns over potential off-target effects or a lack of 
complete inhibition of PA production when using these primary alcohols to inhibit PLD, 
despite the use of the tertiary alcohol (such as Butan-3-ol) as a control (Huang & 
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Frohman, 2007). Moreover, PLD comprises of two major isoforms, PLD1 and PLD2 
(Hammond et al., 1995; Colley et al., 1997). Therefore, the development of isoform- 
specific inhibitors and the use of isoform specific PLD-knockout mice will aid in the 
study of PLD-mediated signaling in many pathological conditions. The potentially 
different roles of PLD1 and PLD2 in TLR4 signaling have not yet been investigated. 
However, studies have reported their distinct functions in other signaling pathways. 
PLD1, rather than PLD2, was demonstrated to selectively re-localize to the cell 
membrane and selectively activated upon TNFα stimulation (Sethu et al, 2008). PLD1 is 
suggested to be an inducible protein, rapidly regulated during culture conditions and 
preferentially induced during cell activation whereas PLD2 seems to be a constitutive 
enzyme in circulating monocytes (Locati et al, 2001). Moreover, activation of isoform-
specific PLDs appears to be cell type and stimuli dependent ((Jenkins & Frohman, 2005). 
Therefore, for therapeutic intervention, it may be important to identify the specific 
isoform of PLD that is regulated in TLR4 signaling. Such findings may help elucidate the 
mechanistic role for RSV as a signaling blocker of either PLD1 or PLD2 upon TLR4 
activation. Taken together, the down-regulation of the activities of signaling molecules 
(PLD, SphK, ERK1/2 and NF-κB) by RSV leads to decreased production of pro-
inflammatory cytokines and chemokines in human primary monocytes. This is the first 
study that delineates the molecular signaling pathways underlying the anti-inflammatory 
mechanisms of RSV in the LPS-induced inflammatory responses. 
In addition to its modulation of TLR4 signaling pathway upon exogenous 
endotoxins activation, RSV is able to induce endogenous protein degradation of the 
TLR4 adaptor molecule MyD88. Many studies have reported that RSV is able to induce 
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autophagic mechanism which leads to protein degradation (Opipari et al, 2004; 
Vingtdeux et al, 2010). In concordance to that, our data show that this RSV-induced 
MyD88 degradation is also autophagy-dependent. Autophagy has been suggested to have 
protective role in inflammation, especially neuro-inflammation, due to its contribution in 
the removal of defective proteins. Therefore, RSV-induced autophagic mechanism may 
play a role in regulating the TLR4 signaling, thus further contribute to the anti-
inflammatory effect of RSV. 
Moreover, autophagy has been implicated in many immune conditions including 
sepsis, yet its role in sepsis remains unclear (Chien et al, 2011; Hsieh et al, 2009). Studies 
have tried to elucidate the functional role of autophagy in sepsis. Autophagy and 
apoptosis are shown to co-exist after trauma-hemorrhage and sepsis. The inter-
relationship between autophagy and apoptosis might unveil novel therapeutic approaches 
for the detection and treatment of sepsis. In addition, HMGB1 has been shown to be 
implicated in autophagic mechanisms. Inhibition of HMGB1 release or loss of HMGB1 
correlates with decrease in the number of autophagolysosomes and autophagic flux under 
conditions of oxidative stress (Skinner, 2010; Tang et al, 2010)). In our study, we have 
not yet looked into the relationship between autophagy and HMGB1 release in human 
monocytes. There is a possibility that the inhibitory effect of RSV on HMGB1 release 
might be a result of its effect on autophagic mechanisms. 
 SphK, which has been shown to play important roles in the TLR4 signaling 
pathway in human monocytes (chapter III), may also be implicated in autophagic 
mechanisms. The roles of SphK in autophagic mechanisms remain controversial. 
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Knocking down SphK1 by siRNA abolishes starvation-induced autophagy (Lavieu et al, 
2006). In contrast, SphK inhibitors promotes tumor cell autophagy (Beljanski et al, 2010); 
(Coward et al, 2009). The differences observed may be due to the different functions of 
autophagy in different cell types and conditions. However, these studies focus on the 
roles of SphK in regulating autophagic mechanism. There is no study reporting if 
autophagy regulates receptor activated SphK activity. Our study contributes to the field 
by investigating whether the RSV-mediated autophagy blocks the LPS-activated SphK 
activity in human monocytes. As SphK has been shown to be important in the activation 
of NF-κB and the subsequent production of pro-inflammatory cytokines (chapter III), it is 
interesting to examine if RSV-mediated autophagy regulates SphK activity which in turn 
modulates the production of pro-inflammatory mediators. Our data (chapter V) suggest 
that the RSV-mediated autophagy may be a mechanism contributes to the inhibition of 
LPS-activated SphK activity. Therefore, there might be interplay between autophagic 
mechanisms and TLR4 signaling pathways in the presence of RSV. 
Although RSV has been shown to be anti-inflammatory in several diseases in vivo, 
its health benefits on sepsis or septic shock has yet to be investigated. To assess the 
therapeutic potential of RSV in sepsis, we investigated whether the in vivo injection of 
RSV protects against septic shock in a CLP model of polymicrobial sepsis. Most of the 
current studies have undertaken a prophylactic approach whereby RSV is given to mice 
before they are challenged with endotoxins. In contrast, our study takes a therapeutic 
approach whereby the mice are subjected to sepsis first and then treated with RSV at 
indicated time points. CLP model is chosen in favor of the endotoxic shock model 
because it effectively mimics the patho-physiological conditions of septic patients. Using 
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the CLP-induced sepsis model, we found that therapeutic treatment with RSV 
significantly improves the survival rate of mice, lowers the bacterial load, and attenuates 
serum cytokines, chemokines and HMGB1 releases in vivo, thus conferring protection 
against lethality in septic shock. Moreover, RSV is a relatively non-toxic compound, 
widely studied as an antioxidant, and its protective effects occurred in therapeutically 
achievable, safe dose (Patel et al, 2011). Therefore, our study have raised the possibility 
of using RSV as a therapeutic agent in the clinical treatment of sepsis, and offered 
insights into the physiological and molecular mechanisms of RSV that modulates the 
inflammatory cascade in sepsis. The combination of conventional therapy in sepsis with 
immune modulators such as RSV may be advantageous in treating sepsis by potentially 
reducing the dose of the agents used, or by sensitizing the affected individuals to 
conventional strategies in the management of inflammatory disorders. Nonetheless, more 
detailed and comprehensive in vitro and in vivo work and clinical trials are warranted in 











 Based on the findings in this thesis, there are several interesting directions for 
future work, particularly in the areas of identifying novel signaling molecules in the LPS 
pathway, and cross-talking between the RSV-mediated autophagy and the TLR4-
signaling pathway. To gain a better understanding of these areas, further studies are 
proposed as follows: 
 
(1) Identify the specific isoform of PLD and SphK that mediate LPS signaling in 
vitro and sepsis in vivo 
 There are two isoforms of PLD (PLD1 and PLD2) and two isoforms of SphK 
(SphK1 and SphK2) present in human primary monocytes. However, there are limited 
studies that looked into isoform-specific activities of these two enzymes in TLR4 
signaling in vitro or in vivo. PLD1 is only activated upon receptor stimulation whereas 
PLD2 appears to be constitutively active in immune cells (Norton et al, 2011). SphK1 
and SphK2 also play distinct roles in different inflammatory diseases (Lai et al, 2009). 
For therapeutic intervention, it is important to identify the specific isoform of PLD and 
SphK that are regulated in TLR4 signaling and regulated by RSV. Therefore, future work 
will involve examining the pro-inflammatory cytokines, chemokines and HMGB1 
releases in the sepsis model after knocking down isoform-specific PLD and/or SphK. 
 (2) Validate the RSV-mediated autophagic mechanism and its role in modulating 
TLR4 activation 
Atg proteins such as ULK1, Atg5 and Atg7 are of great importance in regulating 
autophagic process. To further explore how RSV-induced autophagy regulates LPS-
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activated inflammatory responses, experiments will be designed to investigate the effects 
on the LPS-mediated physiological responses after knocking down ULK1, Atg5 or Atg7 
in human primary monocytes. 
(3) Investigate the involvement of PLD and/or SphK in the RSV-mediated 
autophagic mechanism  
 We have demonstrated the roles of PLD and SphK in TLR4 signaling pathways in 
human monocytes upon LPS activation. These two enzymes are also implicated in 
autophagic mechanisms in immune cells (Dall'armi et al, 2010; Lavieu et al, 2008). It will 
















































Ahn KS, Sethi G, Aggarwal BB (2007) Nuclear factor-kappa B: from clone to clinic. 
Curr Mol Med 7: 619-637 
 
Akira S, Takeda K (2004) Toll-like receptor signalling. Nat Rev Immunol 4: 499-511 
 
Alves-Filho J, de Freitas A, Russo M, Cunha F (2006) Toll-like receptor 4 signaling leads 
to neutrophil migration impairment in polymicrobial sepsis. Crit Care Med 34: 461-470 
 
Alves-Filho J, de Freitas A, Spiller F, Souto F, Cunha F (2008) The role of neutrophils in 
severe sepsis. Shock 30 Suppl 1: 3-9 
 
Andersson U, Wang H, Palmblad K, Aveberger A, Bloom O, Erlandsson-Harris H, 
Janson A, Kokkola R, Zhang M, Yang H, Tracey K (2000) High mobility group 1 protein 
(HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp 
Med 192: 565-570 
 
Angus DC, Crowther MA (2003) Unraveling severe sepsis: why did OPTIMIST fail and 
what's next? JAMA 290: 256-258 
 
Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR (2001) 
Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and 
associated costs of care. Crit Care Med 29: 1303-1310 
 
Asensi M, Medina I, Ortega A, Carretero J, Baño MC, Obrador E, Estrela JM (2002) 
Inhibition of cancer growth by resveratrol is related to its low bioavailability. Free Radic 
Biol Med 33: 387-398 
 
Athar M, Back JH, Kopelovich L, Bickers DR, Kim AL (2009) Multiple molecular 
targets of resveratrol: Anti-carcinogenic mechanisms. Arch Biochem Biophys 486: 95-
102 
 
Bastin J, Lopes-Costa A, Djouadi F (2011) Exposure to resveratrol triggers 
pharmacological correction of fatty acid utilization in human fatty acid oxidation-
deficient fibroblasts. Hum Mol Genet 20: 2048-2057 
 
Baur J, Sinclair D (2006) Therapeutic potential of resveratrol: the in vivo evidence. Nat 




Bechoua S, Daniel LW (2001) Phospholipase D is required in the signaling pathway 
leading to p38 MAPK activation in neutrophil-like HL-60 cells, stimulated by N-formyl-
methionyl-leucyl-phenylalanine. J Biol Chem 276: 31752-31759 
 
Beljanski V, Knaak C, Smith CD (2010) A novel sphingosine kinase inhibitor induces 
autophagy in tumor cells. J Pharmacol Exp Ther 333: 454-464 
 
Berenson LS, Yang J, Sleckman BP, Murphy TL, Murphy KM (2006) Selective 
requirement of p38alpha MAPK in cytokine-dependent, but not antigen receptor-
dependent, Th1 responses. J Immunol 176: 4616-4621 
 
Bereswill S, Muñoz M, Fischer A, Plickert R, Haag LM, Otto B, Kühl AA, 
Loddenkemper C, Göbel UB, Heimesaat MM (2010) Anti-inflammatory effects of 
resveratrol, curcumin and simvastatin in acute small intestinal inflammation. PLoS One 5: 
e15099 
 
Bernard GR, Ely EW, Wright TJ, Fraiz J, Stasek JE, Russell JA, Mayers I, Rosenfeld BA, 
Morris PE, Yan SB, Helterbrand JD (2001) Safety and dose relationship of recombinant 
human activated protein C for coagulopathy in severe sepsis. Crit Care Med 29: 2051-
2059 
 
Beutler B (2004) Innate immunity: an overview. Mol Immunol 40: 845-859 
 
Billich A, Ettmayer P (2004) Fluorescence-based assay of sphingosine kinases. Anal 
Biochem 326: 114-119 
 
Birrell M, McCluskie K, Wong S, Donnelly L, Barnes P, Belvisi M (2005) Resveratrol, 
an extract of red wine, inhibits lipopolysaccharide induced airway neutrophilia and 
inflammatory mediators through an NF-kappaB-independent mechanism. FASEB J 19: 
840-841 
 
Bjørkøy G, Lamark T, Pankiv S, Øvervatn A, Brech A, Johansen T (2009) Monitoring 
autophagic degradation of p62/SQSTM1. Methods Enzymol 452: 181-197 
 
BLIGH EG, DYER WJ (1959) A rapid method of total lipid extraction and purification. 
Can J Biochem Physiol 37: 911-917 
 





Brown FD, Thompson N, Saqib KM, Clark JM, Powner D, Thompson NT, Solari R, 
Wakelam MJ (1998) Phospholipase D1 localises to secretory granules and lysosomes and 
is plasma-membrane translocated on cellular stimulation. Curr Biol 8: 835-838 
 
Brown HA, Gutowski S, Kahn RA, Sternweis PC (1995) Partial purification and 
characterization of Arf-sensitive phospholipase D from porcine brain. J Biol Chem 270: 
14935-14943 
 
Buehrer BM, Bell RM (1993) Sphingosine kinase: properties and cellular functions. Adv 
Lipid Res 26: 59-67 
 
Buras J, Holzmann B, Sitkovsky M (2005) Animal models of sepsis: setting the stage. 
Nat Rev Drug Discov 4: 854-865 
 
Cadwallader KA, Uddin M, Condliffe AM, Cowburn AS, White JF, Skepper JN, 
Ktistakis NT, Chilvers ER (2004) Effect of priming on activation and localization of 
phospholipase D-1 in human neutrophils. Eur J Biochem 271: 2755-2764 
 
Cadwell K, Liu JY, Brown SL, Miyoshi H, Loh J, Lennerz JK, Kishi C, Kc W, Carrero 
JA, Hunt S, Stone CD, Brunt EM, Xavier RJ, Sleckman BP, Li E, Mizushima N, 
Stappenbeck TS, Virgin HW (2008) A key role for autophagy and the autophagy gene 
Atg16l1 in mouse and human intestinal Paneth cells. Nature 456: 259-263 
 
Cai S, Exton JH (2001) Determination of interaction sites of phospholipase D1 for RhoA. 
Biochem J 355: 779-785 
 
Calandra T, Froidevaux C, Martin C, Roger T (2003) Macrophage migration inhibitory 
factor and host innate immune defenses against bacterial sepsis. J Infect Dis 187 Suppl 2: 
S385-390 
 
Calandra T, Roger T (2003) Macrophage migration inhibitory factor: a regulator of innate 
immunity. Nat Rev Immunol 3: 791-800 
 
Cao Q, Jing C, Tang X, Yin Y, Han X, Wu W (2011) Protective effect of resveratrol on 





Carpenter S, O'Neill LA (2009) Recent insights into the structure of Toll-like receptors 
and post-translational modifications of their associated signalling proteins. Biochem J 
422: 1-10 
 
Carty M, Goodbody R, Schröder M, Stack J, Moynagh PN, Bowie AG (2006) The human 
adaptor SARM negatively regulates adaptor protein TRIF-dependent Toll-like receptor 
signaling. Nat Immunol 7: 1074-1081 
 
Cathcart M (2009) Signal-activated phospholipase regulation of leukocyte chemotaxis. J 
Lipid Res 50 Suppl: S231-236 
 
Chien WS, Chen YH, Chiang PC, Hsiao HW, Chuang SM, Lue SI, Hsu C (2011) 
Suppression of autophagy in rat liver at late stage of polymicrobial sepsis. Shock 35: 506-
511 
 
Choi OH, Kim JH, Kinet JP (1996) Calcium mobilization via sphingosine kinase in 
signalling by the Fc epsilon RI antigen receptor. Nature 380: 634-636 
 
Clément M, Hirpara J, Chawdhury S, Pervaiz S (1998) Chemopreventive agent 
resveratrol, a natural product derived from grapes, triggers CD95 signaling-dependent 
apoptosis in human tumor cells. Blood 92: 996-1002 
 
Cohen J (2002) The immunopathogenesis of sepsis. Nature 420: 885-891 
 
Cook DN (1996) The role of MIP-1 alpha in inflammation and hematopoiesis. J Leukoc 
Biol 59: 61-66 
 
Cottart CH, Nivet-Antoine V, Laguillier-Morizot C, Beaudeux JL (2010) Resveratrol 
bioavailability and toxicity in humans. Mol Nutr Food Res 54: 7-16 
 
Courtois G, Gilmore TD (2006) Mutations in the NF-kappaB signaling pathway: 
implications for human disease. Oncogene 25: 6831-6843 
 
Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420: 860-867 
 
Coward J, Ambrosini G, Musi E, Truman JP, Haimovitz-Friedman A, Allegood JC, 
Wang E, Merrill AH, Schwartz GK (2009) Safingol (L-threo-sphinganine) induces 
177 
 
autophagy in solid tumor cells through inhibition of PKC and the PI3-kinase pathway. 
Autophagy 5: 184-193 
 
Crişan TO, Plantinga TS, van de Veerdonk FL, Farcaş MF, Stoffels M, Kullberg BJ, van 
der Meer JW, Joosten LA, Netea MG (2011) Inflammasome-independent modulation of 
cytokine response by autophagy in human cells. PLoS One 6: e18666 
 
Cui Y, English K (1997) Phosphatidic acid-mediated regulation of neutrophil plasma 
membrane CD45-phosphotyrosine phosphatase. Cell Signal 9: 257-263 
 
Cutler A, Brombacher F (2005) Cytokine therapy. Ann N Y Acad Sci 1056: 16-29 
 
Dall'armi C, Hurtado-Lorenzo A, Tian H, Morel E, Nezu A, Chan RB, Yu WH, Robinson 
KS, Yeku O, Small SA, Duff K, Frohman MA, Wenk MR, Yamamoto A, Di Paolo G 
(2010) The phospholipase D1 pathway modulates macroautophagy. Nat Commun 1: 142 
 
Das S, Das D (2007) Anti-inflammatory responses of resveratrol. Inflamm Allergy Drug 
Targets 6: 168-173 
 
Dawson RM (1967) The formation of phosphatidylglycerol and other phospholipids by 
the transferase activity of phospholipase D. Biochem J 102: 205-210 
 
Delgado M (2009) Autophagy and pattern recognition receptors in innate immunity. 
Immunol Rev 227: 189-202 
 
Delgado M, Gomariz RP, Martinez C, Abad C, Leceta J (2000) Anti-inflammatory 
properties of the type 1 and type 2 vasoactive intestinal peptide receptors: role in lethal 
endotoxic shock. Eur J Immunol 30: 3236-3246 
 
Delgado MA, Deretic V (2009) Toll-like receptors in control of immunological 
autophagy. Cell Death Differ 16: 976-983 
 
Delgado MA, Elmaoued RA, Davis AS, Kyei G, Deretic V (2008a) Toll-like receptors 
control autophagy. EMBO J 27: 1110-1121 
 
Delgado MA, Elmaoued RA, Davis AS, Kyei G, Deretic V (2008b) Toll-like receptors 




Delon C, Manifava M, Wood E, Thompson D, Krugmann S, Pyne S, Ktistakis NT (2004) 
Sphingosine kinase 1 is an intracellular effector of phosphatidic acid. J Biol Chem 279: 
44763-44774 
 
Deretic V (2009) Multiple regulatory and effector roles of autophagy in immunity. Curr 
Opin Immunol 21: 53-62 
 
Deretic V, Levine B (2009) Autophagy, immunity, and microbial adaptations. Cell Host 
Microbe 5: 527-549 
 
Docherty JJ, Fu MM, Hah JM, Sweet TJ, Faith SA, Booth T (2005) Effect of resveratrol 
on herpes simplex virus vaginal infection in the mouse. Antiviral Res 67: 155-162 
 
Dong C, Davis RJ, Flavell RA (2002) MAP kinases in the immune response. Annu Rev 
Immunol 20: 55-72 
 
Du G, Altshuller YM, Kim Y, Han JM, Ryu SH, Morris AJ, Frohman MA (2000) Dual 
requirement for rho and protein kinase C in direct activation of phospholipase D1 through 
G protein-coupled receptor signaling. Mol Biol Cell 11: 4359-4368 
 
Dumitru CD, Ceci JD, Tsatsanis C, Kontoyiannis D, Stamatakis K, Lin JH, Patriotis C, 
Jenkins NA, Copeland NG, Kollias G, Tsichlis PN (2000) TNF-alpha induction by LPS is 
regulated posttranscriptionally via a Tpl2/ERK-dependent pathway. Cell 103: 1071-1083 
 
Dyson A, Singer M (2009) Animal models of sepsis: why does preclinical efficacy fail to 
translate to the clinical setting? Crit Care Med 37: S30-37 
 
Eichacker PQ, Parent C, Kalil A, Esposito C, Cui X, Banks SM, Gerstenberger EP, Fitz 
Y, Danner RL, Natanson C (2002) Risk and the efficacy of antiinflammatory agents: 
retrospective and confirmatory studies of sepsis. Am J Respir Crit Care Med 166: 1197-
1205 
 
Emoto M, Klarlund JK, Waters SB, Hu V, Buxton JM, Chawla A, Czech MP (2000) A 
role for phospholipase D in GLUT4 glucose transporter translocation. J Biol Chem 275: 
7144-7151 
 
Erridge C, Bennett-Guerrero E, Poxton IR (2002) Structure and function of 




Exton JH (1997) Phospholipase D: enzymology, mechanisms of regulation, and function. 
Physiol Rev 77: 303-320 
 
Exton JH (1998) Phospholipase D. Biochim Biophys Acta 1436: 105-115 
 
Exton JH (2002) Phospholipase D-structure, regulation and function. Rev Physiol 
Biochem Pharmacol 144: 1-94 
 
Fink MP, Heard SO (1990) Laboratory models of sepsis and septic shock. J Surg Res 49: 
186-196 
 
Fisher CJ, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, Abraham E, Schein RM, 
Benjamin E (1996) Treatment of septic shock with the tumor necrosis factor receptor:Fc 
fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 334: 1697-
1702 
 
Fitzgerald KA, Palsson-McDermott EM, Bowie AG, Jefferies CA, Mansell AS, Brady G, 
Brint E, Dunne A, Gray P, Harte MT, McMurray D, Smith DE, Sims JE, Bird TA, 
O'Neill LA (2001) Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal 
transduction. Nature 413: 78-83 
 
Flierl M, Rittirsch D, Nadeau B, Day D, Zetoune F, Sarma J, Huber-Lang M, Ward P 
(2008a) Functions of the complement components C3 and C5 during sepsis. FASEB J 22: 
3483-3490 
 
Flierl MA, Rittirsch D, Gao H, Hoesel LM, Nadeau BA, Day DE, Zetoune FS, Sarma JV, 
Huber-Lang MS, Ferrara JL, Ward PA (2008b) Adverse functions of IL-17A in 
experimental sepsis. FASEB J 22: 2198-2205 
 
Fujishima Y, Nishiumi S, Masuda A, Inoue J, Nguyen NM, Irino Y, Komatsu M, Tanaka 
K, Kutsumi H, Azuma T, Yoshida M (2011) Autophagy in the intestinal epithelium 
reduces endotoxin-induced inflammatory responses by inhibiting NF-κB activation. Arch 
Biochem Biophys 506: 223-235 
 
Gacar N, Gocmez S, Utkan T, Gacar G, Komsuoglu I, Tugay M, Utkan NZ (2011) 
Effects of Resveratrol on Ileal Smooth Muscle Reactivity in Polymicrobial Sepsis Model. 




Ghosh S, Hayden MS (2008) New regulators of NF-kappaB in inflammation. Nat Rev 
Immunol 8: 837-848 
 
Gomez-Cambronero J (2010) New concepts in phospholipase D signaling in 
inflammation and cancer. ScientificWorldJournal 10: 1356-1369 
 
Gomez-Cambronero J, Keire P (1998) Phospholipase D: a novel major player in signal 
transduction. Cell Signal 10: 387-397 
 
Hamdi SM, Cariven C, Coronas S, Malet N, Chap H, Perret B, Salles JP, Record M 
(2008) Potential role of phospholipase D2 in increasing interleukin-2 production by T-
lymphocytes through activation of mitogen-activated protein kinases ERK1/ERK2. 
Biochim Biophys Acta 1781: 263-269 
 
Harada H, Quearry B, Ruiz-Vela A, Korsmeyer SJ (2004) Survival factor-induced 
extracellular signal-regulated kinase phosphorylates BIM, inhibiting its association with 
BAX and proapoptotic activity. Proc Natl Acad Sci U S A 101: 15313-15317 
 
Hassan-Khabbar S, Vamy M, Cottart CH, Wendum D, Vibert F, Savouret JF, Thérond P, 
Clot JP, Waligora AJ, Nivet-Antoine V (2010) Protective effect of post-ischemic 
treatment with trans-resveratrol on cytokine production and neutrophil recruitment by rat 
liver. Biochimie 92: 405-410 
 
Hoebe K, Du X, Georgel P, Janssen E, Tabeta K, Kim SO, Goode J, Lin P, Mann N, 
Mudd S, Crozat K, Sovath S, Han J, Beutler B (2003) Identification of Lps2 as a key 
transducer of MyD88-independent TIR signalling. Nature 424: 743-748 
 
Horng T, Barton GM, Flavell RA, Medzhitov R (2002) The adaptor molecule TIRAP 
provides signalling specificity for Toll-like receptors. Nature 420: 329-333 
 
Hotchkiss RS, Opal S (2010) Immunotherapy for sepsis--a new approach against an 
ancient foe. N Engl J Med 363: 87-89 
 
Hsieh YC, Athar M, Chaudry IH (2009) When apoptosis meets autophagy: deciding cell 
fate after trauma and sepsis. Trends Mol Med 15: 129-138 
 
Huang C, Rajfur Z, Borchers C, Schaller MD, Jacobson K (2003) JNK phosphorylates 




Huang J, Klionsky DJ (2007) Autophagy and human disease. Cell Cycle 6: 1837-1849 
 
Huang P, Frohman MA (2007) The potential for phospholipase D as a new therapeutic 
target. Expert Opin Ther Targets 11: 707-716 
 
Huang W, Tang Y, Li L (2010) HMGB1, a potent proinflammatory cytokine in sepsis. 
Cytokine 51: 119-126 
 
Hubbard W, Choudhry M, Schwacha M, Kerby J, Rue Lr, Bland K, Chaudry I (2005) 
Cecal ligation and puncture. Shock 24 Suppl 1: 52-57 
 
Hug H, Sarre TF (1993) Protein kinase C isoenzymes: divergence in signal transduction? 
Biochem J 291 ( Pt 2): 329-343 
 
Høyer-Hansen M, Bastholm L, Szyniarowski P, Campanella M, Szabadkai G, Farkas T, 
Bianchi K, Fehrenbacher N, Elling F, Rizzuto R, Mathiasen IS, Jäättelä M (2007) Control 
of macroautophagy by calcium, calmodulin-dependent kinase kinase-beta, and Bcl-2. Mol 
Cell 25: 193-205 
 
Ibrahim F, Pang S, Melendez A (2004) Anaphylatoxin signaling in human neutrophils. A 
key role for sphingosine kinase. J Biol Chem 279: 44802-44811 
 
Issuree P, Pushparaj P, Pervaiz S, Melendez A (2009) Resveratrol attenuates C5a-induced 
inflammatory responses in vitro and in vivo by inhibiting phospholipase D and 
sphingosine kinase activities. FASEB J 
 
Iyer SS, Agrawal RS, Thompson CR, Thompson S, Barton JA, Kusner DJ (2006) 
Phospholipase D1 regulates phagocyte adhesion. J Immunol 176: 3686-3696 
 
Iyori M, Kataoka H, Shamsul H, Kiura K, Yasuda M, Nakata T, Hasebe A, Shibata K 
(2008) Resveratrol modulates phagocytosis of bacteria through an NF-kappaB-dependent 
gene program. Antimicrob Agents Chemother 52: 121-127 
 
Jackowski S, Rock CO (1989) Stimulation of phosphatidylinositol 4,5-bisphosphate 




Janssens S, Beyaert R (2003a) Functional diversity and regulation of different 
interleukin-1 receptor-associated kinase (IRAK) family members. Mol Cell 11: 293-302 
 
Janssens S, Beyaert R (2003b) Role of Toll-like receptors in pathogen recognition. Clin 
Microbiol Rev 16: 637-646 
 
Jeffrey KL, Camps M, Rommel C, Mackay CR (2007) Targeting dual-specificity 
phosphatases: manipulating MAP kinase signalling and immune responses. Nat Rev Drug 
Discov 6: 391-403 
 
Jenkins GM, Frohman MA (2005) Phospholipase D: a lipid centric review. Cell Mol Life 
Sci 62: 2305-2316 
 
Johnson GL, Lapadat R (2002) Mitogen-activated protein kinase pathways mediated by 
ERK, JNK, and p38 protein kinases. Science 298: 1911-1912 
 
Jolly PS, Bektas M, Watterson KR, Sankala H, Payne SG, Milstien S, Spiegel S (2005) 
Expression of SphK1 impairs degranulation and motility of RBL-2H3 mast cells by 
desensitizing S1P receptors. Blood 105: 4736-4742 
 
Jolly PS, Rosenfeldt HM, Milstien S, Spiegel S (2002) The roles of sphingosine-1-
phosphate in asthma. Mol Immunol 38: 1239-1245 
 
Jones DH, Bax B, Fensome A, Cockcroft S (1999) ADP ribosylation factor 1 mutants 
identify a phospholipase D effector region and reveal that phospholipase D participates in 
lysosomal secretion but is not sufficient for recruitment of coatomer I. Biochem J 341 
( Pt 1): 185-192 
 
Kang Y, Kim S, Shimada S, Otsuka M, Seit-Nebi A, Kwon B, Watts T, Han J (2007) Cell 
surface 4-1BBL mediates sequential signaling pathways 'downstream' of TLR and is 
required for sustained TNF production in macrophages. Nat Immunol 8: 601-609 
 
Katz M, Amit I, Yarden Y (2007) Regulation of MAPKs by growth factors and receptor 
tyrosine kinases. Biochim Biophys Acta 1773: 1161-1176 
 
Kee T, Vit P, Melendez A (2005) Sphingosine kinase signalling in immune cells. Clin 




Keh D, Boehnke T, Weber-Cartens S, Schulz C, Ahlers O, Bercker S, Volk HD, Doecke 
WD, Falke KJ, Gerlach H (2003) Immunologic and hemodynamic effects of "low-dose" 
hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, 
crossover study. Am J Respir Crit Care Med 167: 512-520 
 
Kim AL, Zhu Y, Zhu H, Han L, Kopelovich L, Bickers DR, Athar M (2006) Resveratrol 
inhibits proliferation of human epidermoid carcinoma A431 cells by modulating MEK1 
and AP-1 signalling pathways. Exp Dermatol 15: 538-546 
 
Kim SY, Ahn BH, Min KJ, Lee YH, Joe EH, Min DS (2004) Phospholipase D isozymes 
mediate epigallocatechin gallate-induced cyclooxygenase-2 expression in astrocyte cells. 
J Biol Chem 279: 38125-38133 
 
Kim Y, Kim JE, Lee SD, Lee TG, Kim JH, Park JB, Han JM, Jang SK, Suh PG, Ryu SH 
(1999) Phospholipase D1 is located and activated by protein kinase C alpha in the plasma 
membrane in 3Y1 fibroblast cell. Biochim Biophys Acta 1436: 319-330 
 
Klionsky DJ (2010) The molecular machinery of autophagy and its role in physiology 
and disease. Semin Cell Dev Biol 21: 663 
 
Klionsky DJ, Codogno P, Cuervo AM, Deretic V, Elazar Z, Fueyo-Margareto J, Gewirtz 
DA, Kroemer G, Levine B, Mizushima N, Rubinsztein DC, Thumm M, Tooze SA (2010) 
A comprehensive glossary of autophagy-related molecules and processes. Autophagy 6 
 
Klionsky DJ, Cuervo AM, Seglen PO (2007) Methods for monitoring autophagy from 
yeast to human. Autophagy 3: 181-206 
 
Kohama T, Olivera A, Edsall L, Nagiec MM, Dickson R, Spiegel S (1998) Molecular 
cloning and functional characterization of murine sphingosine kinase. J Biol Chem 273: 
23722-23728 
 
Kolgazi M, Sener G, Cetinel S, Gedik N, Alican I (2006) Resveratrol reduces renal and 
lung injury caused by sepsis in rats. J Surg Res 134: 315-321 
 
Kono Y, Nishiuma T, Okada T, Kobayashi K, Funada Y, Kotani Y, Jahangeer S, 
Nakamura S, Nishimura Y (2010) Sphingosine kinase 1 regulates mucin production via 




Kroemer G, Mariño G, Levine B (2010) Autophagy and the integrated stress response. 
Mol Cell 40: 280-293 
 
Kumar A, Sharma SS (2010) NF-kappaB inhibitory action of resveratrol: a probable 
mechanism of neuroprotection in experimental diabetic neuropathy. Biochem Biophys 
Res Commun 394: 360-365 
 
Kumar S, Boehm J, Lee JC (2003) p38 MAP kinases: key signalling molecules as 
therapeutic targets for inflammatory diseases. Nat Rev Drug Discov 2: 717-726 
 
Kundu J, Chun K, Kim S, Surh Y (2004) Resveratrol inhibits phorbol ester-induced 
cyclooxygenase-2 expression in mouse skin: MAPKs and AP-1 as potential molecular 
targets. Biofactors 21: 33-39 
 
Lai W, Goh H, Bao Z, Wong W, Melendez A, Leung B (2008a) The role of sphingosine 
kinase in a murine model of allergic asthma. J Immunol 180: 4323-4329 
 
Lai W, Irwan A, Goh H, Howe H, Yu D, Valle-Oñate R, McInnes I, Melendez A, Leung 
B (2008b) Anti-inflammatory effects of sphingosine kinase modulation in inflammatory 
arthritis. J Immunol 181: 8010-8017 
 
Lai W, Irwan A, Goh H, Melendez A, McInnes I, Leung B (2009) Distinct roles of 
sphingosine kinase 1 and 2 in murine collagen-induced arthritis. J Immunol 183: 2097-
2103 
 
Lavieu G, Scarlatti F, Sala G, Carpentier S, Levade T, Ghidoni R, Botti J, Codogno P 
(2006) Regulation of autophagy by sphingosine kinase 1 and its role in cell survival 
during nutrient starvation. J Biol Chem 281: 8518-8527 
 
Lavieu G, Scarlatti F, Sala G, Carpentier S, Levade T, Ghidoni R, Botti J, Codogno P 
(2008) Sphingolipids in macroautophagy. Methods Mol Biol 445: 159-173 
 
Lee C, Xu DZ, Feketeova E, Kannan KB, Yun JK, Deitch EA, Fekete Z, Livingston DH, 
Hauser CJ (2004) Attenuation of shock-induced acute lung injury by sphingosine kinase 
inhibition. J Trauma 57: 955-960 
 
Lee EO, Park HJ, Kang JL, Kim HS, Chong YH (2010) Resveratrol reduces glutamate-
mediated monocyte chemotactic protein-1 expression via inhibition of extracellular 
185 
 
signal-regulated kinase 1/2 pathway in rat hippocampal slice cultures. J Neurochem 112: 
1477-1487 
 
Lee HM, Shin DM, Yuk JM, Shi G, Choi DK, Lee SH, Huang SM, Kim JM, Kim CD, 
Lee JH, Jo EK (2011) Autophagy negatively regulates keratinocyte inflammatory 
responses via scaffolding protein p62/SQSTM1. J Immunol 186: 1248-1258 
 
Levine B, Mizushima N, Virgin HW (2011a) Autophagy in immunity and inflammation. 
Nature 469: 323-335 
 
Levine B, Mizushima N, Virgin HW (2011b) Autophagy in immunity and inflammation. 
Nature 469: 323-335 
 
Linch SN, Kelly AM, Danielson ET, Pero R, Lee JJ, Gold JA (2009) Mouse eosinophils 
possess potent antibacterial properties in vivo. Infect Immun 77: 4976-4982 
 
Liscovitch M, Chalifa V, Pertile P, Chen CS, Cantley LC (1994) Novel function of 
phosphatidylinositol 4,5-bisphosphate as a cofactor for brain membrane phospholipase D. 
J Biol Chem 269: 21403-21406 
 
Locati M, Riboldi E, Bonecchi R, Transidico P, Bernasconi S, Haribabu B, Morris AJ, 
Mantovani A, Sozzani S (2001) Selective induction of phospholipase D1 in pathogen-
activated human monocytes. Biochem J 358: 119-125 
 
Lord KA, Hoffman-Liebermann B, Liebermann DA (1990) Nucleotide sequence and 
expression of a cDNA encoding MyD88, a novel myeloid differentiation primary 
response gene induced by IL6. Oncogene 5: 1095-1097 
 
Lotze MT, Tracey KJ (2005) High-mobility group box 1 protein (HMGB1): nuclear 
weapon in the immune arsenal. Nat Rev Immunol 5: 331-342 
 
Luster AD (1998) Chemokines--chemotactic cytokines that mediate inflammation. N 
Engl J Med 338: 436-445 
 
Maceyka M, Sankala H, Hait N, Le Stunff H, Liu H, Toman R, Collier C, Zhang M, Satin 
L, Merrill AJ, Milstien S, Spiegel S (2005) SphK1 and SphK2, sphingosine kinase 





MacKinnon AC, Buckley A, Chilvers ER, Rossi AG, Haslett C, Sethi T (2002) 
Sphingosine kinase: a point of convergence in the action of diverse neutrophil priming 
agents. J Immunol 169: 6394-6400 
 
Madeo F, Tavernarakis N, Kroemer G (2010) Can autophagy promote longevity? Nat 
Cell Biol 12: 842-846 
 
Mahtani KR, Brook M, Dean JL, Sully G, Saklatvala J, Clark AR (2001) Mitogen-
activated protein kinase p38 controls the expression and posttranslational modification of 
tristetraprolin, a regulator of tumor necrosis factor alpha mRNA stability. Mol Cell Biol 
21: 6461-6469 
 
Maiuri MC, Tasdemir E, Criollo A, Morselli E, Vicencio JM, Carnuccio R, Kroemer G 
(2009) Control of autophagy by oncogenes and tumor suppressor genes. Cell Death 
Differ 16: 87-93 
 
Malemud CJ (2007) Inhibitors of stress-activated protein/mitogen-activated protein 
kinase pathways. Curr Opin Pharmacol 7: 339-343 
 
Marshall JC (2003) Such stuff as dreams are made on: mediator-directed therapy in 
sepsis. Nat Rev Drug Discov 2: 391-405 
 
McCarroll SA (2008) Deletion polymorphism upstream of IRGM associated with altered 
IRGM expression and Crohn's disease. Nat Genet 40: 1107-1112 
 
McDermott M, Wakelam MJ, Morris AJ (2004) Phospholipase D. Biochem Cell Biol 82: 
225-253 
 
McLean GW, Carragher NO, Avizienyte E, Evans J, Brunton VG, Frame MC (2005) The 
role of focal-adhesion kinase in cancer - a new therapeutic opportunity. Nat Rev Cancer 5: 
505-515 
 
Medzhitov R (2001) Toll-like receptors and innate immunity. Nat Rev Immunol 1: 135-
145 
 




Melendez A (2008) Sphingosine kinase signalling in immune cells: potential as novel 
therapeutic targets. Biochim Biophys Acta 1784: 66-75 
 
Melendez A, Allen J (2002) Phospholipase D and immune receptor signalling. Semin 
Immunol 14: 49-55 
 
Melendez A, Bruetschy L, Floto R, Harnett M, Allen J (2001) Functional coupling of 
FcgammaRI to nicotinamide adenine dinucleotide phosphate (reduced form) oxidative 
burst and immune complex trafficking requires the activation of phospholipase D1. Blood 
98: 3421-3428 
 
Melendez A, Carlos-Dias E, Gosink M, Allen J, Takacs L (2000) Human sphingosine 
kinase: molecular cloning, functional characterization and tissue distribution. Gene 251: 
19-26 
 
Melendez A, Khaw A (2002) Dichotomy of Ca2+ signals triggered by different 
phospholipid pathways in antigen stimulation of human mast cells. J Biol Chem 277: 
17255-17262 
 
Miloso M, Bertelli AA, Nicolini G, Tredici G (1999) Resveratrol-induced activation of 
the mitogen-activated protein kinases, ERK1 and ERK2, in human neuroblastoma SH-
SY5Y cells. Neurosci Lett 264: 141-144 
 
Milstien S, Spiegel S (2006) Targeting sphingosine-1-phosphate: a novel avenue for 
cancer therapeutics. Cancer Cell 9: 148-150 
 
Minnich DJ, Moldawer LL (2004) Anti-cytokine and anti-inflammatory therapies for the 
treatment of severe sepsis: progress and pitfalls. Proc Nutr Soc 63: 437-441 
 
Mizushima N (2010) Autophagy. FEBS Lett 584: 1279 
 
Mor A, Campi G, Du G, Zheng Y, Foster DA, Dustin ML, Philips MR (2007) The 
lymphocyte function-associated antigen-1 receptor costimulates plasma membrane Ras 
via phospholipase D2. Nat Cell Biol 9: 713-719 
 
Moritz A, Westerman J, de Graan PN, Wirtz KW (1992) Phosphatidylinositol 4-kinase 
and phosphatidylinositol-4-phosphate 5-kinase from bovine brain membranes. Methods 




Morris A, Frohman M, Engebrecht J (1997a) Measurement of phospholipase D activity. 
Anal Biochem 252: 1-9 
 
Morris A, Hammond S, Colley C, Sung T, Jenco J, Sciorra V, Rudge S, Frohman M 
(1997b) Regulation and functions of phospholipase D. Biochem Soc Trans 25: 1151-1157 
 
Morselli E, Maiuri MC, Markaki M, Megalou E, Pasparaki A, Palikaras K, Criollo A, 
Galluzzi L, Malik SA, Vitale I, Michaud M, Madeo F, Tavernarakis N, Kroemer G 
(2010a) Caloric restriction and resveratrol promote longevity through the Sirtuin-1-
dependent induction of autophagy. Cell Death Dis 1: e10 
 
Morselli E, Maiuri MC, Markaki M, Megalou E, Pasparaki A, Palikaras K, Criollo A, 
Galluzzi L, Malik SA, Vitale I, Michaud M, Madeo F, Tavernarakis N, Kroemer G 
(2010b) The life span-prolonging effect of sirtuin-1 is mediated by autophagy. Autophagy 
6: 186-188 
 
Moscat J, Diaz-Meco MT (2009) p62 at the crossroads of autophagy, apoptosis, and 
cancer. Cell 137: 1001-1004 
 
Munz C (2009) Enhancing immunity through autophagy. Annu Rev Immunol 27: 423-449 
 
Nakamura N, Banno Y, Tamiya-Koizumi K (2005) Arf1-dependent PLD1 is localized to 
oleic acid-induced lipid droplets in NIH3T3 cells. Biochem Biophys Res Commun 335: 
117-123 
 
Nakayama K, Ota Y, Okugawa S, Ise N, Kitazawa T, Tsukada K, Kawada M, 
Yanagimoto S, Kimura S (2003) Raf1 plays a pivotal role in lipopolysaccharide-induced 
activation of dendritic cells. Biochem Biophys Res Commun 308: 353-360 
 
Natarajan V, Scribner WM, Morris AJ, Roy S, Vepa S, Yang J, Wadgaonkar R, Reddy 
SP, Garcia JG, Parinandi NL (2001) Role of p38 MAP kinase in diperoxovanadate-
induced phospholipase D activation in endothelial cells. Am J Physiol Lung Cell Mol 
Physiol 281: L435-449 
 
Nathan C (2002) Points of control in inflammation. Nature 420: 846-852 
 
Ness TL, Hogaboam CM, Strieter RM, Kunkel SL (2003) Immunomodulatory role of 




Nguyen Q, Ju S, Park S, Lee S, Yagita H, Lee I, Kim B (2009) Blockade of CD137 
signaling counteracts polymicrobial sepsis induced by cecal ligation and puncture. Infect 
Immun 77: 3932-3938 
 
Nguyen T, Mustafa F, Pervaiz S, Ng F, Lim L (2008) ERK1/2 activation is required for 
resveratrol-induced apoptosis in MDA-MB-231 cells. Int J Oncol 33: 81-92 
 
Niessen F, Schaffner F, Furlan-Freguia C, Pawlinski R, Bhattacharjee G, Chun J, Derian 
C, Andrade-Gordon P, Rosen H, Ruf W (2008a) Dendritic cell PAR1-S1P3 signalling 
couples coagulation and inflammation. Nature 452: 654-658 
 
Niessen F, Schaffner F, Furlan-Freguia C, Pawlinski R, Bhattacharjee G, Chun J, Derian 
CK, Andrade-Gordon P, Rosen H, Ruf W (2008b) Dendritic cell PAR1-S1P3 signalling 
couples coagulation and inflammation. Nature 452: 654-658 
 
Nishiuma T, Nishimura Y, Okada T, Kuramoto E, Kotani Y, Jahangeer S, Nakamura S 
(2008) Inhalation of sphingosine kinase inhibitor attenuates airway inflammation in 
asthmatic mouse model. Am J Physiol Lung Cell Mol Physiol 294: L1085-1093 
 
Norton LJ, Zhang Q, Saqib KM, Schrewe H, Macura K, Anderson KE, Lindsley CW, 
Brown HA, Rudge SA, Wakelam MJ (2011) PLD1 rather than PLD2 regulates phorbol-
ester-, adhesion-dependent and Fc{gamma}-receptor-stimulated ROS production in 
neutrophils. J Cell Sci 124: 1973-1983 
 
Noursadeghi M, Cohen J (2000) Immunopathogenesis of severe sepsis. J R Coll 
Physicians Lond 34: 432-436 
 
O'Hara SP, Splinter PL, Trussoni CE, Gajdos GB, Lineswala PN, Larusso NF (2011) 
Cholangiocyte N-Ras mediates lipopolysaccharide-induced IL6 secretion and 
proliferation. J Biol Chem 
 
O'Neill LA (2010) Stopping sepsis by targeting sphingosine kinase 1. Sci Transl Med 2: 
36ps29 
 
O'Neill LA, Bryant CE, Doyle SL (2009) Therapeutic targeting of Toll-like receptors for 




O'Shea JJ, Murray PJ (2008) Cytokine signaling modules in inflammatory responses. 
Immunity 28: 477-487 
 
Ohanian J, Ohanian V (2001) Lipid second messenger regulation: the role of 
diacylglycerol kinases and their relevance to hypertension. J Hum Hypertens 15: 93-98 
 
Olivera A, Mizugishi K, Tikhonova A, Ciaccia L, Odom S, Proia RL, Rivera J (2007) 
The sphingosine kinase-sphingosine-1-phosphate axis is a determinant of mast cell 
function and anaphylaxis. Immunity 26: 287-297 
 
Olivera A, Rosenthal J, Spiegel S (1996) Effect of acidic phospholipids on sphingosine 
kinase. J Cell Biochem 60: 529-537 
 
Opal SM, Scannon PJ, Vincent JL, White M, Carroll SF, Palardy JE, Parejo NA, Pribble 
JP, Lemke JH (1999) Relationship between plasma levels of lipopolysaccharide (LPS) 
and LPS-binding protein in patients with severe sepsis and septic shock. J Infect Dis 180: 
1584-1589 
 
Opipari AW, Tan L, Boitano AE, Sorenson DR, Aurora A, Liu JR (2004) Resveratrol-
induced autophagocytosis in ovarian cancer cells. Cancer Res 64: 696-703 
 
Oskeritzian CA, Alvarez SE, Hait NC, Price MM, Milstien S, Spiegel S (2008) Distinct 
roles of sphingosine kinases 1 and 2 in human mast-cell functions. Blood 111: 4193-4200 
 
Owens DM, Keyse SM (2007) Differential regulation of MAP kinase signalling by dual-
specificity protein phosphatases. Oncogene 26: 3203-3213 
 
Pankiv S, Clausen TH, Lamark T, Brech A, Bruun JA, Outzen H, Øvervatn A, Bjørkøy G, 
Johansen T (2007) p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of 
ubiquitinated protein aggregates by autophagy. J Biol Chem 282: 24131-24145 
 
Papandreou I, Lim AL, Laderoute K, Denko NC (2008) Hypoxia signals autophagy in 
tumor cells via AMPK activity, independent of HIF-1, BNIP3, and BNIP3L. Cell Death 
Differ 15: 1572-1581 
 
Park BS, Song DH, Kim HM, Choi BS, Lee H, Lee JO (2009) The structural basis of 




Park JB, Kim JH, Kim Y, Ha SH, Yoo JS, Du G, Frohman MA, Suh PG, Ryu SH (2000) 
Cardiac phospholipase D2 localizes to sarcolemmal membranes and is inhibited by alpha-
actinin in an ADP-ribosylation factor-reversible manner. J Biol Chem 275: 21295-21301 
 
Park JM, Greten FR, Li ZW, Karin M (2002) Macrophage apoptosis by anthrax lethal 
factor through p38 MAP kinase inhibition. Science 297: 2048-2051 
 
Pasparakis M (2009) Regulation of tissue homeostasis by NF-kappaB signalling: 
implications for inflammatory diseases. Nat Rev Immunol 9: 778-788 
 
Patel KR, Scott E, Brown VA, Gescher AJ, Steward WP, Brown K (2011) Clinical trials 
of resveratrol. Ann N Y Acad Sci 1215: 161-169 
 
Payne SG, Milstien S, Spiegel S (2002) Sphingosine-1-phosphate: dual messenger 
functions. FEBS Lett 531: 54-57 
 
Pearson KJ, Baur JA, Lewis KN, Peshkin L, Price NL, Labinskyy N, Swindell WR, 
Kamara D, Minor RK, Perez E, Jamieson HA, Zhang Y, Dunn SR, Sharma K, Pleshko N, 
Woollett LA, Csiszar A, Ikeno Y, Le Couteur D, Elliott PJ, Becker KG, Navas P, Ingram 
DK, Wolf NS, Ungvari Z, Sinclair DA, de Cabo R (2008) Resveratrol delays age-related 
deterioration and mimics transcriptional aspects of dietary restriction without extending 
life span. Cell Metab 8: 157-168 
 
Peck-Palmer OM, Unsinger J, Chang KC, Davis CG, McDunn JE, Hotchkiss RS (2008) 
Deletion of MyD88 markedly attenuates sepsis-induced T and B lymphocyte apoptosis 
but worsens survival. J Leukoc Biol 83: 1009–1018 
 
Pelaia G, Cuda G, Vatrella A, Gallelli L, Caraglia M, Marra M, Abbruzzese A, Caputi M, 
Maselli R, Costanzo FS, Marsico SA (2005) Mitogen-activated protein kinases and 
asthma. J Cell Physiol 202: 642-653 
 
Peng X, Frohman MA (2011) Mammalian Phospholipase D Physiological and 
Pathological Roles. Acta Physiol (Oxf) 
 





Pervaiz S, Holme A (2009) Resveratrol: Its Biological Targets and Functional Activity. 
Antioxid Redox Signal 
 
Pettitt TR, Martin A, Horton T, Liossis C, Lord JM, Wakelam MJ (1997) Diacylglycerol 
and phosphatidate generated by phospholipases C and D, respectively, have distinct fatty 
acid compositions and functions. Phospholipase D-derived diacylglycerol does not 
activate protein kinase C in porcine aortic endothelial cells. J Biol Chem 272: 17354-
17359 
 
Pi X, Tan SY, Hayes M, Xiao L, Shayman JA, Ling S, Holoshitz J (2006) Sphingosine 
kinase 1-mediated inhibition of Fas death signaling in rheumatoid arthritis B 
lymphoblastoid cells. Arthritis Rheum 54: 754-764 
 
Pitson SM, Moretti PA, Zebol JR, Lynn HE, Xia P, Vadas MA, Wattenberg BW (2003) 
Activation of sphingosine kinase 1 by ERK1/2-mediated phosphorylation. EMBO J 22: 
5491-5500 
 
Poltorak A, He X, Smirnova I, Liu M, Van Huffel C, Du X, Birdwell D, Alejos E, Silva 
M, Galanos C, Freudenberg M, Ricciardi-Castagnoli P, Layton B, Beutler B (1998) 
Defective LPS signaling in C3 h/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. 
Science 282: 2085-2088 
 
Poolman T, Ng L, Farmer P, Manson M (2005) Inhibition of the respiratory burst by 
resveratrol in human monocytes: correlation with inhibition of PI3K signaling. Free 
Radic Biol Med 39: 118-132 
 
Puissant A, Auberger P (2010) AMPK- and p62/SQSTM1-dependent autophagy mediate 
resveratrol-induced cell death in chronic myelogenous leukemia. Autophagy 6 
 
Puissant A, Robert G, Auberger P (2010a) Targeting autophagy to fight hematopoietic 
malignancies. Cell Cycle 9: 3470-3478 
 
Puissant A, Robert G, Fenouille N, Luciano F, Cassuto J, Raynaud S, Auberger P (2010b) 
Resveratrol promotes autophagic cell death in chronic myelogenous leukemia cells via 
JNK-mediated p62/SQSTM1 expression and AMPK activation. Cancer Res 70: 1042-
1052 
 
Puneet P, Hegde A, Ng S, Lau H, Lu J, Moochhala S, Bhatia M (2006) Preprotachykinin-





Pyne NJ, Long JS, Lee SC, Loveridge C, Gillies L, Pyne S (2009) New Aspects of 
Sphingosine 1-phosphate Signaling in Mammalian Cells. Adv Enzyme Regul 
 
Pyne NJ, Pyne S (2010) Sphingosine 1-phosphate and cancer. Nat Rev Cancer 10: 489-
503 
 
Pyne S (2002) Cellular signaling by sphingosine and sphingosine 1-phosphate. Their 
opposing roles in apoptosis. Subcell Biochem 36: 245-268 
 
Qin S, Wang H, Yuan R, Li H, Ochani M, Ochani K, Rosas-Ballina M, Czura CJ, Huston 
JM, Miller E, Lin X, Sherry B, Kumar A, Larosa G, Newman W, Tracey KJ, Yang H 
(2006) Role of HMGB1 in apoptosis-mediated sepsis lethality. J Exp Med 203: 1637-
1642 
 
Qiu G, Gribbin E, Harrison K, Sinha N, Yin K (2003) Inhibition of gamma interferon 
decreases bacterial load in peritonitis by accelerating peritoneal fibrin deposition and 
tissue repair. Infect Immun 71: 2766-2774 
 
Qu X, Zou Z, Sun Q, Luby-Phelps K, Cheng P, Hogan RN, Gilpin C, Levine B (2007) 
Autophagy gene-dependent clearance of apoptotic cells during embryonic development. 
Cell 128: 931-946 
 
Rice TW, Bernard GR (2004) Advances in Sepsis Treatment. Curr Infect Dis Rep 6: 354-
360 
 
Rice TW, Wheeler AP, Bernard GR, Vincent JL, Angus DC, Aikawa N, Demeyer I, 
Sainati S, Amlot N, Cao C, Ii M, Matsuda H, Mouri K, Cohen J (2010) A randomized, 
double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis. Crit 
Care Med 38: 1685-1694 
 
Riedemann N, Guo R, Bernacki K, Reuben J, Laudes I, Neff T, Gao H, Speyer C, Sarma 
V, Zetoune F, Ward P (2003a) Regulation by C5a of neutrophil activation during sepsis. 
Immunity 19: 193-202 
 
Riedemann N, Guo R, Hollmann T, Gao H, Neff T, Reuben J, Speyer C, Sarma J, Wetsel 
R, Zetoune F, Ward P (2004) Regulatory role of C5a in LPS-induced IL-6 production by 




Riedemann N, Guo R, Ward P (2003b) Novel strategies for the treatment of sepsis. Nat 
Med 9: 517-524 
 
Riedemann N, Guo R, Ward P (2003c) The enigma of sepsis. J Clin Invest 112: 460-467 
 
Rincón M, Flavell RA, Davis RA (2000) The JNK and P38 MAP kinase signaling 
pathways in T cell-mediated immune responses. Free Radic Biol Med 28: 1328-1337 
 
Rittirsch D, Flierl M, Nadeau B, Day D, Huber-Lang M, Mackay C, Zetoune F, Gerard N, 
Cianflone K, Köhl J, Gerard C, Sarma J, Ward P (2008a) Functional roles for C5a 
receptors in sepsis. Nat Med 14: 551-557 
 
Rittirsch D, Flierl M, Ward P (2008b) Harmful molecular mechanisms in sepsis. Nat Rev 
Immunol 8: 776-787 
 
Rius C, Abu-Taha M, Hermenegildo C, Piqueras L, Cerda-Nicolas JM, Issekutz AC, 
Estañ L, Cortijo J, Morcillo EJ, Orallo F, Sanz MJ (2010) Trans- but not cis-resveratrol 
impairs angiotensin-II-mediated vascular inflammation through inhibition of NF-κB 
activation and peroxisome proliferator-activated receptor-gamma upregulation. J 
Immunol 185: 3718-3727 
 
Rizzo MA, Shome K, Vasudevan C, Stolz DB, Sung TC, Frohman MA, Watkins SC, 
Romero G (1999) Phospholipase D and its product, phosphatidic acid, mediate agonist-
dependent raf-1 translocation to the plasma membrane and the activation of the mitogen-
activated protein kinase pathway. J Biol Chem 274: 1131-1139 
 
Roberts PJ, Der CJ (2007) Targeting the Raf-MEK-ERK mitogen-activated protein 
kinase cascade for the treatment of cancer. Oncogene 26: 3291-3310 
 
Robich MP, Osipov RM, Nezafat R, Feng J, Clements RT, Bianchi C, Boodhwani M, 
Coady MA, Laham RJ, Sellke FW (2010) Resveratrol improves myocardial perfusion in 
a swine model of hypercholesterolemia and chronic myocardial ischemia. Circulation 
122: S142-149 
 
Roviezzo F, Del Galdo F, Abbate G, Bucci M, D'Agostino B, Antunes E, De Dominicis 
G, Parente L, Rossi F, Cirino G, De Palma R (2004) Human eosinophil chemotaxis and 





Rudge SA, Wakelam MJ (2009) Inter-regulatory dynamics of phospholipase D and the 
actin cytoskeleton. Biochim Biophys Acta 1791: 856-861 
 
Saitoh T, Akira S (2010) Regulation of innate immune responses by autophagy-related 
proteins. J Cell Biol 189: 925-935 
 
Saitoh T, Fujita N, Jang MH, Uematsu S, Yang BG, Satoh T, Omori H, Noda T, 
Yamamoto N, Komatsu M, Tanaka K, Kawai T, Tsujimura T, Takeuchi O, Yoshimori T, 
Akira S (2008) Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-
1beta production. Nature 456: 264-268 
 
Salomão R, Martins P, Brunialti M, Fernandes ML, Martos L, Mendes M, Gomes N, 
Rigato O (2008) TLR signaling pathway in patients with sepsis. Shock 30 Suppl 1: 73-77 
 
Sanjuan MA (2007) Toll-like receptor signaling in macrophages links the autophagy 
pathway to phagocytosis. Nature 450: 1253-1257 
 
Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005) Phosphorylation and regulation 
of Akt/PKB by the rictor-mTOR complex. Science 307: 1098-1101 
 
Scaffidi P, Misteli T, Bianchi ME (2002) Release of chromatin protein HMGB1 by 
necrotic cells triggers inflammation. Nature 418: 191-195 
 
Scarlatti F, Maffei R, Beau I, Codogno P, Ghidoni R (2008a) Role of non-canonical 
Beclin 1-independent autophagy in cell death induced by resveratrol in human breast 
cancer cells. Cell Death Differ 15: 1318-1329 
 
Scarlatti F, Maffei R, Beau I, Ghidoni R, Codogno P (2008b) Non-canonical autophagy: 
an exception or an underestimated form of autophagy? Autophagy 4: 1083-1085 
 
Sebai H, Ben-Attia M, Sani M, Aouani E, Ghanem-Boughanmi N (2009) Protective 
effect of resveratrol in endotoxemia-induced acute phase response in rats. Arch Toxicol 
83: 335-340 
 
Sebai H, Sani M, Ghanem-Boughanmi N, Aouani E (2010) Prevention of 





Senftleben U, Cao Y, Xiao G, Greten FR, Krähn G, Bonizzi G, Chen Y, Hu Y, Fong A, 
Sun SC, Karin M (2001) Activation by IKKalpha of a second, evolutionary conserved, 
NF-kappa B signaling pathway. Science 293: 1495-1499 
 
Sethu S, Mendez-Corao G, Melendez A (2008) Phospholipase D1 plays a key role in 
TNF-alpha signaling. J Immunol 180: 6027-6034 
 
Sethu S, Pushparaj P, Melendez A (2010) Phospholipase D1 mediates TNFalpha-induced 
inflammation in a murine model of TNFalpha-induced peritonitis. PLoS One 5: e10506 
 
Shakibaei M, Buhrmann C, Mobasheri A (2011) Resveratrol-mediated SIRT-1 
Interactions with p300 Modulate Receptor Activator of NF-{kappa}B Ligand (RANKL) 
Activation of NF-{kappa}B Signaling and Inhibit Osteoclastogenesis in Bone-derived 
Cells. J Biol Chem 286: 11492-11505 
 
Sheedy FJ, O'Neill LA (2007) The Troll in Toll: Mal and Tram as bridges for TLR2 and 
TLR4 signaling. J Leukoc Biol 82: 196-203 
 
Shen MY, Hsiao G, Liu CL, Fong TH, Lin KH, Chou DS, Sheu JR (2007) Inhibitory 
mechanisms of resveratrol in platelet activation: pivotal roles of p38 MAPK and 
NO/cyclic GMP. Br J Haematol 139: 475-485 
 
Shi CS, Kehrl JH (2008) MyD88 and Trif target Beclin 1 to trigger autophagy in 
macrophages. J Biol Chem 283: 33175-33182 
 
Shigematsu S, Ishida S, Hara M, Takahashi N, Yoshimatsu H, Sakata T, Korthuis RJ 
(2003) Resveratrol, a red wine constituent polyphenol, prevents superoxide-dependent 
inflammatory responses induced by ischemia/reperfusion, platelet-activating factor, or 
oxidants. Free Radic Biol Med 34: 810-817 
 
Shuai K, Liu B (2003) Regulation of JAK-STAT signalling in the immune system. Nat 
Rev Immunol 3: 900-911 
 
Skinner M (2010) Autophagy: in the hands of HMGB1. Nat Rev Mol Cell Biol 11: 756-
757 
 
Son YH, Jeong YT, Lee KA, Choi KH, Kim SM, Rhim BY, Kim K (2008) Roles of 
MAPK and NF-kappaB in interleukin-6 induction by lipopolysaccharide in vascular 




Spapen H, Nguyen DN, Troubleyn J, Huyghens L, Schiettecatte J (2010) Drotrecogin alfa 
(activated) may attenuate severe sepsis-associated encephalopathy in clinical septic shock. 
Crit Care 14: R54 
 
Spiegel S, Cuvillier O, Edsall LC, Kohama T, Menzeleev R, Olah Z, Olivera A, Pirianov 
G, Thomas DM, Tu Z, Van Brocklyn JR, Wang F (1998) Sphingosine-1-phosphate in cell 
growth and cell death. Ann N Y Acad Sci 845: 11-18 
 
Spiegel S, English D, Milstien S (2002) Sphingosine 1-phosphate signaling: providing 
cells with a sense of direction. Trends Cell Biol 12: 236-242 
 
Spiegel S, Milstien S (2003) Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat 
Rev Mol Cell Biol 4: 397-407 
 
Spiegel S, Milstien S (2011) The outs and the ins of sphingosine-1-phosphate in 
immunity. Nat Rev Immunol 
 
Spite M, Norling L, Summers L, Yang R, Cooper D, Petasis N, Flower R, Perretti M, 
Serhan C (2009) Resolvin D2 is a potent regulator of leukocytes and controls microbial 
sepsis. Nature 461: 1287-1291 
 
Steinke JW, Borish L (2006) 3. Cytokines and chemokines. J Allergy Clin Immunol 117: 
S441-445 
 
Stewart JR, O'Brian CA (2004) Resveratrol antagonizes EGFR-dependent Erk1/2 
activation in human androgen-independent prostate cancer cells with associated isozyme-
selective PKC alpha inhibition. Invest New Drugs 22: 107-117 
 
Stutchfield J, Cockcroft S (1993) Correlation between secretion and phospholipase D 
activation in differentiated HL60 cells. Biochem J 293 ( Pt 3): 649-655 
 
Suzuki N, Suzuki S, Duncan GS, Millar DG, Wada T, Mirtsos C, Takada H, Wakeham A, 
Itie A, Li S, Penninger JM, Wesche H, Ohashi PS, Mak TW, Yeh WC (2002) Severe 
impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK-4. 
Nature 416: 750-756 
 
Sweeney SE (2009) The as-yet unfulfilled promise of p38 MAPK inhibitors. Nat Rev 




Taha TA, Hannun YA, Obeid LM (2006) Sphingosine kinase: biochemical and cellular 
regulation and role in disease. J Biochem Mol Biol 39: 113-131 
 
Takabe K, Paugh SW, Milstien S, Spiegel S (2008) "Inside-out" signaling of 
sphingosine-1-phosphate: therapeutic targets. Pharmacol Rev 60: 181-195 
 
Tan JC, Rabkin R (2005) Suppressors of cytokine signaling in health and disease. Pediatr 
Nephrol 20: 567-575 
 
Tang D, Kang R, Livesey KM, Cheh CW, Farkas A, Loughran P, Hoppe G, Bianchi ME, 
Tracey KJ, Zeh HJ, Lotze MT (2010) Endogenous HMGB1 regulates autophagy. J Cell 
Biol 190: 881-892 
 
Tang D, Kang R, Xiao W, Zhang H, Lotze MT, Wang H, Xiao X (2009) Quercetin 
prevents LPS-induced high-mobility group box 1 release and proinflammatory function. 
Am J Respir Cell Mol Biol 41: 651-660 
 
Tasdemir E, Maiuri MC, Galluzzi L, Vitale I, Djavaheri-Mergny M, D'Amelio M, Criollo 
A, Morselli E, Zhu C, Harper F, Nannmark U, Samara C, Pinton P, Vicencio JM, 
Carnuccio R, Moll UM, Madeo F, Paterlini-Brechot P, Rizzuto R, Szabadkai G, Pierron 
G, Blomgren K, Tavernarakis N, Codogno P, Cecconi F, Kroemer G (2008) Regulation 
of autophagy by cytoplasmic p53. Nat Cell Biol 10: 676-687 
 
Tergaonkar V (2006) NFkappaB pathway: a good signaling paradigm and therapeutic 
target. Int J Biochem Cell Biol 38: 1647-1653 
 
Tou J, Urbizo C (2008) Diethylstilbestrol inhibits phospholipase D activity and 
degranulation by stimulated human neutrophils. Steroids 73: 216-221 
 
Vallabhapurapu S, Karin M (2009) Regulation and function of NF-kappaB transcription 
factors in the immune system. Annu Rev Immunol 27: 693-733 
 
Van Slambrouck S, Parmar VS, Sharma SK, De Bondt B, Foré F, Coopman P, 
Vanhoecke BW, Boterberg T, Depypere HT, Leclercq G, Bracke ME (2005) Tangeretin 





van Zoelen MA, Verstege MI, Draing C, de Beer R, Veer CV, Florquin S, Bresser P, van 
der Zee JS, Te Velde AA, von Aulock S, van der Poll T (2011) Endogenous MCP-1 
promotes lung inflammation induced by LPS and LTA. Mol Immunol 48: 1468-1476 
 
Varadharaj S, Steinhour E, Hunter MG, Watkins T, Baran CP, Magalang U, Kuppusamy 
P, Zweier JL, Marsh CB, Natarajan V, Parinandi NL (2006) Vitamin C-induced 
activation of phospholipase D in lung microvascular endothelial cells: regulation by MAP 
kinases. Cell Signal 18: 1396-1407 
 
Vingtdeux V, Chandakkar P, Zhao H, d'Abramo C, Davies P, Marambaud P (2010) 
Novel synthetic small-molecule activators of AMPK as enhancers of autophagy and 
amyloid-{beta} peptide degradation. FASEB J 
 
Vitale N, Caumont AS, Chasserot-Golaz S, Du G, Wu S, Sciorra VA, Morris AJ, 
Frohman MA, Bader MF (2001) Phospholipase D1: a key factor for the exocytotic 
machinery in neuroendocrine cells. EMBO J 20: 2424-2434 
 
Vlasenko L, Melendez A (2005) A critical role for sphingosine kinase in anaphylatoxin-
induced neutropenia, peritonitis, and cytokine production in vivo. J Immunol 174: 6456-
6461 
 
Wada T, Penninger JM (2004) Mitogen-activated protein kinases in apoptosis regulation. 
Oncogene 23: 2838-2849 
 
Wadgaonkar R, Patel V, Grinkina N, Romano C, Liu J, Zhao Y, Sammani S, Garcia JG, 
Natarajan V (2009) Differential regulation of sphingosine kinases 1 and 2 in lung injury. 
Am J Physiol Lung Cell Mol Physiol 296: L603-613 
 
Waite KA, Wallin R, Qualliotine-Mann D, McPhail LC (1997) Phosphatidic acid-
mediated phosphorylation of the NADPH oxidase component p47-phox. Evidence that 
phosphatidic acid may activate a novel protein kinase. J Biol Chem 272: 15569-15578 
 
Wakelam MJ, McNee GS, Rudge SA (2010) Cross-talk between phospholipase D and 
MAP kinases activities. Adv Enzyme Regul 50: 57-61 
 
Walker SJ, Wu WJ, Cerione RA, Brown HA (2000) Activation of phospholipase D1 by 




Walle T, Hsieh F, DeLegge MH, Oatis JE, Walle UK (2004) High absorption but very 
low bioavailability of oral resveratrol in humans. Drug Metab Dispos 32: 1377-1382 
 
Walley KR, Lukacs NW, Standiford TJ, Strieter RM, Kunkel SL (1996) Balance of 
inflammatory cytokines related to severity and mortality of murine sepsis. Infect Immun 
64: 4733-4738 
 
Walley KR, Lukacs NW, Standiford TJ, Strieter RM, Kunkel SL (1997) Elevated levels 
of macrophage inflammatory protein 2 in severe murine peritonitis increase neutrophil 
recruitment and mortality. Infect Immun 65: 3847-3851 
 
Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, Frazier A, Yang 
H, Ivanova S, Borovikova L, Manogue KR, Faist E, Abraham E, Andersson J, Andersson 
U, Molina PE, Abumrad NN, Sama A, Tracey KJ (1999) HMG-1 as a late mediator of 
endotoxin lethality in mice. Science 285: 248-251 
 
Wang H, Yang H, Czura CJ, Sama AE, Tracey KJ (2001) HMGB1 as a late mediator of 
lethal systemic inflammation. Am J Respir Crit Care Med 164: 1768-1773 
 
Ward P (2004) The dark side of C5a in sepsis. Nat Rev Immunol 4: 133-142 
 
Ward P (2010) The harmful role of c5a on innate immunity in sepsis. J Innate Immun 2: 
439-445 
 
Watanabe E, Muenzer JT, Hawkins WG, Davis CG, Dixon DJ, McDunn JE, Brackett DJ, 
Lerner MR, Swanson PE, Hotchkiss RS (2009) Sepsis induces extensive autophagic 
vacuolization in hepatocytes: a clinical and laboratory-based study. Lab Invest 89: 549-
561 
 
Watterson K, Sankala H, Milstien S, Spiegel S (2003) Pleiotropic actions of sphingosine-
1-phosphate. Prog Lipid Res 42: 344-357 
 
Weaver CT, Hatton RD, Mangan PR, Harrington LE (2007) IL-17 family cytokines and 
the expanding diversity of effector T cell lineages. Annu Rev Immunol 25: 821-852 
 
Wenzel E, Soldo T, Erbersdobler H, Somoza V (2005) Bioactivity and metabolism of 




White E, Karp C, Strohecker AM, Guo Y, Mathew R (2010) Role of autophagy in 
suppression of inflammation and cancer. Curr Opin Cell Biol 22: 212-217 
 
Wichterman KA, Baue AE, Chaudry IH (1980) Sepsis and septic shock--a review of 
laboratory models and a proposal. J Surg Res 29: 189-201 
 
Wolach B (1997) Neonatal sepsis: pathogenesis and supportive therapy. Semin Perinatol 
21: 28-38 
 
Wymann MP, Schneiter R (2008) Lipid signalling in disease. Nat Rev Mol Cell Biol 9: 
162-176 
 
Xie Z, Klionsky DJ (2007) Autophagosome formation: core machinery and adaptations. 
Nat Cell Biol 9: 1102-1109 
 
Xu Y (2007) Toll-like receptor 4 is a sensor for autophagy associated with innate 
immunity. Immunity 27: 135-144 
 
Xu Y, Jagannath C, Liu XD, Sharafkhaneh A, Kolodziejska KE, Eissa NT (2007) Toll-
like receptor 4 is a sensor for autophagy associated with innate immunity. Immunity 27: 
135-144 
 
Xu YJ, Panagia V, Shao Q, Wang X, Dhalla NS (1996) Phosphatidic acid increases 
intracellular free Ca2+ and cardiac contractile force. Am J Physiol 271: H651-659 
 
Yamamoto M, Sato S, Hemmi H, Hoshino K, Kaisho T, Sanjo H, Takeuchi O, Sugiyama 
M, Okabe M, Takeda K, Akira S (2003) Role of adaptor TRIF in the MyD88-
independent toll-like receptor signaling pathway. Science 301: 640-643 
 
Yamamoto M, Sato S, Hemmi H, Sanjo H, Uematsu S, Kaisho T, Hoshino K, Takeuchi O, 
Kobayashi M, Fujita T, Takeda K, Akira S (2002) Essential role for TIRAP in activation 
of the signalling cascade shared by TLR2 and TLR4. Nature 420: 324-329 
 
Yang SF, Freer S, Benson AA (1967) Transphosphatidylation by phospholipase D. J Biol 
Chem 242: 477-484 
 
Yang Z, Klionsky DJ (2009) An overview of the molecular mechanism of autophagy. 




Yang Z, Klionsky DJ (2010) Mammalian autophagy: core molecular machinery and 
signaling regulation. Curr Opin Cell Biol 22: 124-131 
 
Ye H, Arron JR, Lamothe B, Cirilli M, Kobayashi T, Shevde NK, Segal D, Dzivenu OK, 
Vologodskaia M, Yim M, Du K, Singh S, Pike JW, Darnay BG, Choi Y, Wu H (2002) 
Distinct molecular mechanism for initiating TRAF6 signalling. Nature 418: 443-447 
 
Yin K, Gribbin E, Wang H (2005) Interferon-gamma inhibition attenuates lethality after 
cecal ligation and puncture in rats: implication of high mobility group box-1. Shock 24: 
396-401 
 
Youn H, Lee J, Fitzgerald K, Young H, Akira S, Hwang D (2005) Specific inhibition of 
MyD88-independent signaling pathways of TLR3 and TLR4 by resveratrol: molecular 
targets are TBK1 and RIP1 in TRIF complex. J Immunol 175: 3339-3346 
 
Young KW, Willets JM, Parkinson MJ, Bartlett P, Spiegel S, Nahorski SR, Challiss RA 
(2003) Ca2+/calmodulin-dependent translocation of sphingosine kinase: role in plasma 
membrane relocation but not activation. Cell Calcium 33: 119-128 
 
Yousefi S, Gold JA, Andina N, Lee JJ, Kelly AM, Kozlowski E, Schmid I, Straumann A, 
Reichenbach J, Gleich GJ, Simon HU (2008) Catapult-like release of mitochondrial DNA 
by eosinophils contributes to antibacterial defense. Nat Med 14: 949-953 
 
Zheng LF, Wei QY, Cai YJ, Fang JG, Zhou B, Yang L, Liu ZL (2006) DNA damage 
induced by resveratrol and its synthetic analogues in the presence of Cu (II) ions: 
mechanism and structure-activity relationship. Free Radic Biol Med 41: 1807-1816 
 
Zhi L, Leung B, Melendez A (2006) Sphingosine kinase 1 regulates pro-inflammatory 
responses triggered by TNFalpha in primary human monocytes. J Cell Physiol 208: 109-
115 
 
Ziegler-Heitbrock HW, Fingerle G, Ströbel M, Schraut W, Stelter F, Schütt C, Passlick B, 
Pforte A (1993) The novel subset of CD14+/CD16+ blood monocytes exhibits features of 
tissue macrophages. Eur J Immunol 23: 2053-2058 
 
Zughaier S, Zimmer S, Datta A, Carlson R, Stephens D (2005) Differential induction of 
the toll-like receptor 4-MyD88-dependent and -independent signaling pathways by 















































Supplementary Figure 1. Autophagosome formation after LPS treatment for 18 
hours. Electron microscopy of human monocytes treated with vehicle control, or LPS for 
2h (LPS 2h), or LPS for 6 h (LPS 6 h) or LPS for 18h (LPS 18h). Red arrows indicate 
autophagic vacuole structures.  
